UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended June 30, 2019March 31, 2020
or
☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Commission file number: 001-38196
DUPONT DE NEMOURS, INC.
(Exact name of registrant as specified in its charter)
|
| | | | |
| Delaware | | 81-1224539 | |
| State or other jurisdiction of incorporation or organization | | (I.R.S. Employer Identification No.) | |
|
| | | | | | |
| 974 Centre Road | Building 730 | Wilmington | Delaware | | 19805 | |
| (Address of Principal Executive Offices) | | (Zip Code) | |
(302) 774-1000774-3034
(Registrant’s Telephone Number, Including Area Code)
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Securities registered pursuant to Section 12(b) of the Act:
|
| | |
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
| Common Stock, par value $0.01 per share | DD | New York Stock Exchange |
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
☑ Yes ¨ No
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).
☑ Yes ¨ No
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and "emerging growth company" in Rule 12b-2 of the Exchange Act.
|
| | | | | | | |
| | Large Accelerated Filer | | ☑ | | Accelerated filer | | ¨ |
| | Non-accelerated filer | | ¨ | | Smaller reporting company | | ☐ |
| | | | | | Emerging growth company | | ☐ |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). ¨☐ Yes ☑ No
The registrant had 745,482,399733,797,258 shares of common stock, $0.01 par value, outstanding at August 2, 2019.May 1, 2020.
DuPont de Nemours, Inc.
QUARTERLY REPORT ON FORM 10-Q
For the quarterly period ended June 30, 2019March 31, 2020
TABLE OF CONTENTS
|
| | |
| PAGE |
| | | |
| Item 1. | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| Item 2. | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| Item 3. | | |
| Item 4. | | |
| | | |
| |
| | | |
| Item 1. | | |
| Item 1A. | | |
| Item 2. | | |
| Item 4. | | |
| Item 5. | | |
| Item 6. | | |
| | | |
| |
Throughout this Quarterly Report on Form 10-Q, except as otherwise noted by the context, the terms "DuPont" or "Company" used herein mean DuPont de Nemours, Inc. and its consolidated subsidiaries. On June 1, 2019, DowDuPont Inc. changed its registered name to DuPont de Nemours, Inc. (“DuPont”) (for certain events prior to June 1, 2019, the Company may be referred to as DowDuPont). Beginning on June 3, 2019, the Company's common stock is traded on the New York Stock Exchange under the ticker symbol "DD".
Effective as of 5:00 p.m. onOn April 1, 2019, DowDuPontthe Company completed the previously announced separation of its materials science business into a separate and independent public company by way of a distribution of Dow Inc. (“Dow”) through a pro rata dividend in-kind of all of the then-issued and outstanding shares of Dow’s common stock par value $0.01 per share (the “Dow Common Stock”), to holders of the Company’s common stock, par value $0.01 per share, as of the close of business on March 21, 2019 (the “Dow Distribution”). Dow's historical financial results for periods prior to April 1, 2019 are reflected in DuPont's interim Consolidated Financial Statements as discontinued operations.
Effective as of 12:01 a.m. onOn June 1, 2019, the Company completed the previously announced separation of its agriculture business into a separate and independent public company by way of a distribution of Corteva, Inc. (“Corteva”) through a pro rata dividend in-kind of all of the then-issued and outstanding shares of Corteva’s common stock par value $0.01 per share (the “Corteva Common Stock”), to holders of the Company’s common stock, par value $0.01 per share, as of the close of business on May 24, 2019 (the “Corteva Distribution”). Corteva's historical financial results for periods prior to June 1, 2019 are reflected in DuPont's interim Consolidated Financial Statements as discontinued operations.
Following the Corteva Distribution, DuPont holds the specialty products business. Unless otherwise indicated, the interim Consolidated Financial Statements and Notes thereto present the financial position of DuPont'sbusiness as continuing operations as of June 30, 2019 and December 31, 2018 and theoperations. The results of operations of DuPont for the three and six months ended June 30,March 31, 2019 present the historical financial results of Dow and 2018.Corteva as discontinued operations. The cash flows and comprehensive income related to Dow and Corteva have not been segregated and are included as applicable, in the interim Consolidated Statements of Cash Flows and Consolidated Statements of Comprehensive Income, respectively, for the applicable period. Unless otherwise indicated, the information in the notes to the interim Consolidated Financial Statements refer only to DuPont's continuing operations and do not include discussion of balances or activity of Dow or Corteva.
On December 15, 2019, DuPont and International Flavors & Fragrances Inc. ("IFF") announced entry into definitive agreements to combine DuPont’s Nutrition & Biosciences business (the "N&B Business") with IFF in a transaction that would result in IFF issuing shares to DuPont shareholders. The transaction is expected to close by the end of the first quarter of 2021, subject to approval by IFF shareholders and other customary closing conditions, including regulatory approvals and receipt by DuPont of an opinion of tax counsel.
DuPontTM and all periods presented.products, unless otherwise noted, denoted with TM, SM or ® are trademarks, service marks or registered trademarks of affiliates of DuPont de Nemours, Inc.
FORWARD-LOOKING STATEMENTS
This communication contains "forward-looking statements" within the meaning of the federal securities laws, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In this context, forward-looking statements often address expected future business and financial performance and financial condition, and often contain words such as "expect," "anticipate," "intend," "plan," "believe," "seek," "see," "will," "would," "target," and similar expressions and variations or negatives of these words.
Forward-looking statements address matters that are, to varying degrees, uncertain and subject to risks, uncertainties and assumptions, many of which that are beyond DuPont's control, that could cause actual results to differ materially from those expressed in any forward-looking statements. Forward-looking statements are not guarantees of future results. Some of the important factors that could cause DuPont's actual results to differ materially from those projected in any such forward-looking statements include, but are not limited to: (i) the parties’ ability to meet expectations regarding the timing, completion and accounting and tax treatments of the proposed transaction with IFF; changes in relevant tax and other laws, (ii) failure to obtain necessary regulatory approvals, approval of IFF’s shareholders, anticipated tax treatment or any required financing or to satisfy any of the other conditions to the proposed transaction with IFF, (iii) the possibility that unforeseen liabilities, future capital expenditures, revenues, expenses, earnings, synergies, economic performance, indebtedness, financial condition, losses, future prospects, business and management strategies that could impact the value, timing or pursuit of the proposed transaction with IFF, (iv) risks and costs and pursuit and/or implementation of the separation of the N&B Business, including timing anticipated to achieve allcomplete the expected benefits fromseparation, any changes to the configuration of businesses included in the separation if implemented, (v) risks and costs related to the Dow Distribution and the Corteva Distribution (together, the “Distributions”); (ii) restrictions under intellectual property cross license agreements entered into in connection including (a) with respect to achieving all expected benefits from the Distributions; (iii) non-compete restrictions agreed in connection with the Distributions; (iv)(b) the incurrence of significant costs in connection with the Distributions, including costs to service debt incurred by the Company to establish the relative credit profiles of Corteva, Dow and DuPont and increased costs related to supply, service and other arrangements that, prior to the Dow Distribution, were between entities under the common control of DuPont; (v) risks related to(c) indemnification of certain legacy liabilities of E. I. du Pont de Nemours and Company ("Historical EID") in connection with the Corteva Distribution; (vi)and (d) potential liability arising from fraudulent conveyance and similar laws in connection with the Distributions; (vii)(vi) failure to effectively manage acquisitions, divestitures, alliances, joint ventures and other portfolio changes, including meeting conditions under the Letter Agreement entered in connection with the Corteva Distribution, related to the transfer of certain levels of assets and businesses; (viii)(vii) uncertainty as to the long-term value of DuPont common stock; (ix)(viii) potential inability or reduced access to the capital markets or increased cost of borrowings, including as a result of a
credit rating downgrade (ix) risks and uncertainties related to the novel coronavirus (COVID-19) and the responses thereto (such as voluntary and in some cases, mandatory quarantines as well as shut downs and other restrictions on travel and commercial, social and other activities) on DuPont’s business, results of operations, access to sources of liquidity and financial condition which depend on highly uncertain and unpredictable future developments, including, but not limited to, the duration and spread of the COVID-19 outbreak, its severity, the actions to contain the virus or treat its impact, and how quickly and to what extent normal economic and operating conditions resume and (x) other risks to DuPont's business, operations and results of operations including from: failure to develop and market new products and optimally manage product life cycles; ability, cost and impact on business operations, including the supply chain, of responding to changes in market acceptance, rules, regulations and policies and failure to respond to such changes; outcome of significant litigation, environmental matters and other commitments and contingencies; failure to appropriately manage process safety and product stewardship issues; global economic and capital market conditions, including the continued availability of capital and financing, as well as inflation, interest and currency exchange rates; changes in political conditions, including tariffs, trade disputes and retaliatory actions; impairment of goodwill or intangible assets; the availability of and fluctuations in the cost
of energy and raw materials; business or supply disruption, including in connection with the Distributions; ability to effectively manage costs as the company’s portfolio evolves; security threats, such as acts of sabotage, terrorism or war, global health concerns and pandemics, natural disasters and weather events and patterns which could or could continue to result in a significant operational event for DuPont, adversely impact demand or production; ability to discover, develop and protect new technologies and to protect and enforce DuPont's intellectual property rights; unpredictability and severity of catastrophic events, including, but not limited to, acts of terrorism or outbreak of war or hostilities, as well as management's response to any of the aforementioned factors. These risks are and will be more fully discussed in DuPont's current, quarterly and annual reports and other filings made with the U.S. Securities and Exchange Commission, in each case, as may be amended from time to time in future filings with the SEC. While the list of factors presented here is considered representative, no such list should be considered a complete statement of all potential risks and uncertainties. Unlisted factors may present significant additional obstacles to the realization of forward-looking statements. Consequences of material differences in results as compared with those anticipated in the forward-looking statements could include, among other things, business disruption, operational problems, financial loss, legal liability to third parties and similar risks, any of which could have a material adverse effect on DuPont’s consolidated financial condition, results of operations, credit rating or liquidity. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. DuPont assumes no obligation to publicly provide revisions or updates to any forward-looking statements whether as a result of new information, future developments or otherwise, should circumstances change, except as otherwise required by securities and other applicable laws. A detailed discussion of some of the significant risks and uncertainties which may cause results and events to differ materially from such forward-looking statements is included in the section titled “Risk Factors” in (Part I, Item 1A) of DuPont’s 2019 Annual Report on Form 10-K and in (Part II, Item 1A1A) of this report for the three-month period ended on March 31, 2020 on Form 10-Q).10-Q.
|
|
| PART I - FINANCIAL INFORMATION |
ITEM 1. FINANCIAL STATEMENTS
DuPont de Nemours, Inc.
Consolidated Statements of Operations
| | | | Three Months Ended
June 30, | Six Months Ended
June 30, | Three Months Ended March 31, |
| In millions, except per share amounts (Unaudited) | 2019 | 2018 | 2019 | 2018 | 2020 | 2019 |
| Net sales | $ | 5,468 |
| $ | 5,857 |
| $ | 10,882 |
| $ | 11,454 |
| $ | 5,221 |
| $ | 5,414 |
|
| Cost of sales | 3,496 |
| 4,085 |
| 7,117 |
| 7,890 |
| 3,318 |
| 3,621 |
|
| Research and development expenses | 232 |
| 270 |
| 499 |
| 544 |
| 236 |
| 267 |
|
| Selling, general and administrative expenses | 642 |
| 768 |
| 1,368 |
| 1,570 |
| 633 |
| 726 |
|
| Amortization of intangibles | 252 |
| 266 |
| 508 |
| 531 |
| 533 |
| 256 |
|
| Restructuring and asset related charges - net | 137 |
| 46 |
| 208 |
| 99 |
| 404 |
| 71 |
|
| Goodwill impairment charge | 1,175 |
| — |
| 1,175 |
| — |
| 533 |
| — |
|
| Integration and separation costs | 347 |
| 428 |
| 958 |
| 793 |
| 197 |
| 611 |
|
| Equity in earnings of nonconsolidated affiliates | 49 |
| 54 |
| 89 |
| 111 |
| 39 |
| 40 |
|
| Sundry income (expense) - net | (19 | ) | 82 |
| 65 |
| (16 | ) | 211 |
| 84 |
|
| Interest expense | 165 |
| — |
| 316 |
| — |
| 183 |
| 151 |
|
| (Loss) income from continuing operations before income taxes | (948 | ) | 130 |
| (1,113 | ) | 122 |
| |
| Provision for income taxes on continuing operations | 155 |
| 99 |
| 64 |
| 164 |
| |
| (Loss) income from continuing operations, net of tax | (1,103 | ) | 31 |
| (1,177 | ) | (42 | ) | |
| Loss from continuing operations before income taxes | | (566 | ) | (165 | ) |
| Provision for (benefit from) income taxes on continuing operations | | 44 |
| (91 | ) |
| Loss from continuing operations, net of tax | | (610 | ) | (74 | ) |
| Income from discontinued operations, net of tax | 566 |
| 1,773 |
| 1,212 |
| 2,983 |
| — |
| 646 |
|
| Net (loss) income | (537 | ) | 1,804 |
| 35 |
| 2,941 |
| (610 | ) | 572 |
|
| Net income attributable to noncontrolling interests | 34 |
| 35 |
| 85 |
| 79 |
| 6 |
| 51 |
|
| Net (loss) income available for DuPont common stockholders | $ | (571 | ) | $ | 1,769 |
| $ | (50 | ) | $ | 2,862 |
| $ | (616 | ) | $ | 521 |
|
| | | |
| | | |
| Per common share data: | | | | | |
| (Loss) earnings per common share from continuing operations - basic | $ | (1.48 | ) | $ | 0.03 |
| $ | (1.59 | ) | $ | (0.09 | ) | |
| Income per common share from discontinued operations - basic | 0.72 |
| 2.26 |
| 1.52 |
| 3.78 |
| |
| (Loss) earnings per common share - basic | $ | (0.76 | ) | $ | 2.29 |
| $ | (0.07 | ) | $ | 3.69 |
| |
| (Loss) earnings per common share from continuing operations - diluted | $ | (1.48 | ) | $ | 0.03 |
| $ | (1.59 | ) | $ | (0.09 | ) | |
| Income per common share from discontinued operations - diluted | 0.72 |
| 2.24 |
| 1.52 |
| 3.78 |
| |
| (Loss) earnings per common share - diluted | $ | (0.76 | ) | $ | 2.27 |
| $ | (0.07 | ) | $ | 3.69 |
| |
| Loss per common share from continuing operations - basic | | $ | (0.83 | ) | $ | (0.11 | ) |
| Earnings per common share from discontinued operations - basic | | — |
| 0.80 |
|
| (Loss) Earnings per common share - basic | | $ | (0.83 | ) | $ | 0.69 |
|
| Loss per common share from continuing operations - diluted | | $ | (0.83 | ) | $ | (0.11 | ) |
| Earnings per common share from discontinued operations - diluted | | — |
| 0.80 |
|
| (Loss) Earnings per common share - diluted | | $ | (0.83 | ) | $ | 0.69 |
|
| | | | |
| Weighted-average common shares outstanding - basic | 749.0 |
| 769.6 |
| 749.6 |
| 771.0 |
| 738.6 |
| 750.0 |
|
| Weighted-average common shares outstanding - diluted | 749.0 |
| 774.5 |
| 749.6 |
| 771.0 |
| 738.6 |
| 750.0 |
|
See Notes to the Consolidated Financial Statements.
DuPont de Nemours, Inc.
Consolidated Statements of Comprehensive Income
| | | | Three Months Ended
June 30, | Six Months Ended
June 30, | Three Months Ended March 31, |
| In millions (Unaudited) | 2019 | 2018 | 2019 | 2018 | 2020 | 2019 |
| Net (loss) income | $ | (537 | ) | $ | 1,804 |
| $ | 35 |
| $ | 2,941 |
| $ | (610 | ) | $ | 572 |
|
| Other comprehensive income (loss), net of tax | | |
| | |
| Unrealized gains (losses) on investments | — |
| (14 | ) | 67 |
| (39 | ) | — |
| 67 |
|
| Cumulative translation adjustments | (38 | ) | (2,393 | ) | (135 | ) | (1,060 | ) | (404 | ) | (97 | ) |
| Pension and other post employment benefit plans | 56 |
| 127 |
| 191 |
| 257 |
| 2 |
| 135 |
|
| Derivative instruments | 17 |
| 102 |
| (58 | ) | 119 |
| — |
| (75 | ) |
| Total other comprehensive income (loss) | 35 |
| (2,178 | ) | 65 |
| (723 | ) | |
| Total other comprehensive (loss) income | | (402 | ) | 30 |
|
| Comprehensive (loss) income | (502 | ) | (374 | ) | 100 |
| 2,218 |
| (1,012 | ) | 602 |
|
| Comprehensive income attributable to noncontrolling interests, net of tax | 41 |
| 2 |
| 98 |
| 40 |
| |
| Comprehensive (loss) income attributable to noncontrolling interests, net of tax | | (2 | ) | 57 |
|
| Comprehensive (loss) income attributable to DuPont | $ | (543 | ) | $ | (376 | ) | $ | 2 |
| $ | 2,178 |
| $ | (1,010 | ) | $ | 545 |
|
See Notes to the Consolidated Financial Statements.
DuPont de Nemours, Inc.
Condensed Consolidated Balance Sheets
| | | In millions, except per share amounts (Unaudited) | June 30, 2019 | Dec 31, 2018 | |
| In millions, except share amounts (Unaudited) | | March 31, 2020 | December 31, 2019 |
| Assets | | | | |
| Current Assets | | | | |
| Cash and cash equivalents | $ | 1,661 |
| $ | 8,548 |
| $ | 1,748 |
| $ | 1,540 |
|
| Marketable securities | 8 |
| 29 |
| |
| Accounts and notes receivable - net | 4,214 |
| 3,391 |
| 3,869 |
| 3,802 |
|
| Inventories | 4,390 |
| 4,107 |
| 4,410 |
| 4,319 |
|
| Other current assets | 350 |
| 305 |
| 365 |
| 338 |
|
| Assets of discontinued operations | — |
| 110,275 |
| |
| Total current assets | 10,623 |
| 126,655 |
| 10,392 |
| 9,999 |
|
| Investments | | |
| Investments in nonconsolidated affiliates | 1,653 |
| 1,745 |
| 1,227 |
| 1,204 |
|
| Other investments | 29 |
| 28 |
| 24 |
| 24 |
|
| Noncurrent receivables | 36 |
| 47 |
| 31 |
| 32 |
|
| Total investments | 1,718 |
| 1,820 |
| 1,282 |
| 1,260 |
|
| Property, plant and equipment - net of accumulated depreciation (June 30, 2019 - $4,667; December 31, 2018 - $4,199) | 9,806 |
| 9,917 |
| |
| Property, plant and equipment - net of accumulated depreciation (March 31, 2020 - $5,189; December 31, 2019 - $4,969) | | 9,912 |
| 10,143 |
|
| Other Assets | | | | |
| Goodwill | 33,330 |
| 34,496 |
| 32,317 |
| 33,151 |
|
| Other intangible assets | 14,150 |
| 14,655 |
| 12,834 |
| 13,593 |
|
| Deferred income tax assets | 219 |
| 178 |
| 210 |
| 236 |
|
| Deferred charges and other assets | 997 |
| 134 |
| 1,040 |
| 1,014 |
|
| Total other assets | 48,696 |
| 49,463 |
| 46,401 |
| 47,994 |
|
| Total Assets | $ | 70,843 |
| $ | 187,855 |
| $ | 67,987 |
| $ | 69,396 |
|
| Liabilities and Equity | | | | |
| Current Liabilities | | | | |
| Short-term borrowings and finance lease obligations | $ | 1,621 |
| $ | 15 |
| $ | 3,925 |
| $ | 3,830 |
|
| Accounts payable | 3,020 |
| 2,619 |
| 2,846 |
| 2,934 |
|
| Income taxes payable | 164 |
| 115 |
| 340 |
| 240 |
|
| Accrued and other current liabilities | 1,652 |
| 1,129 |
| 1,434 |
| 1,342 |
|
| Liabilities of discontinued operations | — |
| 69,434 |
| |
| Total current liabilities | 6,457 |
| 73,312 |
| 8,545 |
| 8,346 |
|
| Long-Term Debt | 15,608 |
| 12,624 |
| 13,618 |
| 13,617 |
|
| Other Noncurrent Liabilities | | | | |
| Deferred income tax liabilities | 3,662 |
| 3,912 |
| 3,314 |
| 3,514 |
|
| Pension and other post employment benefits - noncurrent | 1,102 |
| 1,343 |
| 1,155 |
| 1,172 |
|
| Other noncurrent obligations | 1,438 |
| 764 |
| 1,238 |
| 1,191 |
|
| Total other noncurrent liabilities | 6,202 |
| 6,019 |
| 5,707 |
| 5,877 |
|
| Total Liabilities | $ | 28,267 |
| $ | 91,955 |
| $ | 27,870 |
| $ | 27,840 |
|
| Commitments and contingent liabilities | | | | |
| Stockholders' Equity | | | | |
| Common stock (authorized 1,666,666,667 shares of $0.01 par value each; issued 2019: 747,443,517 shares; 2018: 784,143,433 shares) | 7 |
| 8 |
| |
| Common stock (authorized 1,666,666,667 shares of $0.01 par value each; issued 2020: 733,793,781 shares; 2019: 738,564,728 shares) | | 7 |
| 7 |
|
| Additional paid-in capital | 51,129 |
| 81,976 |
| 50,605 |
| 50,796 |
|
| (Accumulated deficit) Retained earnings | (8,299 | ) | 30,257 |
| (9,251 | ) | (8,400 | ) |
| Accumulated other comprehensive loss | (831 | ) | (12,394 | ) | (1,810 | ) | (1,416 | ) |
| Unearned ESOP shares | — |
| (134 | ) | |
| Treasury stock at cost (2019: 0 shares; 2018: 27,817,518 shares) | — |
| (5,421 | ) | |
| Total DuPont's stockholders' equity | 42,006 |
| 94,292 |
| |
| Total DuPont stockholders' equity | | 39,551 |
| 40,987 |
|
| Noncontrolling interests | 570 |
| 1,608 |
| 566 |
| 569 |
|
| Total equity | 42,576 |
| 95,900 |
| 40,117 |
| 41,556 |
|
| Total Liabilities and Equity | $ | 70,843 |
| $ | 187,855 |
| $ | 67,987 |
| $ | 69,396 |
|
See Notes to the Consolidated Financial Statements.
DuPont de Nemours, Inc.
Consolidated Statements of Cash Flows
|
| | | | | | |
| | Three Months Ended March 31, |
| In millions (Unaudited) | 2020 | 2019 |
| Operating Activities | | |
| Net (loss) income | $ | (610 | ) | $ | 572 |
|
| Adjustments to reconcile net income to net cash provided by operating activities: | | |
| Depreciation and amortization | 772 |
| 1,520 |
|
| Credit for deferred income tax and other tax related items | (164 | ) | (368 | ) |
| Earnings of nonconsolidated affiliates less than (in excess of) dividends received | (31 | ) | 767 |
|
| Net periodic pension benefit (credit) cost | 7 |
| (8 | ) |
| Pension contributions | (26 | ) | (153 | ) |
| Net gain on sales of assets, businesses and investments | (197 | ) | (43 | ) |
| Restructuring and asset related charges - net | 404 |
| 287 |
|
| Goodwill impairment charge | 533 |
| — |
|
| Amortization of merger-related inventory step-up | — |
| 205 |
|
| Other net loss | 49 |
| 93 |
|
| Changes in assets and liabilities, net of effects of acquired and divested companies: | | |
| Accounts and notes receivable | (134 | ) | (1,643 | ) |
| Inventories | (134 | ) | (194 | ) |
| Accounts payable | 236 |
| (732 | ) |
| Other assets and liabilities, net | 13 |
| (277 | ) |
| Cash provided by operating activities | 718 |
| 26 |
|
| Investing Activities | | |
| Capital expenditures | (481 | ) | (1,139 | ) |
| Investment in gas field developments | — |
| (25 | ) |
| Proceeds from sales of property and businesses, net of cash divested | 427 |
| 125 |
|
| Acquisitions of property and businesses, net of cash acquired | (73 | ) | — |
|
| Proceeds from sale of ownership interests in nonconsolidated affiliates | — |
| 21 |
|
| Purchases of investments | (1 | ) | (189 | ) |
| Proceeds from sales and maturities of investments | — |
| 212 |
|
| Other investing activities, net | 4 |
| (5 | ) |
| Cash used for investing activities | (124 | ) | (1,000 | ) |
| Financing Activities | | |
| Changes in short-term notes payable | 69 |
| 798 |
|
| Proceeds from issuance of long-term debt | 25 |
| 1,000 |
|
| Payments on long-term debt | (1 | ) | (363 | ) |
| Purchases of common stock | (232 | ) | (1,579 | ) |
| Proceeds from issuance of Company stock | 34 |
| 63 |
|
| Employee taxes paid for share-based payment arrangements | (12 | ) | (76 | ) |
| Distributions to noncontrolling interests | (6 | ) | (11 | ) |
| Dividends paid to stockholders | (222 | ) | (851 | ) |
| Debt extinguishment costs | — |
| (13 | ) |
| Other financing activities, net | 1 |
| — |
|
| Cash used for financing activities | (344 | ) | (1,032 | ) |
| Effect of exchange rate changes on cash, cash equivalents and restricted cash | (45 | ) | 50 |
|
| Increase (Decrease) in cash, cash equivalents and restricted cash | 205 |
| (1,956 | ) |
| Cash, cash equivalents and restricted cash from continuing operations, beginning of period | 1,577 |
| 8,591 |
|
| Cash, cash equivalents and restricted cash from discontinued operations, beginning of period | — |
| 5,431 |
|
| Cash, cash equivalents and restricted cash at beginning of period | 1,577 |
| 14,022 |
|
| Cash, cash equivalents and restricted cash from continuing operations, end of period | 1,782 |
| 6,862 |
|
| Cash, cash equivalents and restricted cash from discontinued operations, end of period | — |
| 5,204 |
|
| Cash, cash equivalents and restricted cash at end of period | $ | 1,782 |
| $ | 12,066 |
|
|
| | | | | | |
| | Six Months Ended
June 30, |
| In millions (Unaudited) | 2019 | 2018 |
| Operating Activities | | |
| Net income | $ | 35 |
| $ | 2,941 |
|
| Adjustments to reconcile net income to net cash used for operating activities: | | |
| Depreciation and amortization | 2,163 |
| 2,980 |
|
| Credit for deferred income tax | (535 | ) | (182 | ) |
| Earnings of nonconsolidated affiliates less than dividends received | 733 |
| 199 |
|
| Net periodic pension benefit (credit) cost | (53 | ) | 56 |
|
| Pension contributions | (463 | ) | (500 | ) |
| Net gain on sales of assets, businesses and investments | (55 | ) | (67 | ) |
| Restructuring and asset related charges - net | 482 |
| 451 |
|
| Goodwill impairment charge | 1,175 |
| — |
|
| Amortization of merger-related inventory step-up | 253 |
| 1,385 |
|
| Other net loss | 274 |
| 466 |
|
| Changes in assets and liabilities, net of effects of acquired and divested companies: | | |
| Accounts and notes receivable | (2,535 | ) | (4,454 | ) |
| Inventories | 302 |
| (215 | ) |
| Accounts payable | (695 | ) | 65 |
|
| Other assets and liabilities, net | (1,132 | ) | (3,172 | ) |
| Cash used for operating activities | (51 | ) | (47 | ) |
| Investing Activities | |
| |
| Capital expenditures | (1,800 | ) | (1,586 | ) |
| Investment in gas field developments | (25 | ) | (46 | ) |
| Proceeds from sales of property and businesses, net of cash divested | 126 |
| 96 |
|
| Distributions and loan repayments from nonconsolidated affiliates | — |
| 55 |
|
| Proceeds from sale of ownership interests in nonconsolidated affiliates | 21 |
| — |
|
| Purchases of investments | (192 | ) | (1,891 | ) |
| Proceeds from sales and maturities of investments | 228 |
| 2,328 |
|
| Proceeds from interests in trade accounts receivable conduits | — |
| 656 |
|
| Other investing activities, net | (15 | ) | (2 | ) |
| Cash used for investing activities | (1,657 | ) | (390 | ) |
| Financing Activities | | |
| Changes in short-term notes payable | 2,517 |
| 800 |
|
| Proceeds from issuance of long-term debt | 4,005 |
| 254 |
|
| Payments on long-term debt | (6,892 | ) | (842 | ) |
| Purchases of treasury stock | (1,681 | ) | (2,000 | ) |
| Proceeds from issuance of Company stock | 67 |
| 142 |
|
| Employee taxes paid for share-based payment arrangements | (76 | ) | (118 | ) |
| Distributions to noncontrolling interests | (12 | ) | (79 | ) |
| Dividends paid to stockholders | (1,165 | ) | (1,755 | ) |
| Cash held by Dow and Corteva at the respective Distributions | (7,315 | ) | — |
|
| Debt extinguishment costs | (104 | ) | — |
|
| Other financing activities, net | (5 | ) | (4 | ) |
| Cash used for financing activities | (10,661 | ) | (3,602 | ) |
| Effect of exchange rate changes on cash, cash equivalents and restricted cash | 48 |
| (171 | ) |
| Decrease in cash, cash equivalents and restricted cash | (12,321 | ) | (4,210 | ) |
| Cash, cash equivalents and restricted cash from continuing operations, beginning of period | 8,591 |
| 4,441 |
|
| Cash, cash equivalents and restricted cash from discontinued operations, beginning of period | 5,431 |
| 9,574 |
|
| Cash, cash equivalents and restricted cash at beginning of period | 14,022 |
| 14,015 |
|
| Cash, cash equivalents and restricted cash from continuing operations, end of period | 1,701 |
| 1,844 |
|
| Cash, cash equivalents and restricted cash from discontinued operations, end of period | — |
| 7,961 |
|
| Cash, cash equivalents and restricted cash at end of period | $ | 1,701 |
| $ | 9,805 |
|
See Notes to the Consolidated Financial Statements.
DuPont de Nemours, Inc.
Consolidated Statements of Equity
For the six months ended June 30, 2019 and 2018
| | | In millions (Unaudited) | Common Stock | Additional Paid-in Capital | Retained Earnings (Accumulated Deficit) | Accumulated Other Comp Loss | Unearned ESOP | Treasury Stock | Non-controlling Interests | Total Equity | Common Stock | Additional Paid-in Capital | Retained Earnings (Accumulated Deficit) | Accumulated Other Comp Loss | Unearned ESOP | Treasury Stock | Non-controlling Interests | Total Equity |
| Balance at December 31, 2017 | $ | 8 |
| $ | 81,272 |
| $ | 28,931 |
| $ | (8,972 | ) | $ | (189 | ) | $ | (1,000 | ) | $ | 1,597 |
| $ | 101,647 |
| |
| Balance at December 31, 2018 | | $ | 8 |
| $ | 81,976 |
| $ | 30,257 |
| $ | (12,394 | ) | $ | (134 | ) | $ | (5,421 | ) | $ | 1,608 |
| $ | 95,900 |
|
| Adoption of accounting standards | — |
| — |
| 996 |
| (1,037 | ) | — |
| — |
| — |
| (41 | ) | — |
| — |
| (111 | ) | — |
| — |
| — |
| — |
| (111 | ) |
| Net income | — |
| — |
| 2,862 |
| — |
| — |
| — |
| 79 |
| 2,941 |
| — |
| — |
| 521 |
| — |
| — |
| — |
| 51 |
| 572 |
|
| Other comprehensive loss | — |
| — |
| — |
| (723 | ) | — |
| — |
| (39 | ) | (762 | ) | |
| Dividends ($2.27 per common share) | — |
| — |
| (2,629 | ) | — |
| — |
| — |
| — |
| (2,629 | ) | |
| Other comprehensive income | | — |
| — |
|
|
| 30 |
| — |
| — |
| 6 |
| 36 |
|
| Dividends ($1.56 per common share) | | — |
| — |
| (1,176 | ) | — |
| — |
| — |
| — |
| (1,176 | ) |
| Common stock issued/sold | — |
| 142 |
| — |
| — |
| — |
| — |
| — |
| 142 |
| — |
| 63 |
| — |
| — |
| — |
| — |
| — |
| 63 |
|
| Stock-based compensation and allocation of ESOP shares | — |
| 285 |
| — |
| — |
| 44 |
| — |
| — |
| 329 |
| — |
| 102 |
| — |
| — |
| 29 |
| — |
| — |
| 131 |
|
| Distributions to non-controlling interests | — |
| — |
| — |
| — |
| — |
| — |
| (73 | ) | (73 | ) | — |
| — |
| — |
| — |
| — |
| — |
| (11 | ) | (11 | ) |
| Purchases of treasury stock | — |
| — |
| — |
| — |
| — |
| (2,000 | ) | — |
| (2,000 | ) | — |
| — |
| — |
| — |
| — |
| (1,579 | ) | — |
| (1,579 | ) |
| Other | — |
| — |
| (18 | ) | — |
| — |
| — |
| 56 |
| 38 |
| — |
| — |
| (5 | ) | — |
| — |
| — |
| — |
| (5 | ) |
| Balance at June 30, 2018 | $ | 8 |
| $ | 81,699 |
| $ | 30,142 |
| $ | (10,732 | ) | $ | (145 | ) | $ | (3,000 | ) | $ | 1,620 |
| $ | 99,592 |
| |
| Balance at March 31, 2019 | | $ | 8 |
| $ | 82,141 |
| $ | 29,486 |
| $ | (12,364 | ) | $ | (105 | ) | $ | (7,000 | ) | $ | 1,654 |
| $ | 93,820 |
|
| | | |
| Balance at December 31, 2018 | $ | 8 |
| $ | 81,976 |
| $ | 30,257 |
| $ | (12,394 | ) | $ | (134 | ) | $ | (5,421 | ) | $ | 1,608 |
| $ | 95,900 |
| |
| Balance at December 31, 2019 | | $ | 7 |
| $ | 50,796 |
| $ | (8,400 | ) | $ | (1,416 | ) | $ | — |
| $ | — |
| $ | 569 |
| $ | 41,556 |
|
| Adoption of accounting standards | — |
| — |
| (111 | ) | — |
| — |
| — |
| — |
| (111 | ) | — |
| — |
| (3 | ) | — |
| — |
| — |
| — |
| (3 | ) |
| Net income | — |
| — |
| (50 | ) | — |
| — |
| — |
| 85 |
| 35 |
| |
| Other comprehensive income | — |
| — |
| — |
| 65 |
| — |
| — |
| 13 |
| 78 |
| |
| Dividends ($1.86 per common share) | — |
| (224 | ) | (1,165 | ) | — |
| — |
| — |
| — |
| (1,389 | ) | |
| Net (loss) income | | — |
| — |
| (616 | ) | — |
| — |
| — |
| 6 |
| (610 | ) |
| Other comprehensive loss | | — |
| — |
| — |
| (394 | ) | — |
| — |
| (8 | ) | (402 | ) |
| Dividends ($0.30 per common share) | | — |
| (222 | ) | — |
| — |
| — |
| — |
| — |
| (222 | ) |
| Common stock issued/sold | — |
| 67 |
| — |
| — |
| — |
| — |
| — |
| 67 |
| — |
| 34 |
| — |
| — |
| — |
| — |
| — |
| 34 |
|
| Stock-based compensation and allocation of ESOP shares | — |
| 153 |
| — |
| — |
| 29 |
| — |
| — |
| 182 |
| |
| Stock-based compensation | | — |
| 30 |
| — |
| — |
| — |
| — |
| — |
| 30 |
|
| Distributions to non-controlling interests | — |
| — |
| — |
| — |
| — |
| — |
| (12 | ) | (12 | ) | — |
| — |
| — |
| — |
| — |
| — |
| (6 | ) | (6 | ) |
| Purchases of treasury stock | — |
| — |
| — |
| — |
| — |
| (1,681 | ) | — |
| (1,681 | ) | — |
| — |
| — |
| — |
| — |
| (232 | ) | — |
| (232 | ) |
| Retirement of treasury stock | — |
| — |
| (7,102 | ) | — |
| — |
| 7,102 |
| — |
| — |
| — |
| — |
| (232 | ) | — |
| — |
| 232 |
| — |
| — |
|
| Spin-off of Dow and Corteva | — |
| (30,843 | ) | (30,123 | ) | 11,498 |
| 105 |
| — |
| (1,124 | ) | (50,487 | ) | |
| Other | (1 | ) | — |
| (5 | ) | — |
| — |
| — |
| — |
| (6 | ) | — |
| (33 | ) | — |
| — |
| — |
| — |
| 5 |
| (28 | ) |
| Balance at June 30, 2019 | $ | 7 |
| $ | 51,129 |
| $ | (8,299 | ) | $ | (831 | ) | $ | — |
| $ | — |
| $ | 570 |
| $ | 42,576 |
| |
| Balance at March 31, 2020 | | $ | 7 |
| $ | 50,605 |
| $ | (9,251 | ) | $ | (1,810 | ) | $ | — |
| $ | — |
| $ | 566 |
| $ | 40,117 |
|
See Notes to the Consolidated Financial Statements.
DuPont de Nemours, Inc.
Consolidated Statements of Equity
For the three months ended June 30, 2019 and 2018
|
| | | | | | | | | | | | | | | | | | | | | | | | |
| In millions (Unaudited) | Common Stock | Additional Paid-in Capital | Retained Earnings (Accumulated Deficit) | Accumulated Other Comp Loss | Unearned ESOP | Treasury Stock | Non-controlling Interests | Total Equity |
| Balance at March 31, 2018 | $ | 8 |
| $ | 81,533 |
| $ | 29,075 |
| $ | (7,497 | ) | $ | (150 | ) | $ | (2,000 | ) | $ | 1,664 |
| $ | 102,633 |
|
| Adoption of accounting standards | — |
| — |
| 1,057 |
| (1,057 | ) | — |
| — |
| — |
| — |
|
| Net income | — |
| — |
| 1,769 |
| — |
| — |
| — |
| 35 |
| 1,804 |
|
| Other comprehensive loss | — |
| — |
| — |
| (2,178 | ) | — |
| — |
| (33 | ) | (2,211 | ) |
| Dividends ($1.14 per common share) | — |
| — |
| (1,749 | ) | — |
| — |
| — |
| — |
| (1,749 | ) |
| Common stock issued/sold | — |
| 34 |
| — |
| — |
| — |
| — |
| — |
| 34 |
|
| Stock-based compensation and allocated ESOP shares | — |
| 132 |
| — |
| — |
| 5 |
| — |
| — |
| 137 |
|
| Distributions to non-controlling interests | — |
| — |
| — |
| — |
| — |
| — |
| (46 | ) | (46 | ) |
| Purchases of treasury stock | — |
| — |
| — |
| — |
| — |
| (1,000 | ) | — |
| (1,000 | ) |
| Other | — |
| — |
| (10 | ) | — |
| — |
| — |
| — |
| (10 | ) |
| Balance at June 30, 2018 | $ | 8 |
| $ | 81,699 |
| $ | 30,142 |
| $ | (10,732 | ) | $ | (145 | ) | $ | (3,000 | ) | $ | 1,620 |
| $ | 99,592 |
|
| | | | | | | | | |
| Balance at March 31, 2019 | $ | 8 |
| $ | 82,141 |
| $ | 29,486 |
| $ | (12,364 | ) | $ | (105 | ) | $ | (7,000 | ) | $ | 1,654 |
| $ | 93,820 |
|
| Net loss | — |
| — |
| (571 | ) | — |
| — |
| — |
| 34 |
| (537 | ) |
| Other comprehensive income | — |
| — |
| — |
| 35 |
| — |
| — |
| 7 |
| 42 |
|
| Dividends ($0.30 per common share) | — |
| (224 | ) | 11 |
| — |
| — |
| — |
| — |
| (213 | ) |
| Common stock issued/sold | — |
| 4 |
| — |
| — |
| — |
| — |
| — |
| 4 |
|
| Stock-based compensation and allocation of ESOP shares | — |
| 51 |
| — |
| — |
| — |
| — |
| — |
| 51 |
|
| Distributions to non-controlling interests | — |
| — |
| — |
| — |
| — |
| — |
| (1 | ) | (1 | ) |
| Purchases of treasury stock | — |
| — |
| — |
| — |
| — |
| (102 | ) | — |
| (102 | ) |
| Retirement of treasury stock | — |
| — |
| (7,102 | ) | — |
| — |
| 7,102 |
| — |
| — |
|
| Spin-off of Dow and Corteva | — |
| (30,843 | ) | (30,123 | ) | 11,498 |
| 105 |
| | (1,124 | ) | (50,487 | ) |
| Other | (1 | ) | — |
| — |
| — |
| | — |
| — |
| (1 | ) |
| Balance at June 30, 2019 | $ | 7 |
| $ | 51,129 |
| $ | (8,299 | ) | $ | (831 | ) | $ | — |
| $ | — |
| $ | 570 |
| $ | 42,576 |
|
See Notes to the Consolidated Financial Statements.10
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
Table of Contents
| | | Note | | Page | | Page |
| 1 | | | | |
| 2 | | | | |
| 3 | | | | |
| 4 | | | | |
| 5 | | | | |
| 6 | | | | |
| 7 | | | | |
| 8 | | | | |
| 9 | | | | |
| 10 | | | | |
| 11 | | | | |
| 12 | | | | |
| 13 | | | | |
| 14 | | | | |
| 15 | | | | |
| 16 | | | | |
| 17 | | | | |
| 18 | | | | |
| 19 | | | | |
| 20 | | | | |
| 21 | | | | |
| 22 | | | |
| 23 | | | |
NOTE 1 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Interim Financial Statements
The accompanying unaudited interim Consolidated Financial Statements have been prepared in accordance with generally accepted accounting principles in the United States of America ("U.S. GAAP") for interim financial information and the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. In the opinion of management, the interim statements reflect all adjustments (including normal recurring accruals) which are considered necessary for the fair statement of the results for the periods presented. Results from interim periods should not be considered indicative of results for the full year. These interim Consolidated Financial Statements should be read in conjunction with the audited Consolidated Financial Statements and notes thereto contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018,2019, collectively referred to as the “2018“2019 Annual Report.” The interim Consolidated Financial Statements include the accounts of the Company and all of its subsidiaries in which a controlling interest is maintained.
Impact of the Novel Coronavirus (“COVID-19”) Pandemic
The COVID-19 pandemic has resulted in significant economic disruption and continues to adversely impact the broader global economy. The extent of the impact on the Company's operational and financial performance will depend on future developments, including, but not limited to, the duration and spread of the outbreak and its impact on the Company's customers and suppliers. As of the date of issuance of these interim Consolidated Financial Statements, the full extent to which the COVID-19 pandemic may materially impact the Company's financial condition, liquidity, or results of operations is uncertain.
Basis of Presentation
Effective August 31, 2017, pursuant to the merger of equals transaction contemplated by the Agreement and Plan of Merger, dated as of December 11, 2015, as amended on March 31, 2017 ("Merger Agreement"), The Dow Chemical Company ("Historical Dow") and E. I. du Pont de Nemours and Company ("Historical EID") each merged with subsidiaries of DowDuPont Inc. ("DowDuPont") and, as a result, Historical Dow and Historical EID became subsidiaries of DowDuPont (the "Merger"). Prior to the Merger, DowDuPont did not conduct any business activities other than those required for its formation and matters contemplated by the Merger Agreement. Historical Dow was determined to be the accounting acquirer in the Merger.
Except as otherwise indicated by the context, the term "Historical Dow" includes Historical Dow and its consolidated subsidiaries, "Historical EID" includes Historical EID and its consolidated subsidiaries, and "Dow Silicones" means Dow Silicones Corporation, a wholly owned subsidiary of Historical Dow.
Spin-OffsDistributions
Effective as of 5:00 p.m. on April 1, 2019, the Company completed the previously announced separation of its materials science business into a separate and independent public company by way of a distribution of Dow Inc. (“Dow”) through a pro rata dividend in-kind of all of the then-issued and outstanding shares of Dow’s common stock par value $0.01 per share (the “Dow Common Stock”), to holders of the Company’s common stock par value $0.01 per share (the “DowDuPont common stock”), as of the close of business on March 21, 2019 (the “Dow Distribution”).
Effective as of 12:01 a.m. on June 1, 2019, the Company completed the previously announced separation of its agriculture business into a separate and independent public company by way of a distribution of Corteva, Inc. (“Corteva”) through a pro rata dividend in-kind of all of the then-issued and outstanding shares of Corteva’s common stock par value $0.01 per share (the “Corteva Common Stock”), to holders of the Company’s common stock par value $0.01 per share, as of the close of business on May 24, 2019 (the “Corteva Distribution” and, together with the Dow Distribution, the “Distributions”).
Following the Corteva Distribution, DuPont holds the specialty products business. On June 1, 2019, DowDuPont changed its registered name from "DowDuPont Inc." to "DuPont de Nemours, Inc." doing business as "DuPont." Beginning on June 3, 2019, the Company's common stock is traded on the NYSE under the ticker symbol "DD".
These interim Consolidated Financial Statements present the financial position of DuPont as of June 30, 2019 and December 31, 2018 and theThe results of operations of DuPont for the three and six months ended June 30,March 31, 2019 and 2018 giving effect to the Distributions, withpresent the historical financial results of Dow and Corteva reflected as discontinued operations. The cash flows and comprehensive income related to Dow and Corteva have not been segregated and are included in the interim Consolidated Statements of Cash Flows and interim Consolidated Statements of Comprehensive Income, respectively, for all periods presented.the applicable period. Unless otherwise indicated, the information in the notes to the interim Consolidated Financial Statements refer only to DuPont's continuing operations and do not include discussion of balances or activity of Dow or Corteva.
Reverse Stock Split
On June 1,December 15, 2019, immediately following the Corteva Distribution, the Company completedentered into definitive agreements to separate and combine the Nutrition & Biosciences business segment (the "N&B Business") with International Flavors & Fragrances Inc. ("IFF") in a 1-for-3 reverse stock split of DuPont's outstanding common stocktax-efficient Reverse Morris Trust transaction, (the "Reverse Stock Split""Proposed N&B Transaction") and as a result, DuPont common stockholders now hold one share of common stock of DuPont for every three shares held prior. The transaction is expected to close by the Reverse Stock Split. The authorized number of shares of common stock was reduced from 5,000,000,000 shares to 1,666,666,667 shares, par value remained $0.01 per share. Stockholders entitled to fractional shares as a resultend of the Reverse Stock Split received a cash paymentfirst quarter of 2021, subject to approval by IFF shareholders and other customary closing conditions, including regulatory approvals and receipt by
DuPont of an opinion of tax counsel. The financial results of the N&B Business are included in lieu of receiving fractional shares. All share and share-related information presented in these interim Consolidated Financial Statements have been retroactively adjusted in all periods presented to reflectcontinuing operations for the decreased number of shares resulting from the Reverse Stock Split. The retroactive adjustments
resulted in the reclassification of $16 million from "Common stock" to "Additional paid-in capital" in the interim Condensed Consolidated Balance Sheets for all periods presented.
Significant Accounting Policies
The Company updated its accounting policy for leases since the issuance of its 2018 Annual Report as a result of the adoption of Accounting Standards Update ("ASU") 2016-02, "Leases (Topic 842)" in the first quarter of 2019. After the completion of the Distributions, the Company updated its accounting policy for inventories. See Note 1, "Summary of Significant Accounting Policies," to the 2018 Annual Report for more information on DuPont's other significant accounting policies.
The Company determines whether an arrangement is a lease at the inception of the arrangement based on the terms and conditions in the contract. A contract contains a lease if there is an identified asset and the Company has the right to control the asset. Operating lease right-of-use ("ROU") assets are included in "Deferred charges and other assets" on the interim Condensed Consolidated Balance Sheets. Operating lease liabilities are included in "Accrued and other current liabilities" and "Other noncurrent obligations" on the interim Condensed Consolidated Balance Sheets. Finance lease ROU assets are included in "Property, plant and equipment - net" and the corresponding lease liabilities are included in "Short-term borrowings and finance lease obligations" and "Long-term debt" on the interim Condensed Consolidated Balance Sheets.
ROU assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at the commencement date based on the present value of lease payments over the lease term. As most of the Company’s leases do not provide the lessor's implicit rate, the Company uses its incremental borrowing rate at the commencement date in determining the present value of lease payments. Lease terms include options to extend the lease when it is reasonably certain those options will be exercised. Leases with an initial term of 12 months or less are not recorded on the balance sheet, and lease expense is recognized on a straight-line basis over the lease term.
The Company has lease agreements with lease and non-lease components, which are accounted for as a single lease component for all asset classes. Additionally, for certain equipment leases, the portfolio approach is applied to account for the operating lease ROU assets and lease liabilities. In the interim Consolidated Statements of Operations, lease expense for operating lease payments is recognized on a straight-line basis over the lease term. For finance leases, interest expense is recognized on the lease liability and the ROU asset is amortized over the lease term.
See Notes 2 and 16 for additional information regarding the Company's leases.
Inventories
Prior to the Corteva Distribution, the Company recorded inventory under the last-in, first-out ("LIFO"), first-in, first-out and average cost methods. During the second quarter, effective after the Corteva Distribution, DuPont elected to change the method of accounting for inventories of the specialty products business recorded under the LIFO method to the average cost method. The effects of the change in accounting principle have been retrospectively applied to all prior periods presented. See Note 10 for more information regarding the change in inventory accounting method.
NOTE 2 - RECENT ACCOUNTING GUIDANCE
Recently Adopted Accounting Guidance
In February 2016, the Financial Accounting Standards Board ("FASB") issued ASU 2016-02, Leases (Topic 842), and associated ASUs related to Topic 842, which requires organizations that lease assets to recognize on the balance sheet the assets and liabilities for the rights and obligations created by those leases. The new guidance requires that a lessee recognize assets and liabilities for leases, and recognition, presentation and measurement in the financial statements depends on whether the lease is classified as a finance or operating lease. In addition, the new guidance requires disclosures to help investors and other financial statement users better understand the amount, timing and uncertainty of cash flows arising from leases. Lessor accounting remains largely unchanged from previous U.S. GAAP but does contain some targeted improvements to align with the new revenue recognition guidance, referred to as "Topic 606," issued in 2014.
The Company adopted the new standard in the first quarter of 2019, which allows for a modified retrospective transition approach, applying the new standard to all leases existing at the date of initial adoption. An entity may choose to use either (1) its effective date or (2) the beginning of the earliest comparative period presented in the financial statement as its date of initial application. The Company has elected to apply the transition requirements at the January 1, 2019 effective date rather than at the beginning of the earliest comparative period presented. This approach allows for a cumulative effect adjustment in the period of adoption, and prior periods are not restated and continue to be reported in accordance with historic accounting under ASC 840 (Leases). In addition, the Company has elected the package of practical expedients permitted under the transition guidance within the new standard which does not require reassessment of prior conclusions related to contracts containing a lease, lease classification and initial direct lease costs. As an accounting policy election, the Company chose to not apply the standard to certain existing land easements, excluded short-term leases (term of 12 months or less) from the balance sheet and accounts for nonlease and lease components in a contract as a single component for all asset classes. The following table summarizes the impact of adoption to the consolidated balance sheet:
|
| | | | | | | | | |
| Summary of Changes to the Consolidated Balance Sheet | As Reported Dec 31, 2018 1 | Effect of Adoption of ASU 2016-02 | Updated Jan 1, 2019 |
| In millions |
| Assets | | | |
| Deferred charges and other assets | $ | 134 |
| $ | 584 |
| $ | 718 |
|
| Total other assets | $ | 49,463 |
| $ | 584 |
| $ | 50,047 |
|
| Assets of discontinued operations | $ | 110,275 |
| $ | 2,787 |
| $ | 113,062 |
|
| Total Assets | $ | 187,855 |
| $ | 3,371 |
| $ | 191,226 |
|
| Liabilities | | | |
| Accrued and other current liabilities | $ | 1,129 |
| $ | 156 |
| $ | 1,285 |
|
| Total current liabilities | $ | 73,312 |
| $ | 156 |
| $ | 73,468 |
|
| Other noncurrent obligations | $ | 764 |
| $ | 428 |
| $ | 1,192 |
|
| Total other noncurrent liabilities | $ | 6,019 |
| $ | 428 |
| $ | 6,447 |
|
| Liabilities of discontinued operations | $ | 69,434 |
| $ | 2,715 |
| $ | 72,149 |
|
| Total Liabilities | $ | 91,955 |
| $ | 3,299 |
| $ | 95,254 |
|
| Stockholders' Equity | | | |
Retained earnings 2 | $ | 30,257 |
| $ | 72 |
| $ | 30,329 |
|
| DuPont's stockholders' equity | $ | 94,292 |
| $ | 72 |
| $ | 94,364 |
|
Total equity | $ | 95,900 |
| $ | 72 |
| $ | 95,972 |
|
| Total Liabilities and Equity | $ | 187,855 |
| $ | 3,371 |
| $ | 191,226 |
|
1.The as reported December 31, 2018 information has been updated to reflect the impact of the reverse stock split and the change in accounting policy discussed in Note 1.
2. The net impact to retained earnings was primarily a result of the recognition of a deferred gain associated with a prior sale-leaseback transaction.
The adoption of the new guidance did not have a material impact on the Company's interim Consolidated Statement of Operations and had no impact on the interim Consolidated Statement of Cash Flows.
Accounting Guidance Issued But Not Adopted at June 30, 2019
In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement, which is part of the FASB disclosure framework project to improve the effectiveness of disclosures in the notes to the financial statements. The amendments in the new guidance remove, modify and add certain disclosure requirements related to fair value measurements covered in ASC 820, Fair Value Measurement. The new standard is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. Early adoption is permitted for either the entire standard or only the requirements that modify or eliminate the disclosure requirements,
with certain requirements applied prospectively, and all other requirements applied retrospectively to all periods presented. The Company is currently evaluating the impact of adopting this guidance.
In August 2018, the FASB issued ASU 2018-15, Intangibles - Goodwill and Other - Internal-Use Software (Subtopic 350-40): Customer's Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That is a Service Contract. This new standard requires a customer in a cloud computing arrangement that is a service contract to follow the internal-use software guidance in ASC 350, Intangibles - Goodwill and Other, to determine which implementation costs to capitalize as assets or expense as incurred. The new standard is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. Early adoption is permitted and an entity can elect to apply the new guidance on a prospective or retrospective basis. The Company is currently evaluating the impact of adopting this guidance and does not expect there to be a significant impact.
In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, which was further updated in November 2018 and May 2019.associated ASUs related to Topic 326. The new guidance introduces the current expected credit loss (CECL)(“CECL”) model, which will require an entityrequires organizations to record an allowance for credit losses for certain financial instruments and financial assets, including trade receivables, based on expected losses rather than incurred losses. Under this update, on initial recognition and at each reporting period, an entity will be required to recognize an allowance that reflects the entity’s current estimate of credit losses expected to be incurred over the life of the financial instrument. This update will bebecame effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019,2019.
The Company adopted the new standard in the first quarter of 2020, which required a modified retrospective transition approach, applying the new standard's cumulative-effect adjustment at the date of initial adoption. This cumulative-effect has been reflected as of January 1, 2020 and prior periods have not been restated. The impact of initial adoption was not material to the Company’s interim Condensed Consolidated Balance Sheet, interim Consolidated Statements of Operations, and interim periods within those fiscal years. Early adoption is permitted. The Company is currently evaluating the impactConsolidated Statement of adopting this guidance on the Consolidated Financial Statements and related disclosures.Cash Flows.
NOTE 3 - DIVESTITURES
Separation Agreements
In connection with the Dow Distribution and the Corteva Distribution, the Company has entered into certain agreements that, among other things, effecteffected the separations, provideprovides for the allocation of assets, employees, liabilities and obligations (including its investments, property and employee benefits and tax-related assets and liabilities) among DuPont, Dow, and Corteva (together, the “Parties” and each a “Party”), and provideprovides a framework for DuPont’s relationship with Dow and Corteva following the Distributions. Effective April 1, 2019, the Parties entered into the following agreements:
the Separation and Distribution Agreement - The Parties entered into an agreement that sets forth, among other things,Agreement; the agreements among the Parties regarding the principal transactions necessary to effect the Distributions. It also sets forth other agreements that govern certain aspects of the Parties’ ongoing relationships after the completion of the Distributions (the "Separation and Distribution Agreement").
Tax Matters Agreement - The Parties entered into an agreement that governs their respective rights, responsibilities and obligations with respect to tax liabilities and benefits, tax attributes,Agreement; the preparation and filing of tax returns, the control of audits and other tax proceedings and other matters regarding taxes.
Employee Matters Agreement - The Parties entered into an agreement that identifies employeesAgreement; and employee-related liabilities (and attributable assets) to be allocated (either retained, transferred and accepted, or assigned and assumed, as applicable) to the Parties as part of the Distributions and describes when and how the relevant transfers and assignments will occur.
Intellectual Property Cross-License Agreement - DuPont entered into an Intellectual Property Cross-License Agreement with Dow (the “DuPont-Dow IP Cross-License Agreement”). The DuPont-Dow IP Cross-License Agreement sets forth the terms and conditions under which the applicable Parties may use in their respective businesses, following each of the Distributions, certain know-how (including trade secrets), copyrights, software, and certain patents and standards, allocated to another Party pursuant to the Separation and Distribution Agreement.
In addition to the agreements above, DuPont has entered into certain various supply agreements with Dow. These agreements provide for different pricing than the historical intercompany and intracompany practices prior to the Distributions.
Effective June 1, 2019, in connection with the Corteva Distribution, DuPont and Corteva entered into the following agreements:
Intellectual Property Cross-License Agreement - DuPont and Corteva entered into an the Intellectual Property Cross-License Agreement (the “DuPont-Corteva IP Cross-License Agreement”). The DuPont-Corteva IP Cross-License Agreement sets forth; the terms and conditions under which the applicable parties may use in their respective businesses, following the Corteva Distribution, certain know-how (including trade secrets), copyrights, software, and certain patents and standards, allocated to another Party pursuant to the Separation and Distribution Agreement.
Letter Agreement - The Company entered into a letter agreement (the "Letter Agreement") with Corteva that sets forth certain additional terms and conditions related to the Corteva Distribution, including certain limitations on DuPont’s and Corteva's ability to transfer certain businesses and assets to third parties without assigning certain of such Party’s indemnification obligations under the Separation and Distribution Agreement to the other Party to the transferee of such businesses and assets or meeting certain other alternative conditions. The Letter Agreement further outlines the allocation between DuPont and Corteva of liabilities associated with certain legal and environmental matters, including liabilities associated with discontinued and/or divested operations and businesses of Historical EID. See Note 15 for more information regarding the allocation.
Amended and Restated Tax Matters Agreement - The Parties entered into an amendment and restatement of the Tax Matters Agreement, between DuPont, Corteva and Dow, effective as of April 1, 2019 (as so amended and restated, the “Amended and Restated Tax Matters Agreement”). The Amended and Restated Tax Matters Agreement governs the Parties’ rights, responsibilities and obligations with respect to tax liabilities and benefits, tax attributes, the preparation and filing of tax returns, the control of audits and other tax proceedings and other matters regarding taxes. The Parties amended and restated the Tax Matters Agreement in connection with the Corteva Distribution in order to allocate between DuPont and Corteva certain rights and obligations of the Company provided in the original form of the Tax Matters Agreement. See Note 7 for additional information on the Tax Matters AgreementAgreement; and the Amended and Restated Tax Matters Agreement.
Materials Science Division
On April 1, 2019, DowDuPont completed the separation of its Materials Science businesses, including the businesses and operations that comprised the Company's former Performance Materials & Coating, Industrial Intermediates & Infrastructure and the Packaging & Specialty Plastics segments, (the "Materials Science Division") through the consummation of the Dow Distribution.
On April 1, 2019, prior to the Dow Distribution, the Company contributed $2,024 million in cash to Dow.
The results of operations of the Materials Science Division are presented as discontinued operations as summarized below:
| | | | Three Months Ended | Six Months Ended | Three Months Ended
March 31, 2019 |
| In millions | June 30, 2018 | June 30, 2019 | June 30, 2018 |
| Net sales | $ | 12,750 |
| $ | 10,867 |
| $ | 24,890 |
| $ | 10,867 |
|
| Cost of sales | 10,266 |
| 8,917 |
| 20,055 |
| 8,917 |
|
| Research and development expenses | 188 |
| 163 |
| 361 |
| 163 |
|
| Selling, general and administrative expenses | 370 |
| 329 |
| 704 |
| 329 |
|
| Amortization of intangibles | 116 |
| 116 |
| 235 |
| 116 |
|
| Restructuring and asset related charges - net | 42 |
| 157 |
| 128 |
| 157 |
|
| Integration and separation costs | 32 |
| 44 |
| 53 |
| 44 |
|
| Equity in earnings of nonconsolidated affiliates | 194 |
| (13 | ) | 395 |
| (13 | ) |
| Sundry income (expense) - net | 21 |
| 99 |
| 117 |
| 99 |
|
| Interest expense | 263 |
| 240 |
| 524 |
| 240 |
|
| Income from discontinued operations before income taxes | 1,688 |
| 987 |
| 3,342 |
| 987 |
|
| Provision for income taxes on discontinued operations | 369 |
| 261 |
| 686 |
| 261 |
|
| Income from discontinued operations, net of tax | 1,319 |
| 726 |
| 2,656 |
| 726 |
|
| Income from discontinued operations attributable to noncontrolling interests, net of tax | 29 |
| 37 |
| 48 |
| 37 |
|
| Income from discontinued operations attributable to DuPont stockholders, net of tax | $ | 1,290 |
| $ | 689 |
| $ | 2,608 |
| $ | 689 |
|
The following table presents depreciation, amortization, and capital expenditures of the discontinued operations related to the Materials Science Division:
|
| | | | | | | | | |
| | Three Months Ended | Six Months Ended |
| In millions | June 30, 2018 | June 30, 2019 | June 30, 2018 |
| Depreciation and amortization | $ | 698 |
| $ | 743 |
| $ | 1,407 |
|
| Capital expenditures | $ | 482 |
| $ | 597 |
| $ | 868 |
|
The carrying amount of major classes of assets and liabilities classified that were included in discontinued operations at December 31, 2018 related to the Material Science Division consist of the following:
|
| | | |
| Dec 31, 2018 |
| In millions |
| Assets | |
| Cash and cash equivalents | $ | 2,723 |
|
| Marketable securities | 100 |
|
| Accounts and notes receivable - net | 8,839 |
|
| Inventories | 6,891 |
|
| Other current assets | 722 |
|
| Investment in nonconsolidated affiliates | 3,321 |
|
| Other investments | 2,646 |
|
| Noncurrent receivables | 358 |
|
| Property, plant, and equipment - net | 21,418 |
|
| Goodwill | 9,845 |
|
| Other intangible assets - net | 4,225 |
|
| Deferred income tax assets | 2,197 |
|
| Deferred charges and other assets | 742 |
|
| Total assets of discontinued operations | $ | 64,027 |
|
| Liabilities | |
| Short-term borrowings and finance lease obligations | $ | 636 |
|
| Accounts payable | 6,867 |
|
| Income taxes payable | 557 |
|
| Accrued and other current liabilities | 2,931 |
|
| Long-Term Debt | 19,254 |
|
| Deferred income tax liabilities | 917 |
|
| Pension and other post employment benefits - noncurrent | 8,929 |
|
| Asbestos-related liabilities - noncurrent | 1,142 |
|
| Other noncurrent obligations | 4,706 |
|
| Total liabilities of discontinued operations | $ | 45,939 |
|
|
| | | |
| | Three Months Ended
March 31, 2019 |
| In millions |
| Depreciation and amortization | $ | 744 |
|
| Capital expenditures | $ | 597 |
|
Agriculture Division
On June 1, 2019, the Company completed the separation of its Agriculture business, including the businesses and operations that comprised the Company's former Agriculture segment (the "Agriculture Division"), through the consummation of the Corteva Distribution.
In 2019, prior to the distribution of Corteva, the Company contributed $7,139 million in cash to Corteva, a portion of which was used to retire indebtedness of Historical EID.
The results of operations of the Agriculture Division are presented as discontinued operations as summarized below:
| | | | Three Months Ended | Six Months Ended | Three Months Ended
March 31, 2019 |
| In millions | June 30, 2019 | June 30, 2018 | June 30, 2019 | June 30, 2018 |
| Net sales | $ | 3,776 |
| $ | 5,638 |
| $ | 7,144 |
| $ | 9,411 |
| $ | 3,368 |
|
| Cost of sales | 2,026 |
| 3,622 |
| 4,218 |
| 6,352 |
| 2,192 |
|
| Research and development expenses | 183 |
| 345 |
| 470 |
| 666 |
| 287 |
|
| Selling, general and administrative expenses | 677 |
| 795 |
| 1,294 |
| 1,373 |
| 617 |
|
| Amortization of intangibles | 74 |
| 106 |
| 176 |
| 196 |
| 102 |
|
| Restructuring and asset related charges - net | 58 |
| 101 |
| 117 |
| 224 |
| 59 |
|
| Integration and separation costs | 272 |
| 98 |
| 430 |
| 169 |
| 158 |
|
| Equity in earnings of nonconsolidated affiliates | (3 | ) | 2 |
| (4 | ) | 1 |
| (1 | ) |
| Sundry income (expense) - net | (7 | ) | 75 |
| 58 |
| 192 |
| 65 |
|
| Interest expense | 28 |
| 97 |
| 91 |
| 186 |
| 63 |
|
| Income from discontinued operations before income taxes | 448 |
| 551 |
| 402 |
| 438 |
| (46 | ) |
| Provision for income taxes on discontinued operations | 48 |
| 97 |
| 82 |
| 106 |
| 34 |
|
| Income from discontinued operations, net of tax | $ | 400 |
| $ | 454 |
| $ | 320 |
| $ | 332 |
| (80 | ) |
| Income from discontinued operations attributable to noncontrolling interests, net of tax | 25 |
| 8 |
| 35 |
| 20 |
| 10 |
|
| Income from discontinued operations attributable to DuPont stockholders, net of tax | $ | 375 |
| $ | 446 |
| $ | 285 |
| $ | 312 |
| $ | (90 | ) |
Restructuring Charges related to the Agriculture Division
Restructuring charges associated with the Agriculture Division were designed to integrate and optimize the organization following the Merger and in preparation for the Distributions. The complete DowDuPont Agriculture Division Restructuring Program is included in the results of operations of the Agriculture Division within discontinued operations, as well as restructuring charges related to the DowDuPont Cost Synergy Program related to the Agriculture Division.
The following table presents depreciation, amortization, and capital expenditures of the discontinued operations related to the Agriculture Division:
|
| | | | | | | | | | | | |
| | Three Months Ended | Six Months Ended |
| In millions | June 30, 2019 | June 30, 2018 | June 30, 2019 | June 30, 2018 |
| Depreciation and amortization | $ | 136 |
| $ | 246 |
| $ | 385 |
| $ | 470 |
|
| Capital expenditures | $ | 161 |
| $ | 94 |
| $ | 383 |
| $ | 207 |
|
The carrying amount of major classes of assets and liabilities classified that were included in discontinued operations at December 31, 2018 related to the Agriculture Division consist of the following:
|
| | | |
| Dec 31, 2018 |
| In millions |
| Assets | |
| Cash and cash equivalents | $ | 2,211 |
|
| Marketable securities | 5 |
|
| Accounts and notes receivable - net | 5,109 |
|
| Inventories | 5,259 |
|
| Other current assets | 1,000 |
|
| Investment in nonconsolidated affiliates | 138 |
|
| Other investments | 27 |
|
| Noncurrent receivables | 72 |
|
| Property, plant and equipment - net | 4,543 |
|
| Goodwill | 14,691 |
|
| Other intangible assets - net | 12,055 |
|
| Deferred income tax assets | (651 | ) |
| Deferred charges and other assets | 1,789 |
|
| Total assets of discontinued operations | $ | 46,248 |
|
| Liabilities | |
| Short-term borrowings and finance lease obligations | $ | 2,151 |
|
| Accounts payable | 3,627 |
|
| Income taxes payable | 185 |
|
| Accrued and other current liabilities | 3,883 |
|
| Long-Term Debt | 5,784 |
|
| Deferred income tax liabilities | 520 |
|
| Pension and other post employment benefits - noncurrent | 5,637 |
|
| Other noncurrent obligations | 1,708 |
|
| Total liabilities of discontinued operations | $ | 23,495 |
|
|
| | | |
| | Three Months Ended
March 31, 2019 |
| In millions |
| Depreciation and amortization | $ | 249 |
|
| Capital expenditures | $ | 222 |
|
Indemnifications
Pursuant toIn connection with the SeparationDistributions, Dow and Distribution AgreementCorteva indemnify the Company against, and the Letter Agreement, DuPont indemnifies both Dow and Corteva against certain litigation, environmental, income taxes, workers' compensation and other liabilities that arose prior to the distribution.Distributions, as applicable. The term of this indemnification is indefinite and includes defense costs and expenses, as well as monetary and non-monetary settlements and judgments. At June 30, 2019,March 31, 2020, the indemnified assets are $172were $134 million within "Accounts and notes receivable, net" and $166$141 million within "Deferred charges and other assets" offset by the correspondingand indemnified liabilities of $127were $80 million within "Accrued and other current liabilities" and $96$95 million within "Other noncurrent obligations."
ForRefer to Note 13 for additional information regarding treatment of litigation and environmental related matters under the Separation and Distribution Agreement and the Letter Agreement refer to Note 15.Agreement.
Other Discontinued Operations ActivitySale of Compound Semiconductor Solutions
ForIn the three and six months ended June 30, 2019,first quarter of 2020, the Company recorded "Income from discontinued operations, netcompleted the sale of tax"its Compound Semiconductor Solutions business unit, a part of $86 millionthe Electronics & Imaging segment, to SK Siltron. The proceeds received in the first quarter of 2020 related to the adjustmentsale of certain unrecognized tax benefitsthe business were approximately $420 million. The sale resulted in a pre-tax gain of $197 million ($102 million net of tax) recorded in "Sundry income (expense) - net" in the Company's interim Consolidated Statements of Operations for positions taken on items from prior years from previously divested businesses and $80 million related to changes in accruals for certain prior year tax positions related to the divested crop protection business and research and development assets of Historical EID.three months ended March 31, 2020.
Integration and Separation Costs
Integration and separation costs for continuing operations to date primarily have consisted of financial advisory, information technology, legal, accounting, consulting, and other professional advisory fees associated with the preparation and execution of activities related to the Merger, post-Merger integration, the Distributions, and beginning in the Distributions. fourth quarter of 2019, the intended separation of the Nutrition & Biosciences business.
These costs are recorded within "Integration and separation costs" within the interim Consolidated Statements of Operations.
| | | | Three Months Ended June 30, | Six Months Ended June 30, | Three Months Ended March 31, |
| In millions | 2019 | 2018 | 2019 | 2018 | 2020 | 2019 |
| Integration and separation costs | $ | 347 |
| $ | 428 |
| $ | 958 |
| $ | 793 |
| $ | 197 |
| $ | 611 |
|
NOTE 4 - REVENUE
Revenue Recognition
Products
Substantially all of DuPont's revenue is derived from product sales. Product sales consist of sales of DuPont's products to supply manufacturers and distributors. DuPont considers purchase orders, which in some cases are governed by master supply agreements, to be a contract with a customer. Contracts with customers are considered to be short-term when the time between order confirmation and satisfaction of the performance obligations is equal to or less than one year.
Disaggregation of Revenue
The Company disaggregates its revenue from contracts with customers by segment and business or major product line and geographic region, as the Company believes it best depicts the nature, amount, timing and uncertainty of its revenue and cash flows. On June 1, 2019,
|
| | | | | | |
| Net Trade Revenue by Segment and Business or Major Product Line | Three Months Ended March 31, |
| In millions | 2020 | 2019 |
| Image Solutions | $ | 148 |
| $ | 154 |
|
| Interconnect Solutions | 266 |
| 238 |
|
| Semiconductor Technologies | 470 |
| 433 |
|
| Electronics & Imaging | $ | 884 |
| $ | 825 |
|
| Food & Beverage | $ | 738 |
| $ | 755 |
|
| Health & Biosciences | 605 |
| 570 |
|
| Pharma Solutions | 208 |
| 210 |
|
| Nutrition & Biosciences | $ | 1,551 |
| $ | 1,535 |
|
| Healthcare & Specialty | $ | 359 |
| $ | 384 |
|
| Industrial & Consumer | 266 |
| 308 |
|
| Mobility Solutions | 519 |
| 625 |
|
| Transportation & Industrial | $ | 1,144 |
| $ | 1,317 |
|
| Safety Solutions | $ | 631 |
| $ | 665 |
|
| Shelter Solutions | 348 |
| 357 |
|
| Water Solutions | 297 |
| 261 |
|
| Safety & Construction | $ | 1,276 |
| $ | 1,283 |
|
| Biomaterials | $ | 34 |
| $ | 59 |
|
| Clean Technologies | 60 |
| 65 |
|
| DuPont Teijin Films | 43 |
| 37 |
|
| Photovoltaic & Advanced Materials | 229 |
| 254 |
|
Sustainable Solutions 1 | — |
| 39 |
|
| Non-Core | $ | 366 |
| $ | 454 |
|
| Total | $ | 5,221 |
| $ | 5,414 |
|
1. The Sustainable Solutions business was divested in the Company realigned certain businesses resulting in changes to its management and reporting structure, including the creationthird quarter of a new Non-Core segment ("Second Quarter Segment Realignment") (refer to Note 23 for additional details). In conjunction with the Second Quarter Segment Realignment, DuPont made the following changes to its major product lines:2019.
Realigned its product lines within Nutrition & Biosciences as Food & Beverage, Health & Biosciences, and Pharma Solutions;
Renamed its product lines within Transportation & Industrial (formerly known as Transportation & Advanced Polymers) as Mobility Solutions, Healthcare & Specialty, and Industrial & Consumer (formerly known as Engineering Polymers, Performance Solutions, and Performance Resins, respectively); and
Realigned and renamed its product lines within Safety & Construction as Safety Solutions, Shelter Solutions, and Water Solutions.16
|
| | | | | | | | | | | | |
| Net Trade Revenue by Segment and Business or Major Product Line | Three Months Ended June 30, | Six Months Ended June 30, |
| In millions | 2019 | 2018 | 2019 | 2018 |
| Advanced Printing | $ | 121 |
| $ | 136 |
| $ | 240 |
| $ | 258 |
|
| Display Technologies | 74 |
| 82 |
| 159 |
| 142 |
|
| Interconnect Solutions | 282 |
| 298 |
| 520 |
| 579 |
|
| Semiconductor Technologies | 381 |
| 405 |
| 764 |
| 806 |
|
| Electronics & Imaging | $ | 858 |
| $ | 921 |
| $ | 1,683 |
| $ | 1,785 |
|
| Food & Beverage | $ | 746 |
| $ | 783 |
| $ | 1,501 |
| $ | 1,527 |
|
| Health & Biosciences | 604 |
| 618 |
| 1,174 |
| 1,236 |
|
| Pharma Solutions | 208 |
| 220 |
| 418 |
| 435 |
|
| Nutrition & Biosciences | $ | 1,558 |
| $ | 1,621 |
| $ | 3,093 |
| $ | 3,198 |
|
| Mobility Solutions | $ | 588 |
| $ | 648 |
| $ | 1,213 |
| $ | 1,269 |
|
| Healthcare & Specialty | 388 |
| 424 |
| 772 |
| 830 |
|
| Industrial & Consumer | 293 |
| 345 |
| 601 |
| 696 |
|
| Transportation & Industrial | $ | 1,269 |
| $ | 1,417 |
| $ | 2,586 |
| $ | 2,795 |
|
| Safety Solutions | $ | 657 |
| $ | 639 |
| $ | 1,322 |
| $ | 1,251 |
|
| Shelter Solutions | 398 |
| 471 |
| 755 |
| 894 |
|
| Water Solutions | 286 |
| 262 |
| 547 |
| 491 |
|
| Safety & Construction | $ | 1,341 |
| $ | 1,372 |
| $ | 2,624 |
| $ | 2,636 |
|
| Biomaterials | $ | 53 |
| $ | 74 |
| $ | 112 |
| $ | 144 |
|
| Clean Technologies | 76 |
| 79 |
| 141 |
| 153 |
|
| DuPont Teijin Films | 42 |
| 51 |
| 79 |
| 98 |
|
| Photovoltaic & Advanced Materials | 230 |
| 283 |
| 484 |
| 571 |
|
| Sustainable Solutions | 41 |
| 39 |
| 80 |
| 74 |
|
| Non-Core | $ | 442 |
| $ | 526 |
| $ | 896 |
| $ | 1,040 |
|
| Total | $ | 5,468 |
| $ | 5,857 |
| $ | 10,882 |
| $ | 11,454 |
|
| | | Net Trade Revenue by Geographic Region | Three Months Ended June 30, | Six Months Ended June 30, | Three Months Ended March 31, |
| In millions | 2019 | 2018 | 2019 | 2018 | 2020 | 2019 |
| U.S. & Canada | $ | 1,826 |
| $ | 1,857 |
| 3,602 |
| 3,643 |
| $ | 1,742 |
| $ | 1,776 |
|
EMEA 1 | 1,291 |
| 1,492 |
| 2,671 |
| 2,957 |
| 1,271 |
| 1,380 |
|
| Asia Pacific | 2,034 |
| 2,178 |
| 3,979 |
| 4,211 |
| 1,913 |
| 1,945 |
|
| Latin America | 317 |
| 330 |
| 630 |
| 643 |
| 295 |
| 313 |
|
| Total | $ | 5,468 |
| $ | 5,857 |
| $ | 10,882 |
| $ | 11,454 |
| $ | 5,221 |
| $ | 5,414 |
|
| |
| 1. | Europe, Middle East and Africa. |
Contract Balances
From time to time, the Company enters into arrangements in which it receives payments from customers based upon contractual billing schedules. The Company records accounts receivables when the right to consideration becomes unconditional. Contract assets include amounts related to the Company’s contractual right to consideration for completed performance obligations not yet invoiced. Contract liabilities primarily reflect deferred revenue from advance payment for product that the Company has received from customers. The Company classifies deferred revenue as current or noncurrent based on the timing of when the Company expects to recognize revenue.
Revenue recognized in the first sixthree months of 20192020 from amounts included in contract liabilities at the beginning of the period was approximately $25$14 million (approximately $23$10 million in the first sixthree months of 2018)2019). The amount of contract assets reclassified to receivables as a result of the right to the transaction consideration becoming unconditional was insignificant. The Company did not recognize any asset impairment charges related to contract assets during the period.
| | | Contract Balances | June 30, 2019 | Dec 31, 2018 | March 31, 2020 | December 31, 2019 |
| In millions |
Accounts and notes receivable - trade 1 | $ | 3,346 |
| $ | 2,960 |
| $ | 3,156 |
| $ | 3,007 |
|
Contract assets - current 2 | $ | 38 |
| $ | 48 |
| $ | 32 |
| $ | 35 |
|
Deferred revenue - current 3 | $ | 106 |
| $ | 71 |
| $ | 69 |
| $ | 43 |
|
Deferred revenue - noncurrent 4 | $ | 15 |
| $ | 7 |
| $ | 29 |
| $ | 34 |
|
| |
| 1. | Included in "Accounts and notes receivable - net" in the interim Condensed Consolidated Balance Sheets. |
| |
| 2. | Included in "Other current assets" in the interim Condensed Consolidated Balance Sheets. |
| |
| 3. | Included in "Accrued and other current liabilities" in the interim Condensed Consolidated Balance Sheets. |
| |
| 4. | Included in "Other noncurrent obligations" in the interim Condensed Consolidated Balance Sheets. |
NOTE 5 - RESTRUCTURING AND ASSET RELATED CHARGES - NET
Charges for restructuring programs and other asset related charges, which includes other asset impairments, were $137 million and $208 million in the three and six months ended June 30, 2019 ($46 million and $99$404 million for the three and six months ended June 30, 2018)March 31, 2020 ($71 million for the three ended March 31, 2019). These charges were recorded in "Restructuring and asset related charges - net" in the interim Consolidated Statements of Operations and consist primarilyOperations. The total liability related to restructuring programs was $230 million at March 31, 2020 ($162 million at December 31, 2019). Restructuring activity consists of the following:
2020 Restructuring Program
In the first quarter of 2020, the Company approved restructuring actions designed to capture near-term cost reductions and to further simplify certain organizational structures in anticipation of the expected closure of the Proposed N&B Transaction (the "2020 Restructuring Program"). As a result of these actions, the Company expects to record total pre-tax restructuring charges up to $180 million, comprised of $125 million of severance and related benefit costs, $50 million of asset related charges, and $5 million of costs related to contract terminations. For the three months ended March 31, 2020, DuPont recorded a pre-tax charge related to the 2020 Restructuring Program in the amount of $111 million, recognized in "Restructuring and asset related charges - net" in the Company's interim Consolidated Statement of Operations, comprised of $96 million of severance and related benefit costs and $15 million of asset related charges. At March 31, 2020, total liabilities related to the 2020 Restructuring Program were $96 million for severance and related benefit costs, recognized in "Accrued and other current liabilities" in the interim Condensed Consolidated Balance Sheets.
The following table summarizes the charges incurred by segment related to the 2020 Restructuring Program:
|
| | | |
| 2020 Restructuring Program Charges by Segment | Three Months Ended March 31, 2020 |
| In millions |
| Electronics & Imaging | $ | 4 |
|
| Nutrition & Biosciences | 6 |
|
| Transportation & Industrial | 24 |
|
| Safety & Construction | 20 |
|
| Non-Core | — |
|
Corporate | 57 |
|
| Total | $ | 111 |
|
The Company expects actions related to this program to be substantially complete by the end of 2020.
2019 Restructuring Program
During the second quarter of 2019 and in connection with the ongoing integration activities, DuPont approved restructuring actions to simplify and optimize certain organizational structures following the completion of the Distributions (the "2019 Restructuring Program"). As a result of these actions, theThe Company expects to record totalhas recorded pre-tax restructuring charges of $85$156 million to $130 million, comprised of approximately $55 million to $80 million of severance and related benefits costs; $30 million to $45 million of asset related charges; and up to $5 million of costs related to contract terminations. For the three and six months ended June 30, 2019, DuPont recorded a pre-tax charge of $53 million, recognized in "Restructuring and asset related charges - net" in the Company's interim Consolidated Statement of Operations comprised of $50 millioninception-to-date, consisting of severance and related benefit costs and $3of $122 million ofand asset related charges.charges of $34 million.
The Company incurred charges for severance and related benefit costs of $18 million related to the 2019 Restructuring Program during the three months ended March 31, 2020. These charges consisted of $1 million related to the Transportation & Industrial segment and $17 million related to Corporate.
The following table summarizes the activities related to the 2019 Restructuring Program:
|
| | | |
| 2019 Restructuring Program | Severance and Related Benefit Costs |
| In millions |
| Reserve balance at December 31, 2019 | $ | 86 |
|
| Current quarter restructuring charges | 18 |
|
| Non-cash compensation | (6 | ) |
| Cash payments | (23 | ) |
| Reserve balance at March 31, 2020 | $ | 75 |
|
At March 31, 2020, the $75 million for severance and related benefit costs was included in "Accrued and other current liabilities" ($86 million at December 31, 2019) in the interim Condensed Consolidated Balance Sheets. The Company expects actions related to this program to be substantially complete by mid-2020. At June 30, 2019, total liabilities related toin the program were $50 million for severance and related benefit costs.second quarter of 2020.
The following table details restructuring charges recorded at our reportable segments for the three and six months ended June 30, 2019:
|
| | | |
| 2019 Restructuring Program Charges by Segment | Three and Six Months Ended June 30, 2019 |
| In millions |
| Electronics & Imaging | $ | 7 |
|
| Nutrition & Biosciences | 14 |
|
| Transportation & Industrial | 12 |
|
| Safety & Construction | 17 |
|
| Non-Core | — |
|
Corporate | 3 |
|
| Total | $ | 53 |
|
DowDuPont Cost Synergy Program
In September and November 2017, the Company approved post-merger restructuring actions under the DowDuPont Cost Synergy Program, which was designed to integrate and optimize the organization following the Merger and in preparation for the Distributions of Dow and Corteva. The portions of the charges, costs and expenses attributable to integration and optimization within the Agriculture and Materials SciencesScience Divisions are reflected in discontinued operations. The Company has recorded pretaxpre-tax restructuring charges attributable to the continuing operations of DuPont of $466$490 million inception-to-date, consisting of severance and related benefit costs of $222$215 million, asset related charges of $184$209 million and contract termination charges of $60$66 million related to charges. The Company does not expect to incur further significant charges related to this program and the program is considered substantially complete at June 30, 2019.
The following tables summarize the charges incurred related to the DowDuPont Cost Synergy ProgramProgram:
|
| | | | | | |
| | Three Months Ended March 31, |
| In millions | 2020 | 2019 |
| Severance and related benefit costs | $ | — |
| $ | 43 |
|
| Contract termination charges | 5 |
| 16 |
|
| Asset related charges | — |
| 13 |
|
Total restructuring and asset related charges - net 1,2 | $ | 5 |
| $ | 72 |
|
1. The charges for the three and six months ended June 30,March 31, 2020 include $5 million related to Safety and Construction.
2. The charges for the three months ended March 31, 2019 include $27 million related to Nutrition & Biosciences, $2 million related to Safety and 2018:Construction, $44 million related to Corporate, and a benefit of $1 million related to Non Core.
|
| | | | | | | | | | | | |
| | Three Months Ended June 30, | Six Months Ended June 30, |
| In millions | 2019 | 2018 | 2019 | 2018 |
| Severance and related benefit costs | $ | 6 |
| $ | 37 |
| $ | 49 |
| $ | 77 |
|
| Contract termination charges | — |
| 3 |
| 16 |
| 15 |
|
| Asset related charges | 16 |
| 6 |
| 29 |
| 7 |
|
Total restructuring and asset related charges - net1 | $ | 22 |
| $ | 46 |
| $ | 94 |
| $ | 99 |
|
| |
1. | The charge for the three and six months ended June 30, 2019 includes $21 million and $92 million which was recognized in "Restructuring and asset related charges - net" and $1 million and $2 million which was recognized in "Equity in earnings of nonconsolidated affiliates" in the interim Consolidated Statements of Operations. |
Charges for the three months ended March 31, 2020 and 2019 include $5 million and $71 million, respectively, recognized in "Restructuring and asset related charges - net." The charge for the three months ended March 31, 2019 also includes $1 million recognized in "Equity in earnings of nonconsolidated affiliates" in the interim Consolidated Statements of Operations.
|
| | | | | | | | | | | | |
| DowDuPont Cost Synergy Program Charges by Segment | Three Months Ended June 30, | Six Months Ended June 30, |
| In millions | 2019 | 2018 | 2019 | 2018 |
| Electronics & Imaging | $ | — |
| $ | 1 |
| $ | — |
| $ | 2 |
|
| Nutrition & Biosciences | 8 |
| — |
| 35 |
| — |
|
| Transportation & Industrial | — |
| — |
| — |
| (1 | ) |
| Safety & Construction | 3 |
| 12 |
| 5 |
| 19 |
|
| Non-Core | 1 |
| (5 | ) | — |
| (6 | ) |
Corporate 1 | 10 |
| 38 |
| 54 |
| 85 |
|
| Total | $ | 22 |
| $ | 46 |
| $ | 94 |
| $ | 99 |
|
| |
1. | Severance and related benefit costs were recorded at Corporate. |
The following table summarizedsummarizes the activities related to the DowDuPont Cost Synergy Program.Program:
|
| | | | | | | | | | | | |
| DowDuPont Cost Synergy Program | Severance and Related Benefit Costs | Contract Termination Charges | Asset Related Charges | Total |
| In millions |
| Reserve balance at Dec 31, 2018 | $ | 126 |
| $ | 16 |
| $ | — |
| $ | 142 |
|
| 2019 restructuring charges | 49 |
| 16 |
| 29 |
| 94 |
|
| Charges against the reserve | — |
| — |
| (29 | ) | (29 | ) |
| Cash payments | (55 | ) | (28 | ) | — |
| (83 | ) |
| Reserve balance at June 30, 2019 | $ | 120 |
| $ | 4 |
| $ | — |
| $ | 124 |
|
|
| | | | | | | | | |
| DowDuPont Cost Synergy Program | Severance and Related Benefit Costs | Contract Termination Charges | Total |
| In millions |
| Reserve balance at December 31, 2019 | $ | 74 |
| $ | 2 |
| $ | 76 |
|
| Current quarter restructuring charges | — |
| 5 |
| 5 |
|
| Cash payments | (22 | ) | — |
| (22 | ) |
| Reserve balance at March 31, 2020 | $ | 52 |
| $ | 7 |
| $ | 59 |
|
At June 30, 2019, $107March 31, 2020, the $59 million was included in "Accrued and other current liabilities" ($12976 million at December 31, 2018) and $17 million was included in "Other noncurrent obligations" ($13 million at December 31, 2018)2019) in the interim Condensed Consolidated Balance Sheets. The DowDuPont Cost Synergy Program is considered substantially complete at March 31, 2020.
Asset Impairments
Equity Method Investment Impairment Related ChargesThe Company reviews and evaluates its long-lived assets for impairment when events and changes in circumstances indicate that the related carrying amount of such assets may not be recoverable and may exceed their fair value. For purposes of determining impairment, assets are grouped at the lowest level for which identifiable cash flows are largely independent of the cash flows of other groups of assets and liabilities.
In preparation for the Corteva Distribution, Historical EID completed the separationfirst quarter of the assets and liabilities2020, expectations of proceeds related to its specialty products businesses into separate legal entities (the “SP Legal Entities”)certain potential divestitures within the Non-Core segment gave rise to fair value indicators and, on May 1, 2019, Historical EID distributed the SP Legal Entities to DowDuPont (the “Internal SP Distribution”). The Internal SP Distribution served as athus, triggering eventevents requiring the Company to perform an impairment analysisa recoverability assessment related to equity method investments held byits biomaterials business unit. The Company performed a long-lived asset impairment test and determined that, based on undiscounted cash flows, the carrying amount of certain long-lived assets was not recoverable. Accordingly, the Company as of May 1, 2019. The Company applied the net asset value method under the cost approach to determineestimated the fair value of the equity method investments in the Nutrition & Biosciences segment. Based on updated projections, the Company determined the fair value of the equity method investment was below the carrying value and had no expectation the fair value would recover in the short-term due to the current economic environment.these assets using a market approach utilizing Level 3 unobservable inputs. As a result, management concluded the impairment was other-than-temporary and recorded anCompany recognized a $270 million pre-tax impairment charge of $63 million inrecorded within “Restructuring and asset related charges - net” in the interim Consolidated Statements of Operations related toOperation for the Nutrition & Biosciences segment. See Notes 13three months ended March 31, 2020 with the charge impacting definite-lived intangible assets and 22 for additional information.property, plant, and equipment.
NOTE 6 - SUPPLEMENTARY INFORMATION
| | | Sundry Income (Expense) - Net | Three Months Ended
June 30, | Six Months Ended
June 30, | Three Months Ended March 31, |
| In millions | 2019 | 2018 | 2019 | 2018 | 2020 | 2019 |
| Non-operating pension and other post employment benefit credits | $ | 18 |
| $ | 28 |
| $ | 39 |
| $ | 55 |
| |
| Non-operating pension and other post employment benefit (OPEB) credits | | $ | 11 |
| $ | 21 |
|
| Interest income | 9 |
| 11 |
| 49 |
| 21 |
| 2 |
| 40 |
|
Net gain on sales of other assets and investments 1 | 10 |
| — |
| 63 |
| 6 |
| |
Foreign exchange (losses) gains, net 2 | (17 | ) | 53 |
| (78 | ) | (122 | ) | |
| Net loss on divestiture and changes in joint venture ownership | — |
| (21 | ) | — |
| (21 | ) | |
Net gain on divestiture and sales of other assets and investments 1,2 | | 197 |
| 53 |
|
Foreign exchange (losses) gains, net | | (8 | ) | (61 | ) |
Miscellaneous income (expenses) - net 3 | (39 | ) | 11 |
| (8 | ) | 45 |
| 9 |
| 31 |
|
| Sundry income (expense) - net | $ | (19 | ) | $ | 82 |
| $ | 65 |
| $ | (16 | ) | $ | 211 |
| $ | 84 |
|
| |
1. | The six months ended June 30, 2019 includes a $51 million gain related to a sale of assets within the Electronics & Imaging product lines. |
| |
2. | Includes a $50 million foreign exchange loss for the six months ended June 30, 2018 related to adjustments to Historical EID's foreign currency exchange contracts as a result of U.S. tax reform. |
| |
3. | Miscellaneous income and expenses - net, for the three months and six months ended June 30, 2019 includes a $48 million charge reflecting a reduction in gross proceeds from lower withholding taxes related to a prior year legal settlement. The miscellaneous income for the three month and six month ended 2018 primarily relates to legal settlements. |
1.The three months ended March 31, 2020 reflects income of $197 million related to the gain on sale of the Compound Semiconductor Solutions business unit within the Electronics & Imaging segment.
2. The three months ended March 31, 2019 includes income of $51 million related to a sale of assets within the Electronics & Imaging segment.
3. Miscellaneous income (expenses) - net for the three months ended March 31, 2019 includes $26 million related to licensing income within the Safety & Construction segment.
Cash, Cash Equivalents and Restricted Cash
TheFrom time to time, the Company is required to set aside funds for various activities that arise in the normal course of business including, but not limited to, legal matters and other agreements.business. These funds typically have legal restrictions associated with them and are deposited in an escrow account or held in a separately identifiable account by the Company. Historical EID entered into a trust agreement in 2013 (as amended and restated in 2017), establishing and requiring Historical EID to fund a trust (the "Trust") for cash obligations under certain non-qualified benefit and deferred compensation plans upon a change in control event as defined in the Trust agreement. Under the Trust agreement, the consummation of the Merger was a change in control event. After the distribution of Corteva, DuPont continues to be responsible for funding the portion of the Trust assets related to Corteva employees were transferred to a new trust for Corteva (the "Corteva Trust"). As a result, the Trust currently held by DuPont relates to funding obligations to DuPont employees. At June 30, 2019,March 31, 2020, the Company had restricted cash of $40$34 million ($4337 million at December 31, 2018)2019) included in "Other current assets" in the interim Condensed Consolidated Balance Sheets which was completely attributed to the Trust.
Accrued and Other Current Liabilities
"Accrued and other current liabilities" in the interim Condensed Consolidated Balance Sheets were $1,652$1,434 million at June 30, 2019March 31, 2020 and $1,129$1,342 million at December 31, 2018.2019. No component of "Accrued and other current liabilities" was more than 5 percent of total current liabilities at March 31, 2020. Accrued payroll, which is a component of "Accrued and other current liabilities," was $366 million at June 30, 2019 and $506$479 million at December 31, 2018.2019. No other componentscomponent of "Accrued and other current liabilities" werewas more than 5 percent of total current liabilities.liabilities at December 31, 2019.
NOTE 7 - INCOME TAXES
For periods between the Merger and the Distributions, DuPont's consolidated federal income tax group and consolidated tax return included the Dow and Corteva entities. Generally, the consolidated tax liability of the DuPont U.S. tax group for each year was apportioned among the members of the consolidated group in accordance with the terms of the Amended and Restated Tax Matters Agreement. DuPont, Corteva and Dow intend that to the extent Federal and/or State corporate income tax liabilities are reduced through the utilization of tax attributes of the other, settlement of any receivable and payable generated from the use of the other party’s sub-group attributes will be in accordance with the Amended and Restated Tax Matters Agreement.
On December 22, 2017, the Tax Cuts and Jobs Act (“The Act”) was enacted. The Act reduces the U.S. federal corporate income tax rate from 35 percent to 21 percent, requires companies to pay a one-time transition tax on earnings of foreign subsidiaries that were previously tax deferred, creates new provisions related to foreign sourced earnings, eliminates the domestic manufacturing deduction and moves towards a territorial system. At December 31, 2018, the Company had completed its accounting for the tax effects of The Act.
As a result of The Act, the Company remeasured its U.S. federal deferred tax assets and liabilities based on the rates at which they are expected to reverse in the future, which is generally 21 percent. For the three and six months ended June 30, 2018, the Company recorded a charge of $7 million and $24 million, respectively, to “Provision for income taxes on continuing operations" in the interim Consolidated Statements of Operations to adjust the provisional amount related to the remeasurement of the Company's deferred tax balance.
For the six months ended June 30, 2018, the Company recorded an indirect impact of The Act related to prepaid tax on the intercompany sale of inventory. The amount recorded related to the inventory was a $54 million charge to "Provision for income taxes on continuing operations."
During the first and second quarters of 2019, in connection with the Distributions, the Company repatriated certain funds from its foreign subsidiaries that were not needed to finance local operations or separation activities. For the first quarter of 2019, the Company recorded a tax charge of $10 million, associated with these repatriation activities to "Provision for income taxes on continuing operations." There were no charges associated with these repatriation activities in the second quarter of 2019. Beyond these repatriations, the Company continues to assert indefinite reinvestment related to certain investments in foreign subsidiaries.
The Company's effective tax rate fluctuates based on, among other factors, where income is earned and the level of income relative to tax attribute.attributes. The effective tax rate on continuing operations for the secondfirst quarter of 20192020 was (16.4)(7.8) percent, compared with an effective tax rate of 76.2 percent for the second quarter of 2018. For the first six months of 2019, the effective tax rate on continuing operations was (5.8) percent, compared with 134.455.2 percent for the first six months of 2018. The negative tax rate in the second quarter of 2019 and2019. The effective tax rate for the first six monthsquarter of 2019,2020 was principally the result of the non-tax-deductible goodwill impairmentsimpairment charge impacting the Nutrition & Biosciences and Non-Core segments. Non-core segment. See Note 11 for more information regarding the goodwill impairment charge.
Each year the Company files hundreds of tax returns in the various national, state and local income taxing jurisdictions in which it operates. These tax returns are subject to examination and possible challenge by the tax authorities. Positions challenged by the tax authorities may be settled or appealed by the Company. As a result, there is an uncertainty in income taxes recognized in the Company’s financial statements in accordance with accounting for income taxes and accounting for uncertainty in income taxes. The ultimate resolution of such uncertainties is not expected to have a material impact on the Company's results of operations.
NOTE 8 - EARNINGS PER SHARE CALCULATIONS
On May 23, 2019, stockholders of DowDuPont approved a reverse stock split of the Company's common stock at a ratio of not less than 2-for-5 and not greater than 1-for-3, with the exact ratio determined by and subject to final approval of the Company’s board of directors. The board of directors approved the Reverse Stock Split with a ratio of 1 new share of DowDuPont common stock for 3 shares of current DowDuPont common stock with par value of $0.01 per share. The Reverse Stock Split became effective immediately following the Corteva Distribution on June 1, 2019. All comparable periods presented have been retrospectively revised to reflect this change.
The following tables provide earnings per share calculations for the three and six months ended June 30, 2019March 31, 2020 and 2018:2019:
| | | Net Income for Earnings Per Share Calculations - Basic & Diluted | Three Months Ended | Six Months Ended | Three Months Ended March 31, |
In millions | June 30, 2019 | June 30, 2018 | June 30, 2019 | June 30, 2018 | 2020 | 2019 |
| (Loss) income from continuing operations, net of tax | $ | (1,103 | ) | $ | 31 |
| $ | (1,177 | ) | $ | (42 | ) | |
| Net income (loss) from continuing operations attributable to noncontrolling interests | 9 |
| (2 | ) | 13 |
| 11 |
| |
| Loss from continuing operations, net of tax | | $ | (610 | ) | $ | (74 | ) |
| Net income from continuing operations attributable to noncontrolling interests | | 6 |
| 4 |
|
Net income from continuing operations attributable to participating securities 1 | — |
| 7 |
| 1 |
| 13 |
| — |
| 1 |
|
| (Loss) income from continuing operations attributable to common stockholders | $ | (1,112 | ) | $ | 26 |
| $ | (1,191 | ) | $ | (66 | ) | |
| Loss from continuing operations attributable to common stockholders | | $ | (616 | ) | $ | (79 | ) |
| Income from discontinued operations, net of tax | 566 |
| 1,773 |
| 1,212 |
| 2,983 |
| — |
| 646 |
|
| Net income from discontinued operations attributable to noncontrolling interests | 25 |
| 37 |
| 72 |
| 68 |
| — |
| 47 |
|
| Income from discontinued operations attributable to common stockholders | 541 |
| 1,736 |
| 1,140 |
| 2,915 |
| — |
| 599 |
|
| Net (loss) income attributable to common stockholders | $ | (571 | ) | $ | 1,762 |
| $ | (51 | ) | $ | 2,849 |
| $ | (616 | ) | $ | 520 |
|
| | | Earnings Per Share Calculations - Basic | Three Months Ended | Six Months Ended | Three Months Ended March 31, |
| June 30, 2019 | June 30, 2018 | June 30, 2019 | June 30, 2018 | |
| Dollars per share | 2020 | 2019 |
| (Loss) income from continuing operations attributable to common stockholders | $ | (1.48 | ) | $ | 0.03 |
| $ | (1.59 | ) | $ | (0.09 | ) | |
| Loss from continuing operations attributable to common stockholders | | $ | (0.83 | ) | $ | (0.11 | ) |
| Income from discontinued operations, net of tax | 0.72 |
| 2.26 |
| 1.52 |
| 3.78 |
| — |
| 0.80 |
|
| Net (loss) income attributable to common stockholders | $ | (0.76 | ) | $ | 2.29 |
| $ | (0.07 | ) | $ | 3.69 |
| $ | (0.83 | ) | $ | 0.69 |
|
| | | Earnings Per Share Calculations - Diluted | Three Months Ended | Six Months Ended | Three Months Ended March 31, |
| June 30, 2019 | June 30, 2018 | June 30, 2019 | June 30, 2018 | |
| Dollars per share | 2020 | 2019 |
| (Loss) income from continuing operations attributable to common stockholders | $ | (1.48 | ) | $ | 0.03 |
| $ | (1.59 | ) | $ | (0.09 | ) | |
| Loss from continuing operations attributable to common stockholders | | $ | (0.83 | ) | $ | (0.11 | ) |
| Income from discontinued operations, net of tax | 0.72 |
| 2.24 |
| 1.52 |
| 3.78 |
| — |
| 0.80 |
|
| Net (loss) income attributable to common stockholders | $ | (0.76 | ) | $ | 2.27 |
| $ | (0.07 | ) | $ | 3.69 |
| $ | (0.83 | ) | $ | 0.69 |
|
| | Share Count Information | Three Months Ended | Six Months Ended | |
| June 30, 2019 | June 30, 2018 | June 30, 2019 | June 30, 2018 | Three Months Ended March 31, |
| Shares in millions | 2020 | 2019 |
| Weighted-average common shares - basic | 749.0 |
| 769.6 |
| 749.6 |
| 771.0 |
| 738.6 |
| 750.0 |
|
| Plus dilutive effect of equity compensation plans | — |
| 4.9 |
| — |
| — |
| — |
| — |
|
| Weighted-average common shares - diluted | 749.0 |
| 774.5 |
| 749.6 |
| 771.0 |
| 738.6 |
| 750.0 |
|
Stock options and restricted stock units excluded from EPS calculations 2 | 2.5 |
| 3.2 |
| 2.4 |
| 2.5 |
| 6.4 |
| 6.4 |
|
| |
| 1. | Historical Dow restricted stock units are considered participating securities due to Historical Dow's practice of paying dividend equivalents on unvested shares. |
2. These outstanding options to purchase shares of common stock and restricted stock units were excluded from the calculation of diluted earnings per share because the effect of including them would have been antidilutive.
NOTE 9 - ACCOUNTS AND NOTES RECEIVABLE - NET
|
| | | | | | |
| In millions | June 30,
2019 | Dec 31,
2018 |
Accounts receivable – trade 1 | $ | 3,288 |
| $ | 2,891 |
|
| Notes receivable – trade | 58 |
| 69 |
|
Other 2 | 868 |
| 431 |
|
| Total accounts and notes receivable - net | $ | 4,214 |
| $ | 3,391 |
|
| |
1. | Accounts receivable – trade is net of allowances of $9 million at June 30, 2019 and $10 million at December 31, 2018. Allowances are equal to the estimated uncollectible amounts. That estimate is based on historical collection experience, current economic and market conditions, and review of the current status of customers' accounts. |
| |
2. | Other includes receivables in relation to value added tax, fair value of derivative instruments, indemnification assets, and general sales tax and other taxes. No individual group represents more than ten percent of total receivables. |
Accounts and notes receivable are carried at amounts that approximate fair value.
NOTE 109 - INVENTORIES
|
| | | | | | |
| Inventories | June 30, 2019 | Dec 31, 2018 |
| In millions |
| Finished goods | $ | 2,645 |
| $ | 2,599 |
|
| Work in process | 888 |
| 833 |
|
| Raw materials | 623 |
| 560 |
|
| Supplies | 234 |
| 115 |
|
| Total inventories | $ | 4,390 |
| $ | 4,107 |
|
Effective June 1, 2019, after the Corteva Distribution, the Company changed its method of valuing certain inventories of the specialty products business from the LIFO method to the average cost method. Management believes that the change in accounting is preferable as it results in a consistent method to value inventory across all regions of the business, it improves comparability with industry peers, and it more closely resembles the physical flow of inventory. The effects of the change in accounting principle from LIFO to average cost have been retrospectively applied to all periods presented. This change resulted in an unfavorable adjustment to "(Accumulated Deficit) Retained Earnings" of $280 million as of January 1, 2018. In addition, certain financial statement line items in the Company’s interim Consolidated Statement of Operations for the three and six months ended June 30, 2018 and interim Condensed Consolidated Balance Sheet as of December 31, 2018 were adjusted as follows:
|
| | | | | | | | | | | | | | | | | | |
| Consolidated Statement of Operations | Three Months Ended June 30, 2018 | Six Months Ended June 30, 2018 |
| In millions | As Computed under LIFO | As Computed under Average Cost | Effect of Change | As Computed under LIFO | As Computed under Average Cost | Effect of Change |
| Cost of sales | $ | 4,086 |
| $ | 4,085 |
| $ | (1 | ) | $ | 7,882 |
| $ | 7,890 |
| $ | 8 |
|
| Provision for income taxes on continuing operations | $ | 99 |
| $ | 99 |
| $ | — |
| $ | 162 |
| $ | 164 |
| $ | 2 |
|
| Net income | $ | 1,803 |
| $ | 1,804 |
| $ | 1 |
| $ | 2,951 |
| $ | 2,941 |
| $ | (10 | ) |
|
| | | | | | | | | |
| Consolidated Balance Sheet | December 31, 2018 |
| In millions | As Computed under LIFO | As Computed under Average Cost | Effect of Change |
| Inventories | $ | 4,472 |
| $ | 4,107 |
| $ | (365 | ) |
| Deferred income tax liabilities | $ | 3,998 |
| $ | 3,912 |
| $ | (86 | ) |
| Retained earnings | $ | 30,536 |
| $ | 30,257 |
| $ | (279 | ) |
Basic and diluted earnings per share from continuing operations were not materially effected for the three and six months ended June 30, 2018, as a result of the above accounting policy change.
There was no impact on cash used by operating activities for prior year periods as a result of the above policy change.
The following table compares the amounts that would have been reported under LIFO with the amounts recorded under the average cost method in the Consolidated Financial Statements as of March 31, 2019 and for the three months then ended:
|
| | | | | | | | | |
| Consolidated Statement of Operations | Three Months Ended March 31, 2019 |
| In millions | As Computed under LIFO | As Computed under Average Cost | Effect of Change |
| Cost of sales | $ | 3,617 |
| $ | 3,621 |
| $ | 4 |
|
| Benefit from income taxes on continuing operations | $ | (86 | ) | $ | (91 | ) | $ | (5 | ) |
| Net income | $ | 571 |
| $ | 572 |
| $ | 1 |
|
|
| | | | | | | | | |
| Consolidated Balance Sheet | March 31, 2019 |
| In millions | As Computed under LIFO | As Computed under Average Cost | Effect of Change |
| Inventories | $ | 4,717 |
| $ | 4,348 |
| $ | (369 | ) |
| Deferred income tax liabilities | $ | 3,679 |
| $ | 3,588 |
| $ | (91 | ) |
| Retained earnings | $ | 29,764 |
| $ | 29,486 |
| $ | (278 | ) |
The following table compares the amounts that would have been reported under LIFO with the amounts recorded under the average cost method in the Consolidated Financial Statements as of June 30, 2019 and for the three and six months then ended:
|
| | | | | | | | | | | | | | | | | | |
| Consolidated Statement of Operations | Three Months Ended June 30, 2019 | Six Months Ended June 30, 2019 |
| In millions | As Computed under LIFO | As Reported under Average Cost | Effect of Change | As Computed under LIFO | As Reported under Average Cost | Effect of Change |
| Cost of sales | $ | 3,498 |
| $ | 3,496 |
| $ | (2 | ) | $ | 7,115 |
| $ | 7,117 |
| $ | 2 |
|
| Provision for income taxes on continuing operations | $ | 152 |
| $ | 155 |
| $ | 3 |
| $ | 66 |
| $ | 64 |
| $ | (2 | ) |
| Net (loss) income | $ | (536 | ) | $ | (537 | ) | $ | (1 | ) | $ | 35 |
| $ | 35 |
| $ | — |
|
|
| | | | | | | | | |
| Consolidated Balance Sheet | June 30, 2019 |
| In millions | As Computed under LIFO | As Reported under Average Cost | Effect of Change |
| Inventories | $ | 4,763 |
| $ | 4,390 |
| $ | (373 | ) |
| Deferred income tax liabilities | $ | 3,750 |
| $ | 3,662 |
| $ | (88 | ) |
| Accumulated deficit | $ | (8,014 | ) | $ | (8,299 | ) | $ | (285 | ) |
Basic and diluted earnings per share from continuing operations were not materially effected for the three months ended March 31, 2019 nor for either the three or six months ended June 30, 2019, as a result of the above accounting policy change.
There was no impact on cash used by operating activities for current year periods as a result of the above policy change.
NOTE 11 - PROPERTY, PLANT, AND EQUIPMENT
|
| | | | | | | | | |
| | Estimated Useful Lives (Years) | June 30, 2019 | Dec 31, 2018 |
| In millions |
| Land and land improvements | 0 | - | 25 | $ | 795 |
| $ | 944 |
|
| Buildings | 1 | - | 50 | 2,656 |
| 2,581 |
|
| Machinery, equipment, and other | 1 | - | 25 | 9,580 |
| 9,133 |
|
| Construction in progress | | | | 1,442 |
| 1,458 |
|
| Total property, plant and equipment | | | | $ | 14,473 |
| $ | 14,116 |
|
| Total accumulated depreciation | | | | $ | 4,667 |
| $ | 4,199 |
|
| Total property, plant and equipment - net |
| | | $ | 9,806 |
| $ | 9,917 |
|
| | | | Three Months Ended
June 30, | Six Months Ended
June 30, | |
| Inventories | | March 31, 2020 | December 31, 2019 |
| In millions | 2019 | 2018 | 2019 | 2018 |
| Depreciation expense | $ | 255 |
| $ | 285 |
| $ | 526 |
| $ | 571 |
| |
| Finished goods | | $ | 2,731 |
| $ | 2,621 |
|
| Work in process | | 858 |
| 855 |
|
| Raw materials | | 589 |
| 599 |
|
| Supplies | | 232 |
| 244 |
|
| Total inventories | | $ | 4,410 |
| $ | 4,319 |
|
NOTE 1210 - NONCONSOLIDATED AFFILIATES
The Company's investments in companies accounted for using the equity method ("nonconsolidated affiliates"), by classification in the interim Condensed Consolidated Balance Sheets, are shown in the following table:
| | | Investments in Nonconsolidated Affiliates | June 30, 2019 | Dec 31, 2018 | Mar 31, 2020 | Dec 31, 2019 |
| In millions |
| Investment in nonconsolidated affiliates | $ | 1,653 |
| $ | 1,745 |
| |
| Investments in nonconsolidated affiliates | | $ | 1,227 |
| $ | 1,204 |
|
| Accrued and other current liabilities | (81 | ) | (81 | ) | (84 | ) | (85 | ) |
| Other noncurrent obligations | (635 | ) | (495 | ) | (351 | ) | (358 | ) |
| Net investment in nonconsolidated affiliates | $ | 937 |
| $ | 1,169 |
| $ | 792 |
| $ | 761 |
|
Subsequent to the Distributions, theThe Company maintained an ownership interest in 2221 nonconsolidated affiliates at June 30, 2019.March 31, 2020. The following table reflects the Company's principal nonconsolidated affiliates and its ownership interest (direct and indirect) for each at June 30, 2019:March 31, 2020:
|
| | | |
| | Country | Ownership Interest |
| | 6/30/2019March 31, 2020 |
| The HSC Group: | | |
DC HSC Holdings LLC 1 | United States | 50.0 | % |
| Hemlock Semiconductor L.L.C. | United States | 50.1 | % |
| |
| 1. | DC HSC Holdings LLC holds an 80.5 percent indirect ownership interest in Hemlock Semiconductor Operations LLC. |
Sales to nonconsolidated affiliates represented less than 3 percent of total net sales for the three months ended March 31, 2020 and 2019. Sales to nonconsolidated affiliates are primarily related to the sale of trichlorosilane, a raw material used in the production of polycrystalline silicon, to the HSC Group
The carrying valueGroup. Sales of the Company's investments inthis raw material to the HSC Group which includes Hemlock Semiconductor L.L.C.are reflected in Non-Core. Purchases from nonconsolidated affiliates represented approximately 2 percent of “Cost of sales” for the three months ended March 31, 2020 and DC HSC Holdings LLC, was adjusted as a result of the HSC Group's adoption of Topic 606 on January 1, 2019 in accordance with the effective date of Topic 606 for non-public companies. The resulting impact to the Company's investments in the 2019.
HSC Group was a reduction to "Investment in nonconsolidated affiliates" of $71 million and an increase to "Other noncurrent obligations" of $168 million, as well as an increase to "Deferred income tax assets" of $56 million and a reduction to "(Accumulated Deficit) Retained earnings" of $183 million in the consolidated balance sheet at January 1, 2019.
The following table reflects the carrying value of the HSC Group investments at June 30, 2019March 31, 2020 and December 31, 2018:2019:
|
| | | | | | | |
| Investment in the HSC Group | | Investment |
| In millions | Balance Sheet Classification | Mar 31, 2020 | Dec 31, 2019 |
| Hemlock Semiconductor L.L.C. | Other noncurrent obligations | $ | (351 | ) | $ | (358 | ) |
| DC HSC Holdings LLC | Investments in nonconsolidated affiliates | $ | 97 |
| $ | 87 |
|
|
| | | | | | | |
| Investment in the HSC Group | | Investment |
| In millions | Balance Sheet Classification | June 30, 2019 | Dec 31, 2018 |
| Hemlock Semiconductor L.L.C. | Other noncurrent obligations | $ | (635 | ) | $ | (495 | ) |
| DC HSC Holdings LLC | Investment in nonconsolidated affiliates | $ | 495 |
| $ | 535 |
|
The following is summarized financial information for the Company's significantprincipal nonconsolidated equity method investments. The amounts shown below represent 100 percent of these equity method investment’sinvestments' results of operations:
| | | Results of Operations | Six Months Ended | Three Months Ended March 31, |
| In millions | June 30, 2019 | June 30, 2018 | 2020 | 2019 |
| Revenues | $ | 312 |
| $ | 400 |
| |
| Costs of good sold | $ | 167 |
| $ | 258 |
| |
Revenues 1 | | $ | 185 |
| $ | 185 |
|
Cost of sales 1 | | $ | 127 |
| $ | 107 |
|
| Income from continuing operations | $ | 135 |
| $ | 164 |
| $ | 40 |
| $ | 63 |
|
| Net income attributed to entities | $ | 119 |
| $ | 145 |
| $ | 35 |
| $ | 52 |
|
| |
| 1. | Includes sales and cost of sales of $22 million and $21 million for the three months ended March 31, 2020 and 2019, respectively, that have not been eliminated between Hemlock Semiconductor L.L.C and DC HSC Holdings in the presentation of the summarized income statement information above. |
NOTE 1311 - GOODWILL AND OTHER INTANGIBLE ASSETS
The changes in the carrying amounts of goodwill during the sixthree months ended June 30, 2019March 31, 2020 were as follows:
|
| | | | | | | | | | | | | | | | | | |
| | Elect. & Imaging | Nutrition & Biosciences | Transp. & Industrial | Safety & Const. | Non-Core | Total |
| In millions |
Balance at December 31, 2019 | $ | 7,092 |
| $ | 11,012 |
| $ | 6,931 |
| $ | 6,711 |
| $ | 1,405 |
| $ | 33,151 |
|
| Acquisitions | — |
| — |
| — |
| 53 |
| — |
| 53 |
|
| Divestitures | (199 | ) | — |
| — |
| — |
| — |
| (199 | ) |
| Impairments | — |
| — |
| — |
| — |
| (533 | ) | (533 | ) |
| Currency Translation Adjustment | (11 | ) | (111 | ) | (25 | ) | (26 | ) | — |
| (173 | ) |
| Measurement Period Adjustments | — |
| — |
| — |
| 18 |
| — |
| 18 |
|
| Balance at March 31, 2020 | $ | 6,882 |
| $ | 10,901 |
| $ | 6,906 |
| $ | 6,756 |
| $ | 872 |
| $ | 32,317 |
|
|
| | | | | | | | | | | | | | | | | | |
| | Elect. & Imaging | Nutrition & Biosciences | Transp. & Industrial | Safety & Const. | Non-Core | Total |
| In millions |
Balance at December 31, 2018 1 | $ | 6,960 |
| $ | 12,109 |
| $ | 6,967 |
| $ | 6,698 |
| $ | 1,762 |
| $ | 34,496 |
|
| Impairments | — |
| (933 | ) | — |
| — |
| (242 | ) | (1,175 | ) |
| Currency Translation Adjustment | (1 | ) | (17 | ) | 8 |
| (6 | ) | — |
| (16 | ) |
| Other Goodwill Adjustments | — |
| (13 | ) | — |
| — |
| 38 |
| 25 |
|
| Balance at June 30, 2019 | $ | 6,959 |
| $ | 11,146 |
| $ | 6,975 |
| $ | 6,692 |
| $ | 1,558 |
| $ | 33,330 |
|
| |
1. | Updated for changes in reportable segments effective in the second quarter of 2019. Refer to Note 23 for additional information. |
The Company tests goodwill for impairment annually during the fourth quarter as of October 1, or more frequently when events or changes in circumstances indicate that the fair value is below its carrying value. As a result of the related acquisition method of accounting in connection with the Merger, Historical EID’s assets and liabilities were measured at fair value resulting in increases to the Company’s goodwill and other intangible assets. The fair value valuation increased the risk that any declines in financial projections, including changes to key assumptions, could have a material, negative impact on the fair value of the Company’s reporting units and assets, and therefore could result in an impairment.
In preparation for the Corteva Distribution, Historical EID completed the separationExpectations of the assets and liabilitiesproceeds related to its specialty products businesses into separate legal entities (the “SP Legal Entities”)certain potential divestitures within the Non-Core segment gave rise to fair value indicators and, on May 1, 2019, Historical EID completed the Internal SP Distribution. The Internal SP Distributionthus, served as a triggering eventevents requiring the Company to perform an impairment analysisanalyses related to goodwill carried by its Historical EID existing reporting units as of May 1, 2019. Subsequent to the Corteva Distribution, on June 1, 2019, the Company realigned certain businesses resulting in changes to its management and reporting structure, including the creation of a new Non-Core segment.goodwill. As part of the Second Quarter Segment Realignment, the Company assessed and re-defined certain reporting units effective June 1, 2019, including reallocation of goodwill on a relative fair value basis as applicable to new reporting units identified. Goodwill impairment analyses were then performed for reporting units impacted by the Second Quarter Segment Realignment.
In connection with the analyses described above, the Company recorded aggregate, pre-tax, non-cash impairment charges of $1,175 million for the three and six months ended June 30, 2019 impacting the Nutrition & Biosciences and Non-Core segments. As part of this analysis, the Company determined that the fair value of its Industrial BiosciencesPhotovoltaic and Advanced Materials (“PVAM”) reporting unit was below carryingits carry value resulting in a pre-tax, non-cash goodwillan impairment charge to goodwill. Valuations of $933 million. The Industrial Biosciencesthe PVAM reporting unit partunder a combination of the Nutrition & Biosciences segment prior to the Second Quarter Segment Realignment, was comprised solely of Historical EID assetsmarket approach and liabilities, the carrying values of which were measured at fair value in connection with the Merger, and thus considered at risk for impairment. Revised financial projections of the Industrial Biosciences reporting unitincome approach reflect unfavorable market conditions, driven by slowed demand in the biomaterials business unit which was realigned to the new Non-Core segment effective June 1, 2019, coupled with challengingsoftening conditions in U.S. bioethanol markets. These revised financial projections resulted in a reduction in the long-term forecasts of sales and profitabilityphotovoltaics markets as compared to prior projections. The $242estimates. In connection with this analysis, the Company recorded a pre-tax, non-cash impairment charge of $533 million in goodwill impairment chargesfor the three months ended March 31, 2020 impacting the Non-Core segment also relates to multiple reporting units comprised solely of Historical EID assets and liabilities, the carrying values of which were measured at fair value in connection with the Merger, and thus considered at risk for impairment. The impairment charges impacting Non-Core were determined through utilization of the market approach which was considered most appropriate as the Company continues to evaluate strategic options for these businesses.segment.
The Company analyses above usingCompany's analysis uses the discounted cash flow modelsmodel (a form of the income approach) utilizing Level 3 unobservable inputs. The Company’s significant assumptions in these analysesthis analysis include, but are not limited to, future cash flow projections, the weighted average cost of capital, the terminal growth rate, and the tax rate. The Company’s estimates of future cash flows are based on current regulatory and economic climates, recent operating results, and planned business strategies. These estimates could be negatively affected by changes in federal, state, or local regulations or economic downturns. Future cash flow estimates are, by their nature, subjective and actual results may differ materially from the Company’s estimates. If the Company’s ongoing estimates of future cash flows are not met, the Company may have to record additional impairment charges in future periods. As referenced, the Company also uses a form of the market approach (utilizes Level 3 unobservable inputs), which is derived from metrics of publicly traded companies or historically completed transactions of comparable businesses. The selection of comparable businesses is based on the markets in which the reporting units operate giving consideration to risk profiles, size, geography, and diversity of products and services.approach. As such, the Company believes the current assumptions and estimates utilized are both reasonable and appropriate.
COVID-19 continues to adversely impact the broader global economy and has caused significant volatility in financial markets. If there is a of lack of recovery or further global softening in certain markets, mainly in which the Transportation & Industrial segment operates in such as automotive, oil & gas and select industrial end-markets, or a sustained decline in the value of the Company's common stock, the Company may be required to perform additional impairment assessments for its goodwill, other intangibles, and long-lived assets, the results of which could result in material impairment charges.
Other Intangible Assets
The gross carrying amounts and accumulated amortization of other intangible assets by major class are as follows:
| | | | June 30, 2019 | December 31, 2018 | March 31, 2020 | December 31, 2019 |
| In millions | Gross Carrying Amount | Accum Amort | Net | Gross Carrying Amount | Accum Amort | Net | Gross Carrying Amount | Accum Amort | Net | Gross Carrying Amount | Accum Amort | Net |
| Intangible assets with finite lives: | | | | | | | | | | | | |
| Developed technology | $ | 4,342 |
| $ | (1,179 | ) | $ | 3,163 |
| $ | 4,362 |
| $ | (1,010 | ) | $ | 3,352 |
| $ | 4,356 |
| $ | (1,523 | ) | $ | 2,833 |
| $ | 4,343 |
| $ | (1,361 | ) | $ | 2,982 |
|
| Trademarks/tradenames | 1,244 |
| (369 | ) | 875 |
| 1,245 |
| (328 | ) | 917 |
| 2,416 |
| (755 | ) | 1,661 |
| 2,433 |
| (455 | ) | 1,978 |
|
| Customer-related | 9,007 |
| (1,973 | ) | 7,034 |
| 9,029 |
| (1,720 | ) | 7,309 |
| 8,920 |
| (2,339 | ) | 6,581 |
| 8,986 |
| (2,229 | ) | 6,757 |
|
| Other | 329 |
| (120 | ) | 209 |
| 306 |
| (114 | ) | 192 |
| 300 |
| (214 | ) | 86 |
| 303 |
| (98 | ) | 205 |
|
| Total other intangible assets with finite lives | $ | 14,922 |
| $ | (3,641 | ) | $ | 11,281 |
| $ | 14,942 |
| $ | (3,172 | ) | $ | 11,770 |
| $ | 15,992 |
| $ | (4,831 | ) | $ | 11,161 |
| $ | 16,065 |
| $ | (4,143 | ) | $ | 11,922 |
|
| Intangible assets with indefinite lives: | | | | | | | | | | | | |
| IPR&D | $ | — |
| $ | — |
| $ | — |
| $ | 15 |
| $ | — |
| $ | 15 |
| |
| Trademarks/tradenames | 2,869 |
| — |
| 2,869 |
| 2,870 |
| — |
| 2,870 |
| 1,673 |
| — |
| 1,673 |
| 1,671 |
| — |
| 1,671 |
|
| Total other intangible assets | 2,869 |
| — |
| 2,869 |
| 2,885 |
| — |
| 2,885 |
| 1,673 |
| — |
| 1,673 |
| 1,671 |
| — |
| 1,671 |
|
| Total | $ | 17,791 |
| $ | (3,641 | ) | $ | 14,150 |
| $ | 17,827 |
| $ | (3,172 | ) | $ | 14,655 |
| $ | 17,665 |
| $ | (4,831 | ) | $ | 12,834 |
| $ | 17,736 |
| $ | (4,143 | ) | $ | 13,593 |
|
During the first quarter of 2020, the Company recorded non-cash impairment charges related to definite-lived intangible assets impacting the Non-Core segment. See Note 5 for further discussion.
The following table provides the net carrying value of other intangible assets by segment:
| | | Net Intangibles by Segment | June 30, 2019 | Dec 31, 2018 | Mar 31, 2020 | Dec 31, 2019 |
| In millions |
| Electronics & Imaging | $ | 1,925 |
| $ | 2,037 |
| $ | 1,764 |
| $ | 1,833 |
|
| Nutrition & Biosciences | 4,664 |
| 4,823 |
| 3,989 |
| 4,377 |
|
| Transportation & Industrial | 3,722 |
| 3,833 |
| 3,524 |
| 3,590 |
|
| Safety & Construction | 3,145 |
| 3,244 |
| 3,048 |
| 3,082 |
|
| Non-Core | 694 |
| 718 |
| 509 |
| 711 |
|
| Total | $ | 14,150 |
| $ | 14,655 |
| $ | 12,834 |
| $ | 13,593 |
|
The following table provides information regarding amortization expense related to other intangible assets:
| | | Amortization Expense | Three Months Ended | Six Months Ended | Three Months Ended March 31, |
| In millions | June 30, 2019 | June 30, 2018 | June 30, 2019 | June 30, 2018 | 2020 | 2019 |
| Other intangible assets | $ | 252 |
| $ | 266 |
| $ | 508 |
| $ | 531 |
| $ | 533 |
| $ | 256 |
|
Total estimated amortization expense for the remainder of 20192020 and the five succeeding fiscal years is as follows:
| | | Estimated Amortization Expense | | |
| In millions | | |
| Remainder of 2019 | $ | 512 |
| |
| 2020 | $ | 1,015 |
| $ | 1,595 |
|
| 2021 | $ | 1,007 |
| $ | 1,008 |
|
| 2022 | $ | 993 |
| $ | 968 |
|
| 2023 | $ | 961 |
| $ | 925 |
|
| 2024 | $ | 856 |
| $ | 826 |
|
| 2025 | | $ | 789 |
|
NOTE 1412 - SHORT-TERM BORROWINGS, LONG-TERM DEBT AND AVAILABLE CREDIT FACILITIES
The following tables summarize the Company's short-term borrowings and finance lease obligations and long-term debt:Debt Offering
|
| | | | | | |
| Short-term borrowings and finance lease obligations | | |
| In millions | June 30, 2019 | Dec 31, 2018 |
| Commercial paper | $ | 1,610 |
| $ | — |
|
| Notes payable to banks and other lenders | 5 |
| 4 |
|
Long-term debt due within one year1 | 6 |
| 11 |
|
| Total short-term borrowings and finance lease obligations | $ | 1,621 |
| $ | 15 |
|
| |
1. | Includes finance lease obligations due within one year. |
The weighted-average interest rate on notes payable and commercial paper at June 30, 2019 and December 31, 2018 was 2.72 percent and 8.25 percent, respectively. The decrease in the interest rate from 2018 is primarily due to commercial paper issuance at lower interest rates. The Company issued $1,610 million of commercial paper in the second quarter of 2019, of which approximately $1,400 million was issued in anticipation of the Corteva Distribution (the “Funding CP Issuance”).
|
| | | | | | | | | | |
| Long-Term Debt | June 30, 2019 | December 31, 2018 |
| In millions | Amount | Weighted Average Rate | Amount | Weighted Average Rate |
| Promissory notes and debentures: | | | | |
| Final maturity 2020 | $ | 2,000 |
| 3.63 | % | $ | 2,000 |
| 3.68 | % |
| Final maturity 2023 | 2,800 |
| 4.14 | % | 2,800 |
| 4.16 | % |
| Final maturity 2024 and thereafter | 7,900 |
| 4.98 | % | 7,900 |
| 4.98 | % |
| Other facilities: | | | | |
| Term loan due 2022 | 3,000 |
| 3.51 | % | — |
| — | % |
| Other loans | 14 |
| 4.18 | % | 14 |
| 4.32 | % |
| Finance lease obligations | 3 |
| | 25 |
| |
| Less: Unamortized debt discount and issuance costs | 103 |
| | 104 |
| |
Less: Long-term debt due within one year 1, 2 | 6 |
| | 11 |
| |
| Total | $ | 15,608 |
| | $ | 12,624 |
| |
| |
1. | Presented net of current portion of unamortized debt issuance costs. |
| |
2. | Includes finance lease obligations due within one year. |
Principal payments of long-term debt for the remainder of 2019 and the five succeeding fiscal years is as follows:
|
| | | |
| Maturities of Long-Term Debt for Next Five Years at June 30, 2019 | Total |
| In millions |
| Remainder of 2019 | $ | 4 |
|
| 2020 | $ | 2,005 |
|
| 2021 | $ | 6 |
|
| 2022 | $ | 3,001 |
|
| 2023 | $ | 2,800 |
|
| 2024 | $ | — |
|
The estimated fair value of the Company's long-term borrowings was determined using Level 2 inputs within the fair value hierarchy, as described in Note 22. Based on quoted market prices for the same or similar issues, or on current rates offered toOn May 1, 2020, the Company for debt of the same remaining maturities, the fair value of the Company's long-term borrowings, not including long-term debt due within one year, was $17,163 million and $13,080 million at June 30, 2019 and December 31, 2018, respectively.
Available Committed Credit Facilities
The following table summarizes the Company's credit facilities:
|
| | | | | | | | | |
| Committed and Available Credit Facilities at June 30, 2019 | | |
| In millions | Effective Date | Committed Credit | Credit Available | Maturity Date | Interest |
| Term Loan Facility | May 2019 | $ | 3,000 |
| $ | — |
| May 2022 | Floating Rate |
| Revolving Credit Facility, Five-year | May 2019 | 3,000 |
| 2,982 |
| May 2024 | Floating Rate |
| 364-day Revolving Credit Facility | June 2019 | 750 |
| 750 |
| June 2020 | Floating Rate |
| Total Committed and Available Credit Facilities | | $ | 6,750 |
| $ | 3,732 |
| | |
Senior Notes
In contemplation of the separations and distributions and in preparation to achieve the intended credit profiles of Corteva, Dow and DuPont, in the fourth quarter of 2018, the Company consummated acompleted an underwritten public underwritten offer of eight seriesoffering of senior unsecured notes (the "2018 Senior Notes") in an aggregate principal amount of $12.7 billion. The 2018 Senior Notes are a senior unsecured obligation of the Company and will rank equally with the Company's future senior unsecured debt outstanding from time to time. On November 1, 2018, the Company announced a $3 billion share buyback program, which expired on March 31, 2019. In the first quarter of 2019, proceeds from the 2018 Senior Notes were used to purchase $1.6 billion of shares. As a result, the share buyback program was complete at March 31, 2019.
Term Loan and Revolving Credit Facilities
In May 2019, the Company fully drew the two term loan facilities it entered into in the fourth quarter of 2018 (the “Term Loan Facilities”“Notes”) in the aggregate principal amount of $3,000 million. In$2 billion of 2.169 percent fixed rate Notes due May 2019,1, 2023 (the “May Debt Offering”). The proceeds from the May Debt Offering are expected to be used by the Company amended its $3,000 million five-year revolving credit facility (the “Five-Year Revolver”) entered intoto repay or redeem the Company’s $0.5 billion in floating rate notes due November 2020 and $1.5 billion of 3.77 percent fixed-rate notes due November 2020 (collectively, the fourth quarter of 2018 to become effective and available as“2020 Notes”). Upon consummation of the amendment. Proposed N&B Transaction, the Company will be required to mail a notice of redemption to holders of the Notes, with a copy to the Trustee, setting forth the date of redemption of all of the Notes on the date (“Special Mandatory Redemption Date”) that is the later of (i) three (3) Business Days after the consummation of the Proposed N&B Transaction and (ii) May 1, 2021. On the Special Mandatory Redemption Date, the Company will be required to redeem all of the Notes at a redemption price equal to 100% of the aggregate principal amount of the Notes plus accrued and unpaid interest, if any, up to but excluding the Special Mandatory Redemption Date. The Indenture also contains certain limitations on the Company’s ability to incur liens and enter into sale lease-back transactions, as well as customary events of default.
Revolving Credit Facility
In addition, in June 2019, the Company entered into a $750 million, 364-day revolving credit facility (the "364-day"Old 364-Day Revolving Credit Facility"). In March 2020, the Company drew down on the Old 364-Day Revolving Credit Facility in the aggregate principal amount of $250 million. In April 2020, the Company repaid the $250 million draw on the Old 364-Day Revolving Credit Facility with interest. On and effective as of April 16, 2020, the Company entered into a new $1.0 billion 364-day revolving credit facility (the “$1B Revolving Credit Facility"). As of the effectiveness of the $1B Revolving Credit Facility, the Old 364-Day Revolving Credit Facility was terminated.
Uncommitted Credit FacilitiesNutrition & Biosciences Financing
In connection with the Proposed N&B Transaction, DuPont and Outstanding LettersNutrition & Biosciences, Inc. (presently a wholly owned subsidiary of CreditDuPont) (“N&B Inc.”) entered into a Bridge Commitment Letter (the “Bridge Letter”) in an aggregate principal amount of $7.5 billion (the “Bridge Loans”) to secure committed financing for a one-time $7.3 billion cash payment, subject to adjustment, to DuPont (the "Special Cash Payment") and related financing fees. The aggregate commitment under the Bridge Letter is reduced by, among other things, (1) the amount of net cash proceeds received by N&B Inc. from any issuance of senior unsecured notes pursuant to a Rule 144A offering or other private placement (the "N&B Notes Offering") and (2) certain qualifying term loan commitments under senior unsecured term loan facilities.
Unused bank credit lines on uncommitted credit facilities were $597 million at June 30, 2019. These lines are available to support short-term liquidity needs and general corporate purposes including letters of credit. Outstanding letters of credit were $133 million at June 30, 2019. These letters of credit support commitments madeIn January 2020, N&B Inc. entered into a senior unsecured term loan agreement in the ordinary courseamount of business.
Debt Covenants$1.25 billion split evenly between three- and Default Provisions
The Company's indenture covenants include customary limitations on liens, sale and leaseback transactions, and mergers and consolidations, subjectfive-year facilities. As a result of entry into the term loan agreement, the commitments under the Bridge Commitment Letter were reduced to certain limitations. The 2018 Senior Notes also contain customary default provisions. There were no material changes to the debt covenants and default provisions.$6.25 billion.
NOTE 1513 - COMMITMENTS AND CONTINGENT LIABILITIES
Litigation and Environmental Matters
As of March 31, 2020, the Company had recorded liabilities of $24 million associated with litigation matters and $77 million associated with environmental matters. These recorded liabilities include the Company’s indemnification obligations to each of Dow and Corteva.
Under the Separation and Distribution Agreement, liabilities, including cost and expenses, associated with litigation and environmental matters that primarily related to the materials science business, the agriculture business or the specialty products business were generally allocated to or retained by Dow, Corteva or the Company, respectively, through retention, assumption or indemnification. Related to the foregoing, at June 30, 2019,March 31, 2020, DuPont has recorded (i) a liability of $36$35 million (although it is reasonably possible that the ultimate cost could range up to $108 million above the amount accrued) for retained or assumed environmental liabilities, (ii) a liability of $2$3 million for retained or assumed litigation liabilities, and (iii) an indemnification liability related to legal and environmental matters of $64$58 million. Liabilities associated with discontinued and/or divested operations and businesses of Historical Dow generally were allocated to or retained by Dow. The allocation of liabilities associated with the discontinued and/or divested operations and businesses of Historical EID is discussed below.
The liabilities allocated to and assumed by Dow and Corteva are reflected as discontinued operationsTable of the Company at December 31, 2018. Such liabilities assumed by Dow as of the consummation of the Dow Distribution on April 1, 2019, include the following matters discussed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018, (the “Annual Report”) and Quarterly Report on Form 10-Q for the three-month period ended March 31, 2019, (the “First Quarterly Report”): Asbestos-Related Matters of Union Carbide Corporation, Urethane Matters, Rocky Flats Matter, Dow Silicones Chapter 11 Related Matters, Midland Off-Site Environmental Matters, Dow Silicones Midland, Michigan, Freeport, Texas, Plaquemine, Louisiana and St. Charles, Louisiana Steam-Assisted Flares Matters, Freeport, Texas, Facility Matter, Mt. Meigs, Alabama Matter, Union Carbide Matter and Union Carbide - Seadrift, Texas and, with indemnity from DuPont and Corteva, the Sabine Plant, Orange Texas-EPA Multimedia Inspection.ContentsSuch liabilities assumed by Corteva as of the consummation of the Corteva Distribution on June 1, 2019, include the following matters discussed in the Company’s Annual Report and the First Quarterly Report: La Porte Plant, La Porte, Texas - Crop Protection-Release Incident Investigation and La Porte Plant, La Porte, Texas - EPA Multimedia Inspection.
Discontinued and/or Divested Operations and Businesses ("DDOB") Liabilities of Historical EID
Under the Separation and Distribution Agreement and the Letter Agreement between Corteva and DuPont, DDOB liabilities of Historical EID primarily related to Historical EID’s agriculture business were allocated to or retained by Corteva and those primarily related to Historical EID’s specialty products business were allocated to or retained by the Company. Historical EID DDOB liabilities not primarily related to Historical EID’s agriculture business or specialty products business (“Stray Liabilities”), are allocated as followsfollows:
Generally, indemnifiable losses as defined in the Separation and Distribution Agreement, (“Indemnifiable Losses”) for Stray Liabilities, to the extent they do not arise out of actions related to or resulting from the development, testing, manufacture or sale of PFAS, defined below, (“Non-PFAS Stray Liabilities”) that are known as of April 1, 2019 are borne by Corteva up to a specified amount set forth in the schedules to the Separation and Distribution Agreement and/or Letter Agreement. Non-PFAS Stray Liabilities in excess of such specified amounts and any Non-PFAS Stray Liabilities not listed in the schedules to the Separation and Distribution Agreement or Letter Agreement are borne by Corteva and/or DuPont up to separate, aggregate thresholds of $200 million each to the extent Corteva or DuPont, as applicable, incurs an Indemnifiable Loss. Once Corteva’s or DuPont’s $200 million threshold is met, the other would generally bear all Non-PFAS Stray Liabilities until meeting its $200 million threshold. After the respective $200 million thresholds are met, DuPont will bear 71 percent of such losses and Corteva will bear 29 percent of such losses.
Generally, Corteva and the Company will each bear 50 percent of the first $300 million (up to $150 million each) for Indemnifiable Losses arising out of actions to the extent related to or resulting from the development, testing, manufacture or sale of per- or polyfluoroalkyl substances, which include collectively perfluorooctanoic acids and its salts (“PFOA”), perfluorooctanesulfonic acid (“PFOS”) and perfluorinated chemicals and compounds (“PFCs”) (all such substances, “PFAS” and such Stray Liabilities referred to as “PFAS Stray Liabilities”). Indemnifiable Losses to the extent related to PFAS Stray Liabilities in excess of $300 million generally will be borne 71 percent by the Company and 29 percent by Corteva, unless either Corteva or DuPont has met its $200 million threshold. In that event, the other company would bear all PFAS Stray Liabilities until that company meets its $200 million threshold, at which point DuPont will bear 71 percent of such losses and Corteva will bear 29 percent of such losses.
Indemnifiable Losses incurred by the companies in relation to PFAS Stray Liabilities up to $300 million (e.g., up to $150 million each) will be applied to each company’s respective $200 million threshold.
Non-PFAS Stray Liabilities
While DuPont believes it is probable that it will incur a liability related to Non-PFAS Stray Liabilities, such liability is not reasonably estimable at June 30, 2019.March 31, 2020. Therefore, at June 30, 2019,March 31, 2020, DuPont has not recorded an accrual related to Non-PFAS Liabilities.
PFAS Stray Liabilities
DuPont expects to continue to incur costs and expenses such as attorneys’ fees and expenses and court costs in connection with the Chemours suit,matters described below. While such costs and expenses are Indemnifiable Losses,below, which the Company will expense them as incurred in accordance with its accounting policy for litigation matters. The Company believes the probability of ultimate liability with respect to the Chemours suit is remote.
Generally, The Chemours Company (“Chemours”), with reservations, including as to alleged fraudulent conveyance and voidable transactions, is defending and indemnifying Historical EID in the PFAS Matters discussed below. Although Chemours has refused the tender of the Company’s defense in the limited actions in which the Company has been named, DuPont believes it is remote that it will ultimately incur a liability in connection with these PFAS Matters. However, in the highly improbable event that Chemours is unable to pay or is successful in limiting its obligations under the Chemours Separation Agreement, defined below, it could impact the Company’s business, financial condition, results of operations and cash flows.
Chemours Suit
On July 1, 2015, Historical EID completed the separation of Historical EID’s Performance Chemicals segment through the spinoff of all the issued and outstanding stock of The Chemours Company (“Chemours”) to holders of Historical EID common stock. In connection with the spin, Historical EID and Chemours entered into a Separation Agreement (as amended, the "Chemours Separation Agreement"). Pursuant to the Chemours Separation Agreement, Chemours is obligated to indemnify Historical EID, including its current or former affiliates, against certain litigation, environmental and other liabilities that arose prior to the Chemours Separation. The term of this indemnification is generally indefinite and includes defense costs and expenses, as well as monetary and non-monetary settlements and judgments.
In 2017, Historical EID and Chemours amended the Chemours Separation Agreement to provide for a limited sharing of potential future PFOA liabilities for a five-year period that began on July 6, 2017. The amended agreement provides that during that five-year period, Chemours will annually pay the first $25 million of future PFOA liabilities and, if that amount is exceeded, Historical EID will pay any excess amount up to the next $25 million, with Chemours annually bearing any excess liabilities above that amount. If Historical EID were required to pay PFOA liabilities pursuant to the amended agreement, fifty percent of such obligation would be borne by the Company in accordance with the Letter Agreement. In connection with the foregoing, the Company has not recorded or paid a PFOA liability. At the end of the five-year period, this limited sharing agreement will expire, and Chemours’ indemnification obligations under the Chemours Separation Agreement will continue unchanged.
On May 13, 2019, Chemours filed suit in the Delaware Court of Chancery against Historical EID, Corteva and the Company in an attempt to limit its responsibility for the litigation and environmental liabilities allocated to and assumed by Chemours under the Chemours Separation Agreement. Chemours is asking the court to rewrite the Chemours Separation Agreement by either limiting Chemours’ liabilities or, alternatively, ordering the return to Chemours of all or a portion of a $3.91 billion dividend that Chemours paid to Historical EID, Chemours’ then-sole-shareholder, just prior to the spin of Chemours. DuPont and Corteva, acting jointly, have filed a motion to dismiss the lawsuit for lack of subject matter jurisdiction and have initiated an arbitration of the dispute as required under the Chemours Separation Agreement. In December 2019, following argument, the Delaware Court of Chancery stayed arbitration pending resolution of the motion to dismiss. On March 30, 2020, the Court of Chancery granted the motion to dismiss and rejected Chemours’ arguments in their entirety. Chemours filed a notice of appeal on April 17, 2020 and may file a motion to stay the arbitration process pending consideration of such an appeal by the Delaware Supreme Court. In the interim, the confidential arbitration process will proceed.
Indemnifiable Losses related to the Chemours suit are PFAS Stray Liabilities subject to the sharing arrangement between DuPont and Corteva, described above. The Company believes the probability of a final unappealable judgment of liability with respect to the Chemours suit to be remote; the defendants continue to vigorously defend full indemnity rights as set forth in the Chemours Separation Agreement.
PFAS Matters
Historical EID is a party to legal proceedings relating to the use of PFOA and PFCs by its former Performance Chemicals segment. Indemnifiable Losses related to PFAS liabilities allocated to and assumed by Chemours under the Chemours Separation Agreement generally are PFAS Stray Liabilities subject to the sharing arrangement between DuPont and Corteva, described above.
Generally, Chemours, with reservations, including as to alleged fraudulent conveyance and voidable transactions, is defending and indemnifying Historical EID in the PFAS Matters discussed below. Although Chemours has refused the tender of the Company’s defense in the actions in which the Company has been named, DuPont believes it is remote that it will ultimately incur a liability in connection with these PFAS Matters.
Personal Injury and Other PFAS Actions
DuPont, which was formed after the spinoffspin-off of Chemours, as a subsidiary of Historical EID and Historical Dow, is not named in the personal injury and other PFAS actions discussed below.
Personal Injury
In 2004.2004, Historical EID settled a West Virginia state court class action, Leach v. DuPont, which alleged that PFOA from Historical EID’s former Washington Works facility had contaminated area drinking water supplies and affected the health of area residents. Historical EID has residual liabilities under the Leach settlement related to providing PFOA water treatment to six area water districts and private well users and to fund, through an escrow account, up to $235 million for a medical monitoring program for eligible class members.
Members of the Leach class have standing to pursue personal injury claims for just six health conditions that an expert panel appointed under the Leach settlement reported in 2012 had a “probable link” (as defined in the settlement) with PFOA: pregnancy-induced hypertension, including preeclampsia; kidney cancer; testicular cancer; thyroid disease; ulcerative colitis; and diagnosed high cholesterol. In 2017, Chemours and Historical EID each paid $335 million to settle the multi-district litigation in the U.S. District Court for the Southern District of Ohio (“Ohio MDL”), thereby resolving claims of about 3,550 plaintiffs alleging injury
from exposure to PFOA in drinking water. The Ohio MDL2017 settlement did not resolve claims of plaintiffsLeach class members who did not have claims in the Ohio MDL or whose claims are based on diseases first diagnosed after February 11, 2017. ThereAbout 80 claims alleging personal injury, including kidney and testicular cancer claims, have been filed since the 2017 settlement. These claims are several dozen claimscurrently pending in the Ohio MDL. The first two cases, one captioned “Abbott v E. I. du Pont de Nemours and Company” and the other “Swartz v. E. I. du Pont de Nemours and Company”, involving a testicular cancer and a kidney cancer claim, respectively, proceeded to trial in January 2020. In the Abbott case, the jury returned a verdict in March 2020 against Historical EID, awarding $50 million in compensatory damages to the plaintiff and his wife, who claimed that exposure to PFOA in drinking water caused him to develop testicular cancer. Historical EID will appeal the verdict. The plaintiffs also sought but were not awarded punitive damages. In the Swartz matter, the jury could not reach a verdict. Therefore, the court declared a mistrial and the matter will be retried at a later date. The trials in the cases originally scheduled for June 2020 have been postponed to August 2020 due to the COVID-19 pandemic.
Natural Resource Damage Claims and Other Claims for Environmental Damages
In addition to the actions described above, there are about 100 cases alleging damages to natural resources, the environment and/or property as well as various other allegations. DuPont is named as a defendant in certain of these actions as discussed below.
Drinking Water
Since May 2017, a number of municipal water districts and state attorneys general have filed lawsuits against Historical EID, Chemours, 3M, and others, claiming contamination of public water systems by certain PFAS compounds. Such actions are currently pending in Ohio, Michigan, New Jersey, New Hampshire, New York, and Vermont. Generally, the states seek economic impact damages for alleged harm to natural resources, punitive damages, and present and future costs to cleanup contamination from certain PFAS compounds and to abate the alleged nuisance.
DuPont is a named party in the New Jersey suit related to its site in Parlin, New Jersey. In addition, the New Jersey Attorney General and New Jersey State Department of Environmental Protection filed two directives, one of which names DuPont. The directives seek information on the historical and current use of PFAS. DuPont is also a named party to the Vermont suit and the Michigan suit. The amended complaints in the New Jersey and Vermont cases and the complaint filed by Michigan include additional causes of action based on allegations that the transfer by Historical EID of certain PFAS liabilities to Chemours prior to spinning off Chemours resulted in a fraudulent conveyance or voidable transaction.
Lawsuits have been filed by residents and several water districts against Historical EID and Chemours in New York federal and state courts, including a putative class action, alleging exposure to PFOA from third-party defendant manufacturing operations and seeking compensatory, consequential and punitive damages, medical monitoring and attorneys’ fees, expenses and interest.
Other PFAS Actions
A case is pending in the Southern District of Ohio seeking certification of a nationwide class of individuals who have detectable levels of PFAS in their blood serum. The suit was filed against several defendants in addition to Chemours and Historical EID. The complaint specifically seeks, among other things, the creation of a “PFAS Science Panel” to study the effects of PFAS, but expressly states that the class does not seek compensatory damages for personal injuries.
There are several actions pending in federal court against Historical EID and Chemours, relating to discharges of PFCs, including GenX, into the Cape Fear River. GenX is a polymerization processing aid and a replacement for PFOA introduced by Historical EID which Chemours continues to manufacture at its Fayetteville Works facility in Bladen County, North Carolina. One of these actions is a consolidated putative class action that asserts claims for damages and other relief on behalf of putative classes of property owners and residents in areas near or who draw drinking water from the Cape Fear River. Another action is a consolidated action brought by various North Carolina water authorities, including the Cape Fear Public Utility Authority and Brunswick County, that seek actual and punitive damages as well as injunctive relief. In addition, an action is pending in North Carolina state court on behalf of about 100 plaintiffs who own wells and property near the Fayetteville Works facility. The plaintiffs seek damages for nuisance allegedly caused by releases of certain PFCs from the site.
Natural Resource Damage Claims and Other Claims for Environmental DamagesAqueous Film Forming Foam
DuPont, which was formed afterBeginning in April 2019, several dozen lawsuits involving water contamination arising from the spinoffuse of Chemours as a subsidiary of Historical EID and Historical Dow, is named in certain of the actions discussed below.
Drinking Water
Since May 2017, a number of municipal water districts and state attorneys general havePFAS-containing aqueous firefighting foams (“AFFF”) were filed lawsuits against Historical EID, Chemours, 3M and others, claiming contaminationother AFFF manufacturers and in different parts of public water systems by certain PFAS compounds. Such actions are currently pendingthe country. Most were consolidated in Alabama, Ohio, New Jersey, New Hampshire, South Dakota and Vermont. Generally, the states seek economic impact damages for alleged harm to natural resources, punitive damages, and present and future costs to cleanup contamination from certain PFAS compounds and to abate the alleged nuisance.
DuPont is a named party in the New Jersey suit related to its site in Parlin, New Jersey. In addition, the New Jersey Attorney General and New Jersey State Department of Environmental Protection filed two directives, one of which names DuPont. The directives seek information on the historical and current use of PFAS. DuPont is also a named party to the Vermont suit. The complaints filed in New Jersey and Vermont were recently amended to introduce additional causes of action based on allegations that the transfer by Historical EID of certain PFAS liabilities to Chemours prior to spinning off Chemours resulted in a fraudulent conveyance or voidable transaction.
Firefighting Foam
Historical EID and Chemours are named in about 20 cases originally filed in Louisiana, Michigan, New Hampshire, New Jersey, New Mexico, New York, Ohio, Oklahoma, South Dakota, Tennessee and Texas. The Company is named in the New Hampshire action. These cases were transferred to a multi-district litigation docket in federal district court in South Carolina (the “SC MDL”), which includes. Many of those cases also name DuPont as a defendant. Those actions largely seek remediation of the alleged PFAS contamination in and around military bases and airports as well as medical monitoring of affected residents.
As of the latter part of April 2020, approximately 150 cases. The suits allege contamination of neighboring drinking and groundwater from the use of aqueous firefighting foams on military installations, air force bases, commercial airports and refineries. The claims against Historical EID and Chemours involve alleged sales of PFOA and PFOS products to foam manufacturers, including 3M, who are also defendants600 personal injury cases have been filed directly in the SC MDL.MDL and assert claims on behalf of individual firefighters and others who allege that exposure to PFAS in firefighting foam caused them to develop cancer, including kidney and testicular cancer. DuPont has been named as a defendant in approximately 565 personal injury AFFF cases. DuPont is seeking the dismissal of DowDuPont and DuPont from these actions. Historical EID and the Company have never made or sold firefightingaqueous film forming foam, PFOS or PFOS containing products.
Additionally, a case filed by a former firefighter is pending in the Southern District of Ohio seeking certification of a nationwide class of individuals who have detectable levels of PFAS in their blood serum. The suit was filed against 3M and several other defendants in addition to Chemours and Historical EID. The complaint specifically seeks, among other things, the creation of a “PFAS Science Panel” to study the effects of PFAS, but expressly states that the class does not seek compensatory damages for personal injuries. In February 2020, the court denied the defendants' motion to transfer this case to the SC MDL.
Other Litigation Matters
In addition to the specific matters described above, the Company is party to other claims and lawsuits arising out of the normal course of business with respect to product liability, patent infringement, governmental regulation, contract and commercial litigation, and other actions. Certain of these actions may purport to be class actions and seek damages in very large amounts. It is the opinion of the Company’s management that the possibility is remote that the aggregate of all such other claims and lawsuits will have a material adverse impact on the results of operations, financial condition and cash flows of the Company.
Environmental Matters
Accruals for environmental matters are recorded when it is probable that a liability has been incurred and the amount of the liability can be reasonably estimated based on current law and existing technologies. At June 30, 2019,March 31, 2020, the Company had accrued obligations of $78$77 million for probable environmental remediation and restoration costs, inclusive of $36$35 million retained and assumed following the Distributions and $42 million of indemnified liabilities. These obligations are included in "Accrued and other current liabilities" and "Other noncurrent obligations" in the interim Condensed Consolidated Balance Sheets. This is management’s best estimate of the costs for remediation and restoration with respect to environmental matters for which the Company has accrued liabilities, although it is reasonably possible that the ultimate cost with respect to these particular matters could range up to $170$171 million above the amount accrued at June 30, 2019.March 31, 2020. Consequently, it is reasonably possible that environmental remediation and restoration costs in excess of amounts accrued could have a material impact on the Company’s results of operations, financial condition and cash flows. Inherent uncertainties exist in these estimates primarily due to unknown conditions, changing governmental regulations and legal standards regarding liability, and emerging remediation technologies for handling site remediation and restoration. At December 31, 2018,2019, the Company had accrued obligations of $51$77 million for probable environmental remediation and restoration costs.
Pursuant to the Separation and Distribution Agreement, the Company'sCompany is required to indemnify certain clean-up responsibilities and associated remediation costs. The accrued environmental obligations of $78$77 million as of June 30, 2019March 31, 2020 includes amount for which the Company indemnifies Dow and Corteva. At June 30, 2019,March 31, 2020, the Company has indemnified Dow and Corteva $8 million and $34 million, respectively.
Guarantees
Obligations for Equity Affiliates & Others
The Company has directly guaranteed various debt obligations under agreements with third parties related to equity affiliates and customers. At June 30, 2019March 31, 2020 and December 31, 2018,2019, the Company had directly guaranteed $185 million and $199$187 million, respectively, of such obligations. These amounts represent the maximum potential amount of future (undiscounted) payments that the Company could be required to make under the guarantees. The Company would be required to perform on these guarantees in the event of default by the guaranteed party.
The Company assesses the payment/performance risk by assigning default rates based on the duration of the guarantees. These default rates are assigned based on the external credit rating of the counterparty or through internal credit analysis and historical default history for counterparties that do not have published credit ratings. For counterparties without an external rating or available credit history, a cumulative average default rate is used.
In certain cases, the Company has recourse to assets held as collateral, as well as personal guarantees from customers. Assuming liquidation, these assets are estimated to cover approximately 1110 percent of the $19$21 million of guaranteed obligations of customers. The following table provides a summary of the final expiration year and maximum future payments for each type of guarantee: |
| | | | |
| Guarantees at March 31, 2020 | Final Expiration Year | Maximum Future Payments |
| In millions |
Obligations for customers 1: | | |
| Bank borrowings | 2020 | $ | 21 |
|
Obligations for non-consolidated affiliates 2: | | |
| Bank borrowings | 2020 | $ | 164 |
|
| Total guarantees | | $ | 185 |
|
1. Existing guarantees for select customers, as part of contractual agreements. The terms of the guarantees are equivalent to the terms of the customer loans that are primarily made to finance customer invoices. Of the total maximum future payments, $21 million had terms less than a year. |
| | | | |
| Guarantees at June 30, 2019 | Final Expiration Year | Maximum Future Payments |
| In millions |
Obligations for customers1: | | |
| Bank borrowings | 2020 | $ | 19 |
|
Obligations for non-consolidated affiliates2: | | |
| Bank borrowings | 2019 | $ | 166 |
|
| Total guarantees | | $ | 185 |
|
| |
1. | Existing guarantees for select customers, as part of contractual agreements. The terms of the guarantees are equivalent to the terms of the customer loans that are primarily made to finance customer invoices. Of the total maximum future payments, $18 million had terms less than a year. |
| |
2. | Existing guarantees for non-consolidated affiliates' liquidity needs in normal operations. |
NOTE 16 - LEASES29
The Company has operating and finance leases for real estate, an airplane, railcars, fleet, certain machinery and equipment, and information technology assets. The Company’s leases have remaining lease terms
Certain ofNOTE 14 - OPERATING LEASES
Operating lease costs for the Company'sthree months ended March 31, 2020 and 2019 were $42 million and $44 million, respectively. Operating cash flows from operating leases include residual value guarantees. These residual value guaranteeswere $42 million and $41 million for the three months ended March 31, 2020 and 2019, respectively.
Operating lease right-of-use assets and lease liabilities are recognized at the commencement date based on a percentagethe present value of the lessor's asset acquisition price and the amount of such guarantee declineslease payments over the course of the lease term. The portion of residual value guarantees that are probable of payment is included in the relatedNew operating lease liability on the accompanying consolidated balance sheet other than certain finance leases that include the maximum residual value guarantee amount in the measurement of the related liability given the election to use the package of practical expedients at the date of adoption. At June 30, 2019, the Company has future maximum payments for residual value guarantees in operating leases of $19 million with final expirations through 2024. The Company's lease agreements do not contain any material restrictive covenants.
The components of lease cost for operatingassets and finance leases for the three and six months ended June 30, 2019 were as follows:
|
| | | | | | |
| In millions | Three Months Ended June 30, 2019 | Six Months Ended June 30, 2019 |
| Operating lease cost | $ | 46 |
| $ | 90 |
|
| Finance lease cost | | |
| Amortization of right-of-use assets | (3 | ) | 3 |
|
| Interest on lease liabilities | — |
| — |
|
| Total finance lease cost | (3 | ) | 3 |
|
| Short-term lease cost | 1 |
| 2 |
|
| Variable lease cost | 2 |
| 3 |
|
| Sublease income | 5 |
| 12 |
|
| Total lease cost | $ | 41 |
| $ | 86 |
|
New leasesliabilities entered into during the sixthree months ended June 30, 2019March 31, 2020 were not considered material. Supplemental cash flow information related to leases was as follows:
|
| | | |
| In millions | Six Months Ended June 30, 2019 |
| Cash paid for amounts included in the measurement of lease liabilities: | |
| Operating cash flows from operating leases | $ | 92 |
|
| Operating cash flows from finance leases | $ | — |
|
| Financing cash flows from finance leases | $ | 3 |
|
$57 million and immaterial for the three months ended March 31, 2019. Supplemental balance sheet information related to leases was as follows:
|
| | | |
| In millions | June 30, 2019 |
| Operating Leases | |
|
Operating lease right-of-use assets1 | $ | 539 |
|
Current operating lease liabilities2 | 144 |
|
Noncurrent operating lease liabilities3 | 394 |
|
| Total operating lease liabilities | $ | 538 |
|
| | |
| Finance Leases | |
|
| Property, plant, and equipment, gross | $ | 13 |
|
| Accumulated depreciation | 5 |
|
| Property, plant, and equipment, net | $ | 8 |
|
| Short-term borrowings and finance lease obligations | $ | 1 |
|
| Long-Term Debt | 2 |
|
| Total finance lease liabilities | $ | 3 |
|
|
| | | | | | |
| In millions | March 31, 2020 | December 31, 2019 |
| Operating Leases | |
| |
Operating lease right-of-use assets 1 | $ | 589 |
| $ | 556 |
|
Current operating lease liabilities 2 | 143 |
| 138 |
|
Noncurrent operating lease liabilities 3 | 444 |
| 416 |
|
| Total operating lease liabilities | $ | 587 |
| $ | 554 |
|
| |
| 1. | Included in "Deferred charges and other assets" in the interim Condensed Consolidated Balance Sheet. |
| |
| 2. | Included in "Accrued and other current liabilities" in the interim Condensed Consolidated Balance Sheet. |
| |
| 3. | Included in "Other noncurrent obligations" in the interim Condensed Consolidated Balance Sheet. |
DuPont utilizes the incremental borrowing rate in determining the present value of lease payments unless the implicit rate is readily determinable.
|
| | |
Lease Term and Discount Rate | June 30, 2019 |
Weighted-average remaining lease term (years) | |
Operating leases | 5.12 |
|
Finance leases | 4.72 |
|
Weighted average discount rate | |
Operating leases | 3.40 | % |
Finance leases | 3.32 | % |
Maturities of lease liabilities were as follows:
|
| | | | | | |
| Maturity of Lease Liabilities at June 30, 2019 | Operating Leases | Finance Leases |
| In millions |
| 2019 | $ | 92 |
| $ | 1 |
|
| 2020 | 126 |
| 1 |
|
| 2021 | 95 |
| 1 |
|
| 2022 | 77 |
| — |
|
| 2023 | 43 |
| — |
|
| 2024 and thereafter | 179 |
| 1 |
|
| Total lease payments | $ | 612 |
| $ | 4 |
|
| Less: Interest | 74 |
| 1 |
|
| Present value of lease liabilities | $ | 538 |
| $ | 3 |
|
Future minimum lease payments for operating leases accounted for under ASC 840, "Leases," with remaining non-cancelable terms in excess of one year at December 31, 2018 were as follows:
|
| | | |
| Minimum Lease Commitments at December 31, 2018 |
| In millions |
| 2019 | $ | 654 |
|
| 2020 | 497 |
|
| 2021 | 418 |
|
| 2022 | 363 |
|
| 2023 | 297 |
|
| 2024 and thereafter | 1,063 |
|
| Total | $ | 3,292 |
|
| Total minimum lease commitments from discontinued operations | 2,980 |
|
| Total minimum lease commitments from continuing operations | $ | 312 |
|
NOTE 1715 - STOCKHOLDERS' EQUITY
On May 23, 2019, stockholders of DowDuPont approved a 1-for-3 reverse stock split of DowDuPont shares of common stock with par value of $0.01 per share, which became effective immediately following the Corteva Distribution on June 1, 2019. All comparable periods presented have been retrospectively revised to reflect this change.
Treasury Stock
On June 25, 2019, the Company retired 37 million shares of its common stock held in treasury. The shares were returned to the status of authorized but unissued shares. As a result, the treasury stock balance decreased by $7,102 million. As a part of the retirement, the Company reduced "Common stock" and "(Accumulated Deficit) Retained Earnings" by $0.04 million and $7,102 million, respectively.
The following table provides a reconciliation of DuPont Common Stock activity for the six months ended June 30, 2019:
|
| | | | |
| Shares of DuPont Common Stock | Issued | Held in Treasury |
| In thousands |
| Balance at December 31, 2018 | 784,143 |
| 27,818 |
|
| Issued | 2,112 |
| — |
|
| Repurchased | — |
| 10,993 |
|
| Retired | (38,811 | ) | (38,811 | ) |
| Balance at June 30, 2019 | 747,444 |
| — |
|
Share Repurchase Program
On June 1, 2019, the Company's Board of Directors approved a new $2 billion share buyback program, which expires on June 1, 2021. During the first quarter, the Company repurchased and retired 6.1 million shares for $232 million. At June 30, 2019,March 31, 2020, the Company had repurchased and retired 1.416.9 million shares under this program at a total cost of $102$982 million.
Accumulated Other Comprehensive Loss
The following table summarizes the activity related to each component of accumulated other comprehensive loss ("AOCL") for the sixthree months ended June 30, 2019March 31, 2020 and 2018:2019:
|
| | | | | | | | | | | | | | | |
| Accumulated Other Comprehensive Loss | Unrealized Gains (Losses) on Investments | Cumulative Translation Adj | Pension and OPEB | Derivative Instruments | Total |
| In millions |
| 2019 | | | | | |
Balance at January 1, 2019 | $ | (51 | ) | $ | (3,785 | ) | $ | (8,476 | ) | $ | (82 | ) | $ | (12,394 | ) |
| Other comprehensive income (loss) before reclassifications | 68 |
| (79 | ) | (7 | ) | (65 | ) | (83 | ) |
| Amounts reclassified from accumulated other comprehensive loss | (1 | ) | (18 | ) | 142 |
| (10 | ) | 113 |
|
| Net other comprehensive income (loss) | $ | 67 |
| $ | (97 | ) | $ | 135 |
| $ | (75 | ) | $ | 30 |
|
| Balance at March 31, 2019 | $ | 16 |
| $ | (3,882 | ) | $ | (8,341 | ) | $ | (157 | ) | $ | (12,364 | ) |
| 2020 | | | | | |
| Balance at January 1, 2020 | $ | — |
| $ | (1,070 | ) | $ | (345 | ) | $ | (1 | ) | $ | (1,416 | ) |
| Other comprehensive loss before reclassifications | — |
| (396 | ) | (2 | ) | — |
| (398 | ) |
| Amounts reclassified from accumulated other comprehensive loss | — |
| — |
| 4 |
| — |
| 4 |
|
| Net other comprehensive (loss) income | $ | — |
| $ | (396 | ) | $ | 2 |
| $ | — |
| $ | (394 | ) |
| Balance at March 31, 2020 | $ | — |
| $ | (1,466 | ) | $ | (343 | ) | $ | (1 | ) | $ | (1,810 | ) |
|
| | | | | | | | | | | | | | | |
| Accumulated Other Comprehensive Loss | Unrealized Gains (Losses) on Investments | Cumulative Translation Adj | Pension and OPEB | Derivative Instruments | Total |
| In millions |
| 2018 | | | | | |
| Balance at January 1, 2018 | $ | 17 |
| $ | (1,935 | ) | $ | (6,923 | ) | $ | (111 | ) | $ | (8,952 | ) |
| Other comprehensive income (loss) before reclassifications | (41 | ) | (1,058 | ) | 9 |
| 75 |
| (1,015 | ) |
| Amounts reclassified from accumulated other comprehensive income (loss) | 2 |
| (2 | ) | 248 |
| 44 |
| 292 |
|
| Net other comprehensive income (loss) | $ | (39 | ) | $ | (1,060 | ) | $ | 257 |
| $ | 119 |
| $ | (723 | ) |
Reclassification of stranded tax effects 1 | $ | (1 | ) | $ | (107 | ) | $ | (927 | ) | $ | (22 | ) | $ | (1,057 | ) |
| Balance at June 30, 2018 | $ | (23 | ) | $ | (3,102 | ) | $ | (7,593 | ) | $ | (14 | ) | $ | (10,732 | ) |
| | | | | | |
| 2019 | | | | | |
| Balance at January 1, 2019 | $ | (51 | ) | $ | (3,785 | ) | $ | (8,476 | ) | $ | (82 | ) | $ | (12,394 | ) |
| Other comprehensive income (loss) before reclassifications | 68 |
| (117 | ) | 49 |
| (43 | ) | (43 | ) |
| Amounts reclassified from accumulated other comprehensive income (loss) | (1 | ) | (18 | ) | 142 |
| (15 | ) | 108 |
|
| Net other comprehensive income (loss) | $ | 67 |
| $ | (135 | ) | $ | 191 |
| $ | (58 | ) | $ | 65 |
|
| Spin-offs of Dow and Corteva | $ | (16 | ) | $ | 3,179 |
| $ | 8,196 |
| $ | 139 |
| $ | 11,498 |
|
| Balance at June 30, 2019 | $ | — |
| $ | (741 | ) | $ | (89 | ) | $ | (1 | ) | $ | (831 | ) |
| |
1. | Amounts reclassified to retained earnings as a result of the adoption of ASU 2018-02, Income Statement—Reporting Comprehensive Income (Topic 220), Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income, which was adopted April 1, 2018. The ASU allowed a reclassification from AOCL to retained earnings for stranded tax effects resulting from The Act. |
The tax effects on the net activity related to each component of other comprehensive income (loss) for the three and six months ended June 30,March 31, 2020 and 2019 and 2018 were as follows:
| | Tax Benefit (Expense) 1 | Three Months Ended
June 30, | Six Months Ended
June 30, | |
| Tax Benefit (Expense) | | Three Months Ended March 31, |
| In millions | 2019 | 2018 | 2019 | 2018 | 2020 | 2019 |
| Unrealized gains (losses) on investments | $ | — |
| $ | 3 |
| $ | (18 | ) | $ | 9 |
| $ | — |
| $ | (18 | ) |
| Cumulative translation adjustments | — |
| (25 | ) | (1 | ) | (20 | ) | — |
| (1 | ) |
| Pension and other post employment benefit plans | 34 |
| (34 | ) | 2 |
| (64 | ) | (1 | ) | (32 | ) |
| Derivative instruments | (8 | ) | (7 | ) | 16 |
| (8 | ) | — |
| 24 |
|
| Tax expense from income taxes related to other comprehensive income items | $ | 26 |
| $ | (63 | ) | $ | (1 | ) | $ | (83 | ) | $ | (1 | ) | $ | (27 | ) |
| |
1. | Prior period amounts were updated to conform with the current year presentation. |
A summary of the reclassifications out of AOCL for the three and six months ended June 30,March 31, 2020 and 2019 and 2018 is provided as follows:
| | | Reclassifications Out of Accumulated Other Comprehensive Loss | Three Months Ended
June 30, | Six Months Ended
June 30, | Income Classification | Three Months Ended
March 31, | Income Classification |
| In millions | 2019 | 2018 | 2019 | 2018 | 2020 | 2019 |
| Unrealized (gains) losses on investments | $ | — |
| $ | 1 |
| $ | (1 | ) | $ | 3 |
| See (1) below | |
| Unrealized gains on investments | | $ | — |
| $ | (1 | ) | See (1) below |
| Tax expense (benefit) | — |
| — |
| — |
| (1 | ) | See (2) below | — |
| — |
| See (2) below |
| After tax | $ | — |
| $ | 1 |
| $ | (1 | ) | $ | 2 |
| | $ | — |
| $ | (1 | ) | |
| Cumulative translation adjustments | $ | — |
| $ | (2 | ) | $ | (18 | ) | $ | (2 | ) | See (3) below | $ | — |
| $ | (18 | ) | See (3) below |
| Pension and other post employment benefit plans | $ | (25 | ) | $ | 156 |
| $ | 142 |
| $ | 310 |
| See (4) below | $ | 3 |
| $ | 167 |
| See (4) below |
| Tax benefit | 25 |
| (34 | ) | — |
| (62 | ) | See (2) below | |
| Tax expense (benefit) | | 1 |
| (25 | ) | See (2) below |
| After tax | $ | — |
| $ | 122 |
| $ | 142 |
| $ | 248 |
| | $ | 4 |
| $ | 142 |
| |
| Derivative Instruments | $ | (7 | ) | $ | 26 |
| $ | (18 | ) | $ | 52 |
| See (5) below | $ | — |
| $ | (11 | ) | See (5) below |
| Tax benefit | 2 |
| (3 | ) | 3 |
| (8 | ) | See (2) below | |
| Tax expense | | — |
| 1 |
| See (2) below |
| After tax | $ | (5 | ) | $ | 23 |
| $ | (15 | ) | $ | 44 |
| | $ | — |
| $ | (10 | ) | |
| Total reclassifications for the period, after tax | $ | (5 | ) | $ | 144 |
| $ | 108 |
| $ | 292 |
| | $ | 4 |
| $ | 113 |
| |
| |
1. | "Net sales" and "Sundry income (expense) - net." |
| |
2. | "Provision for income taxes on continuing operations." |
| |
3. | "Sundry income (expense) - net." |
| |
4. | These AOCL components are included in the computation of net periodic benefit cost of the Company's defined benefit pension and other post employment benefit plans. See Note 19 for additional information. |
| |
5. | "Cost of sales," "Sundry income (expense) - net" and "Interest expense". |
1. "Net sales" and "Sundry income (expense) - net."
2. "Provision for income taxes on continuing operations."
3. "Sundry income (expense) - net."
4. These AOCL components are included in the computation of net periodic benefit cost of the Company's defined benefit pension and other post employment benefit plans. See Note 17 for additional information.
5. "Cost of sales," "Sundry income (expense) - net" and "Interest expense."
NOTE 1816 - NONCONTROLLING INTERESTS
Ownership interests in the Company's subsidiaries held by parties other than the Company are presented separately from the Company's equity in the interim Condensed Consolidated Balance Sheets as "Noncontrolling interests." The amount of consolidated net income attributable to the Company and the noncontrolling interests areis both presented on the face of the interim Consolidated Statements of Operations.
The following table summarizes the activity for equity attributable to noncontrolling interests for the three and six months ended June 30, 2019March 31, 2020 and 2018:2019:
|
| | | | | | |
| Noncontrolling Interests | Three Months Ended March 31, |
| In millions | 2020 | 2019 |
| Balance at beginning of period | $ | 569 |
| $ | 1,608 |
|
| Net income attributable to noncontrolling interests | 6 |
| 51 |
|
| Distributions to noncontrolling interests | (6 | ) | (11 | ) |
| Cumulative translation adjustments | (8 | ) | 7 |
|
| Other | 5 |
| (1 | ) |
| Balance at end of period | $ | 566 |
| $ | 1,654 |
|
|
| | | | | | | | | | | | |
| Noncontrolling Interests | Three Months Ended June 30, | Six Months Ended June 30, |
| In millions | 2019 | 2018 | 2019 | 2018 |
| Balance at beginning of period | $ | 1,654 |
| $ | 1,664 |
| $ | 1,608 |
| $ | 1,597 |
|
| Net income attributable to noncontrolling interests | 34 |
| 35 |
| 85 |
| 79 |
|
Distributions to noncontrolling interests 1 | (1 | ) | (46 | ) | (12 | ) | (73 | ) |
| Noncontrolling interests from Merger | — |
| — |
| — |
| 56 |
|
| Cumulative translation adjustments | 9 |
| (34 | ) | 16 |
| (40 | ) |
| Spin-off of Dow and Corteva | (1,124 | ) | — |
| (1,124 | ) | — |
|
| Other | (2 | ) | 1 |
| (3 | ) | 1 |
|
| Balance at end of period | $ | 570 |
| $ | 1,620 |
| $ | 570 |
| $ | 1,620 |
|
| |
1. | Net of dividends paid to a joint venture, which were reclassified to "Equity in earnings of nonconsolidated affiliates" in the interim Consolidated Statements of Operations, totaled zero for the three months ended June 30, 2019 ($6 million for the three months ended June 30, 2018) and zero for the six months ended June 30, 2019 ($6 million for the six months ended June 30, 2018). |
NOTE 1917 - PENSION PLANS AND OTHER POST EMPLOYMENT BENEFITS
In connection with the Distributions, the Historical Dow U.S. qualified defined benefit plan and the Historical EID U.S. principal qualified defined benefit plan were separated from the Company to Dow and Corteva, respectively. The Company retained a portion of pension liabilities and select other post employment benefit plans relating to foreign benefit plans for both Historical EID and Historical Dow. The Company also retained an immaterial portionA summary of the non-qualified USCompany's pension liabilitiesplans and other post employment benefit plans relatingbenefits can be found in Note 20 to the Consolidated Financial Statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019. Historical Dow and Historical EID USdid not merge their defined benefit plans.
The Employee Matters Agreement with Dow and Corteva provides that employees of Dow and Corteva no longer participate in benefit plans sponsored or maintained by the Company, and that employees of the Company no longer participate in benefit plans sponsored or maintained by either Dow or Corteva, as of the effective time of the Dow Distribution and Corteva Distribution, respectively. At June 30, 2019, the Company's pension and other post employment benefit plans retained an underfunded status of $980 million after certain assets and obligations were separated from the Company to Dow and Corteva plans effective as a result of the Dow Distribution and Corteva Distribution, respectively.Merger.
The following sets forth the components of the Company's net periodic benefit (credit) cost for defined benefit pension plans and other post employment benefits:
|
| | | | | | | | | | | | |
| Net Periodic Benefit (Credit) Cost for All Plans | Three Months Ended | Six Months Ended |
| In millions | June 30, 2019 | June 30, 2018 | June 30, 2019 | June 30, 2018 |
| Defined Benefit Pension Plans: | | | | |
| Service cost | $ | 18 |
| $ | 165 |
| $ | 149 |
| $ | 332 |
|
| Interest cost | 144 |
| 406 |
| 591 |
| 814 |
|
| Expected return on plan assets | (206 | ) | (705 | ) | (919 | ) | (1,414 | ) |
| Amortization of prior service credit | (1 | ) | (6 | ) | (7 | ) | (12 | ) |
| Amortization of net loss | 2 |
| 169 |
| 135 |
| 340 |
|
Curtailment/settlement 1 | (2 | ) | (4 | ) | (2 | ) | (4 | ) |
| Net periodic benefit (credit) cost - total | $ | (45 | ) | $ | 25 |
| $ | (53 | ) | $ | 56 |
|
| Less: discontinued operations | 41 |
| (35 | ) | 45 |
| (73 | ) |
| Net periodic benefit credit - continuing operations | $ | (4 | ) | $ | (10 | ) | $ | (8 | ) | $ | (17 | ) |
| Other Post Employment Benefits: | | | | |
| Service cost | $ | 1 |
| $ | 5 |
| $ | 5 |
| $ | 10 |
|
| Interest cost | 15 |
| 33 |
| 52 |
| 65 |
|
| Amortization of net gain | — |
| (6 | ) | (6 | ) | (12 | ) |
| Net periodic benefit cost - total | $ | 16 |
| $ | 32 |
| $ | 51 |
| $ | 63 |
|
| Less: discontinued operations | (16 | ) | (32 | ) | (50 | ) | (63 | ) |
| Net periodic benefit cost - continuing operations | $ | — |
| $ | — |
| $ | 1 |
| $ | — |
|
|
| | | | | | |
| Net Periodic Benefit (Credit) Cost for All Plans | Three Months Ended March 31, |
| In millions | 2020 | 2019 |
| Defined Benefit Pension Plans: | | |
Service cost 1 | $ | 18 |
| $ | 131 |
|
Interest cost 2 | 14 |
| 447 |
|
Expected return on plan assets 3 | (28 | ) | (713 | ) |
Amortization of prior service credit 4 | (1 | ) | (6 | ) |
Amortization of net loss 5 | 4 |
| 133 |
|
| Net periodic benefit (credit) cost - total | $ | 7 |
| $ | (8 | ) |
| Less: Net periodic benefit (credit) cost - discontinued operations | — |
| (4 | ) |
| Net periodic benefit credit - continuing operations | $ | 7 |
| $ | (4 | ) |
| Other Post Employment Benefits: | | |
Service cost 1 | $ | — |
| $ | 4 |
|
Interest cost 2 | — |
| 37 |
|
Amortization of net gain 5 | — |
| (6 | ) |
| Net periodic benefit cost - total | $ | — |
| $ | 35 |
|
| Less: Net periodic benefit (credit) cost - discontinued operations | — |
| 34 |
|
| Net periodic benefit cost - continuing operations | $ | — |
| $ | 1 |
|
1. The 2018 impact relates toservice cost from continuing operations was $16 million for the curtailmentthree months ended March 31, 2019. The activity from OPEBs was immaterial.
| |
| 2. | The interest cost from continuing operations was $21 million for the three months ended March 31, 2019. The activity from OPEBs was immaterial. |
3. The expected return on plan assets from continuing operations was $43 million for the three months ended March 31, 2019. The activity from OPEBs was immaterial.
4. The amortization of prior service credit from continuing operations was immaterial for the three months ended March 31, 2019 for both pensions and settlementOPEBs.
5. The amortization of pension plans inunrecognized net loss from continuing operations was $2 million for the U.S. and Australia all of which have been transferred to Corteva and included in Discontinued Operations.three months ended March 31, 2019. The 2019 impact relates to the curtailment of pension plans in Canada which have been retained by DuPont and included in Continuing Operations. activity from OPEBs was immaterial.
NetThe continuing operations portion of the net periodic benefit (credit) cost, other than the service cost component, is included in "Sundry income (expense) - net" in the interim Consolidated Statements of Operations.
DuPont expects to make additional contributions in the aggregate of approximately $240$60 million by year-end 2019 to certain non-US pension and other post employment benefit plans.2020.
NOTE 2018 - STOCK-BASED COMPENSATION
On May 23, 2019, stockholdersA summary of DowDuPont approved a reverse stock split of DowDuPont shares of common stock. DowDuPont's Board of Directors established a reverse stock split ratio of 1 new share of DowDuPont common stockthe Historical Dow and Historical DuPont stock-based compensation plans can be found in Note 21 to the Consolidated Financial Statements included in the Company’s Annual Report on Form 10-K for every 3 shares of current DowDuPont common stock with par value of $0.01 per share. The stock split became effective immediately following the Corteva Distribution on June 1,year ended December 31, 2019. All comparable periods presented have been retrospectively revised to reflect this change.
Historical Dow and Historical EID did not merge their equity incentive plans as a result of the Merger. The Historical Dow and Historical EID stock-based compensation plans were assumed by DowDuPontthe Company and remained in place with the ability to grant and issue DowDuPont common stock until the Distributions.
There was minimal grant activity in the first five months of 2019 under the Dow Chemical Company 2012 Stock Incentive Plan (the "2012 Plan"). In the first quarter of 2019, Historical EID granted 1.1 million restricted stock units ("RSUs") with a weighted-average fair value of $70.52 per share under the E. I. du Pont de Nemours and Company Equity and Incentive Plan (the "DuPont EIP"). There was minimal grant activity in April and May of 2019 under the DuPont EIP.
Effect of the Distributions on Equity Awards
In accordance with the Employee Matters Agreement between DuPont, Dow and Corteva, certain executives and employees were entitled to receive equity compensation awards of DuPont in replacement of previously outstanding awards granted under Historical Dow and Historical EID equity incentive plans. At the time of the Dow Distribution, equity awards denominated in DowDuPont common stock held by DuPont employees were adjusted using a formula designed to preserve the intrinsic value of the awards immediately prior to the Dow Distribution, and either remained denominated in DowDuPont common stock, or were adjusted into a combination of equity awards denominated in both DowDuPont common stock and Dow common stock. For employees of Dow Inc., outstanding share-based compensation awards denominated in DowDuPont common stock were adjusted to equity awards denominated in either Dow common stock, or into a combination of equity awards denominated in both DowDuPont common stock and Dow common stock using a formula designed to preserve the intrinsic value of the awards immediately prior to the Dow Distribution.
At the time of the Corteva Distribution, equity awards denominated in DowDuPont common stock held by DuPont employees were adjusted using a formula designed to preserve the intrinsic value of the awards immediately prior to the Corteva Distribution, and were either adjusted into DuPont common stock, or were adjusted into a combination of equity awards denominated in both DuPont common stock and Corteva common stock. For Corteva employees, outstanding share-based compensation awards denominated in DowDuPont common stock were adjusted to equity awards denominated in either Corteva common stock, or into a combination of equity awards denominated in both DuPont common and Corteva common stock using a formula designed to preserve the intrinsic value of the awards immediately prior to the Corteva Distribution. For Dow employees, outstanding DowDuPont equity awards at the time of the Corteva Distribution were adjusted into a combination of equity awards denominated in both DuPont common stock and Corteva common stock using a formula designed to preserve the intrinsic value of the awards immediately prior to the Corteva Distribution.
Immediately following the Corteva Distribution, on June 1, 2019, DuPont adopted the DupontDuPont Omnibus Incentive Plan ("DuPont OIP") which grants stock-based compensationprovides for equity-based and cash incentive awards to certain employees, directors, independent contractors and consultants through grantsin the form of stock options, RSUs,restricted stock units ("RSUs") and other stock-based awards. Theperformance-based restricted stock units ("PSUs"). Upon adoption of the DuPont OIP, has two subplans to reflectthe Historical Dow and Historical EID plans were maintained and rolled into the DuPont EIP and the 2012 Plan.OIP as separate subplans. The equity awards under these subplans have the same terms and conditions that were applicable to the awards under the DuPont EIPHistorical Dow and 2012 PlanHistorical EID plans immediately prior to the Distributions. All new awards will be granted by the OIP. Under the DuPont OIP, a maximum of 1510 million shares of common stock may be awarded. From the period June 1 to June 30, 2019, there was minimal grant activity under the DuPont OIP.are available for award as of March 31, 2020.
DuPont recognized share-based compensation expense in continuing operations of $34$41 million and $32$21 million duringfor the three months ended June 30,March 31, 2020 and 2019, and 2018, respectively, and $55 million and $52 million during the six months ended June 30, 2019 and 2018, respectively. The income tax benefits related to stock-based compensation arrangements were $7$9 million and $12$4 million for the three and six months ended June 30,March 31, 2020 and 2019, respectively, and $7 million and $11 million for the three and six months ended June 30, 2018, respectively.
Performance Stock Units32
In June 2019, DuPont approved performance stock units ("PSUs") to certain members of senior leadership. The approved PSU's are expected to be granted in the thirdfirst quarter of 2019.2020, the Company granted 1.0 million RSUs, 0.8 million stock options and 0.3 million PSUs. The weighted-average fair values per share associated with the grants were $53.49 per RSU, $8.84 per stock option and $50.23 per PSU. The stock options had a weighted-average exercise price per share of $53.50.
NOTE 2119 - FINANCIAL INSTRUMENTS
The following table summarizes the fair value of financial instruments at June 30, 2019March 31, 2020 and December 31, 2018:2019:
| | | Fair Value of Financial Instruments | June 30, 2019 | December 31, 2018 | March 31, 2020 | December 31, 2019 |
| In millions | Cost | Gain | Loss | Fair Value | Cost | Gain | Loss | Fair Value | Cost | Gain | Loss | Fair Value | Cost | Gain | Loss | Fair Value |
Cash equivalents | $ | 532 |
| $ | — |
| $ | — |
| $ | 532 |
| $ | 8,226 |
| $ | — |
| $ | — |
| $ | 8,226 |
| $ | 771 |
| $ | — |
| $ | — |
| $ | 771 |
| $ | 417 |
| $ | — |
| $ | — |
| $ | 417 |
|
Restricted cash equivalents 1 | $ | 40 |
| $ | — |
| $ | — |
| $ | 40 |
| $ | 43 |
| $ | — |
| $ | — |
| $ | 43 |
| $ | 34 |
| $ | — |
| $ | — |
| $ | 34 |
| $ | 37 |
| $ | — |
| $ | — |
| $ | 37 |
|
| Marketable securities | $ | 8 |
| $ | — |
| $ | — |
| $ | 8 |
| $ | 29 |
| $ | — |
| $ | — |
| $ | 29 |
| |
Equity securities 2 | $ | 4 |
| $ | — |
| $ | — |
| $ | 4 |
| $ | 2 |
| $ | — |
| $ | — |
| $ | 2 |
| |
| Total cash and restricted cash equivalents, marketable securities and other investments | $ | 584 |
| $ | — |
| $ | — |
| $ | 584 |
| $ | 8,300 |
| $ | — |
| $ | — |
| $ | 8,300 |
| |
| Total cash and restricted cash equivalents | | $ | 805 |
| $ | — |
| $ | — |
| $ | 805 |
| $ | 454 |
| $ | — |
| $ | — |
| $ | 454 |
|
| Long-term debt including debt due within one year | $ | (15,614 | ) | $ | — |
| $ | (1,555 | ) | $ | (17,169 | ) | $ | (12,635 | ) | $ | 5 |
| $ | (461 | ) | $ | (13,091 | ) | $ | (15,620 | ) | $ | 38 |
| $ | (1,209 | ) | $ | (16,791 | ) | $ | (15,618 | ) | $ | — |
| $ | (1,633 | ) | $ | (17,251 | ) |
| Derivatives relating to: | | | | | | | | | | | | |
Foreign currency 3 | — |
| 11 |
| (6 | ) | 5 |
| — |
| 37 |
| (6 | ) | 31 |
| |
Foreign currency 2 | | — |
| 12 |
| (11 | ) | 1 |
| — |
| 6 |
| (7 | ) | (1 | ) |
| Total derivatives | $ | — |
| $ | 11 |
| $ | (6 | ) | $ | 5 |
| $ | — |
| $ | 37 |
| $ | (6 | ) | $ | 31 |
| $ | — |
| $ | 12 |
| $ | (11 | ) | $ | 1 |
| $ | — |
| $ | 6 |
| $ | (7 | ) | $ | (1 | ) |
| |
| 1. | Classified as "Other current assets" in the interim Condensed Consolidated Balance Sheets. |
| |
| 2. | Equity securities with a readily determinable fair value. Presented in accordance with ASU 2016-01. "Financial Instruments - Overall (Subtopic 825-10): Recognition and Measurementnet of Financial Assets and Financial Liabilities."cash collateral where master netting arrangements allow. |
3. Presented net of cash collateral where master netting arrangements allow.
Derivative Instruments
Objectives and Strategies for Holding Derivative Instruments
In the ordinary course of business, the Company enters into contractual arrangements (derivatives) to reduce its exposure to foreign currency, interest rate and commodity price risks. The Company has established a variety of derivative programs to be utilized for financial risk management. These programs reflect varying levels of exposure coverage and time horizons based on an assessment of risk.
Derivative programs have procedures and controls and are approved by the Corporate Financial Risk Management Committee, consistent with the Company's financial risk management policies and guidelines. Derivative instruments used are forwards, options, futures and swaps. TheAs of the first quarter of 2020, the Company has not designated any derivatives or non-derivatives as hedging instruments.
The Company's financial risk management procedures also address counterparty credit approval, limits and routine exposure monitoring and reporting. The counterparties to these contractual arrangements are major financial institutions and major commodity exchanges. The Company is exposed to credit loss in the event of nonperformance by these counterparties. The Company utilizes collateral support annex agreements with certain counterparties to limit its exposure to credit losses. The Company anticipates performance by counterparties to these contracts and therefore no material loss is expected. Market and counterparty credit risks associated with these instruments are regularly reported to management.
The notional amounts of the Company's derivative instruments were as follows:
| | | Notional Amounts | June 30, 2019 | Dec 31, 2018 | March 31, 2020 | Dec 31, 2019 |
| In millions |
| Derivatives not designated as hedging instruments: | | | | |
| Foreign currency contracts | $ | (80 | ) | $ | 2,057 |
| |
Foreign currency contracts 1 | | $ | (344 | ) | $ | 26 |
|
| Commodity contracts | $ | 8 |
| $ | 9 |
| $ | 12 |
| $ | 11 |
|
| |
| 1. | Presented net of contracts bought and sold. |
Derivatives not Designated in Hedging Relationships
Foreign Currency Contracts
The Company routinely uses forward exchange contracts to reduce its net exposure, by currency, related to foreign currency-denominated monetary assets and liabilities of its operations so that exchange gains and losses resulting from exchange rate changes are minimized. The netting of such exposures precludes the use of hedge accounting; however, the required revaluation of the forward contracts and the associated foreign currency-denominated monetary assets and liabilities intends to achieve a minimal earnings impact, after taxes. The Company also usesmay use foreign currency exchange contracts to offset a portion of the Company's
exposure to certain foreign currency-denominated revenues so that gains and losses on the contracts offset changes in the USD value of the related foreign currency-denominated revenues.
Commodity Contracts
The Company utilizes options, futures and swaps that are not designated as hedging instruments to reduce exposure to commodity price fluctuations on purchases of inventory such as soybeans, soybean oil and soybean meal.
Fair Value of Derivative Instruments
Asset and liability derivatives subject to an enforceable master netting arrangement with the same counterparty are presented on a net basis in the interim Condensed Consolidated Balance Sheets. The presentation of the Company's derivative assets and liabilities is as follows:
| | | | | June 30, 2019 | | March 31, 2020 |
| In millions | Balance Sheet Classification | Gross | Counterparty and Cash Collateral Netting 1 | Net Amounts Included in the Consolidated Balance Sheet | Balance Sheet Classification | Gross | Counterparty and Cash Collateral Netting 1 | Net Amounts Included in the Consolidated Balance Sheet |
| Asset derivatives: | | | | |
| Derivatives not designated as hedging instruments: | | | | |
| Foreign currency contracts | Other current assets | 27 |
| (16 | ) | 11 |
| Other current assets | $ | 34 |
| $ | (22 | ) | $ | 12 |
|
| Total asset derivatives | | $ | 27 |
| $ | (16 | ) | $ | 11 |
| | $ | 34 |
| $ | (22 | ) | $ | 12 |
|
| | | | | |
| Liability derivatives: | | | | |
| Derivatives not designated as hedging instruments: | | | | |
| Foreign currency contracts | Accrued and other current liabilities | $ | 20 |
| $ | (14 | ) | $ | 6 |
| Accrued and other current liabilities | $ | 33 |
| $ | (22 | ) | $ | 11 |
|
| Total liability derivatives | | $ | 20 |
| $ | (14 | ) | $ | 6 |
| | $ | 33 |
| $ | (22 | ) | $ | 11 |
|
| | | | | December 31, 2018 | | December 31, 2019 |
| In millions | Balance Sheet Classification | Gross | Counterparty and Cash Collateral Netting 1 | Net Amounts Included in the Consolidated Balance Sheet | Balance Sheet Classification | Gross | Counterparty and Cash Collateral Netting 1 | Net Amounts Included in the Consolidated Balance Sheet |
| Asset derivatives: | | | | |
| Derivatives not designated as hedging instruments: | | | | |
| Foreign currency contracts | Other current assets | $ | 72 |
| $ | (35 | ) | $ | 37 |
| Other current assets | $ | 16 |
| $ | (10 | ) | $ | 6 |
|
| Total asset derivatives | | $ | 72 |
| $ | (35 | ) | $ | 37 |
| | $ | 16 |
| $ | (10 | ) | $ | 6 |
|
| | | | | |
| Liability derivatives: | | | | |
| Derivatives not designated as hedging instruments: | | | | |
| Foreign currency contracts | Accrued and other current liabilities | $ | 21 |
| $ | (15 | ) | $ | 6 |
| Accrued and other current liabilities | $ | 17 |
| $ | (10 | ) | $ | 7 |
|
| Total liability derivatives | | $ | 21 |
| $ | (15 | ) | $ | 6 |
| | $ | 17 |
| $ | (10 | ) | $ | 7 |
|
| |
| 1. | Counterparty and cash collateral amounts represent the estimated net settlement amount when applying netting and set-off rights included in master netting arrangements between the Company and its counterparties and the payable or receivable for cash collateral held or placed with the same counterparty. |
Effect of Derivative Instruments
Foreign currency derivatives not designated as hedges are used to offset foreign exchange gains or losses resulting from the underlying exposures of foreign currency-denominated assets and liabilities. The amount charged on a pretaxpre-tax basis related to foreign currency derivatives not designated as a hedge, which was included in “Sundry income (expense) - net” in the interim Consolidated Statements of Operations, was a lossgain of $13$4 million for the three months ended June 30, 2019March 31, 2020 ($177 million gain for the three months ended June 30, 2018) and a loss of $60 million for the six months ended June 30, 2019 ($447 million loss for the six months ended June 30, 2018)March 31, 2019). The income statement effects of other derivatives were immaterial.
Reclassification from AOCL
The Company does not expect to reclassify gains or losses related to foreign currency contracts from AOCL to income within the next 12 months.months and there are currently no such amounts included within AOCL.
NOTE 2220 - FAIR VALUE MEASUREMENTS
Fair Value Measurements on a Recurring Basis
The following tables summarize the basis used to measure certain assets and liabilities at fair value on a recurring basis:
| | | Basis of Fair Value Measurements on a Recurring Basis at June 30, 2019 | Significant Other Observable Inputs (Level 2) | |
| Basis of Fair Value Measurements on a Recurring Basis at March 31, 2020 | Significant Other Observable Inputs (Level 2) |
| In millions | Significant Other Observable Inputs (Level 2) |
| Assets at fair value: | |
Cash equivalents and restricted cash equivalents 1 | $ | 572 |
| $ | 805 |
|
Marketable securities 2 | 8 |
| |
Equity securities 3 | 4 |
| |
Derivatives relating to: 4 | | |
Derivatives relating to: 2 | | |
| Foreign currency contracts | 27 |
| 34 |
|
| Total assets at fair value | $ | 611 |
| $ | 839 |
|
| Liabilities at fair value: | | |
Long-term debt including debt due within one year 5 | $ | 17,169 |
| |
Derivatives relating to: 4 | | |
Long-term debt including debt due within one year 3 | | $ | 16,791 |
|
Derivatives relating to: 2 | | |
| Foreign currency contracts | 20 |
| 33 |
|
| Total liabilities at fair value | $ | 17,189 |
| $ | 16,824 |
|
| |
| 1. | Treasury bills, time deposits, and money market funds included in "Cash and cash equivalents" and money market funds included in "Other current assets" in the interim Condensed Consolidated Balance Sheets and held at amortized cost, which approximates fair value. |
| |
| 2. | Primarily time deposits with maturities of greater than three months at time of acquisition. |
| |
3. | The Company’s investments in equity securities are included in “Other investments” in the interim Condensed Consolidated Balance Sheets. |
| |
4. | See Note 2119 for the classification of derivatives in the interim Condensed Consolidated Balance Sheets. |
| |
5.3. | See Note 21Fair value is based on quoted market prices for informationthe same or similar issues, or on fair value measurementscurrent rates offered to the company for debt of long-term debt.the same remaining maturities and terms. |
| | | Basis of Fair Value Measurements on a Recurring Basis at Dec 31, 2018 | Significant Other Observable Inputs (Level 2) | |
| Basis of Fair Value Measurements on a Recurring Basis at December 31, 2019 | Significant Other Observable Inputs (Level 2) |
| In millions | Significant Other Observable Inputs (Level 2) |
| Assets at fair value: | |
Cash equivalents and restricted cash equivalents 1 | $ | 8,269 |
| $ | 454 |
|
Marketable securities 2 | 29 |
| |
Equity securities 3 | 2 |
| |
Derivatives relating to: 4 | | |
Derivatives relating to: 2 | | |
| Foreign currency contracts | 72 |
| 16 |
|
| Total assets at fair value | $ | 8,372 |
| $ | 470 |
|
| Liabilities at fair value: | | |
Long-term debt including debt due within one year 5 | $ | 13,091 |
| |
Derivatives relating to: 4 | | |
Long-term debt including debt due within one year 3 | | $ | 17,251 |
|
Derivatives relating to: 2 | | |
| Foreign currency contracts | 21 |
| 17 |
|
| Total liabilities at fair value | $ | 13,112 |
| $ | 17,268 |
|
| |
1. | Treasury bills, time deposits, and money market funds included in "Cash and cash equivalents" and money market funds included in "Other current assets" in the interim Condensed Consolidated Balance Sheets and held at amortized cost, which approximates fair value. |
| |
2. | Primarily time deposits with maturities of greater than three months at time of acquisition. |
| |
3. | The Company’s investments in equity securities are included in “Other investments” in the interim Condensed Consolidated Balance Sheets. |
| |
4. | See Note 21 for the classification of derivatives in the interim Condensed Consolidated Balance Sheets |
| |
5. | See Note 21 for information on fair value measurements of long-term debt. |
1. Treasury bills, time deposits, and money market funds included in "Cash and cash equivalents" and money market funds included in "Other current assets" in the interim Condensed Consolidated Balance Sheets and held at amortized cost, which approximates fair value.
2. See Note 19 for the classification of derivatives in the interim Condensed Consolidated Balance Sheets
3. Fair value is based on quoted market prices for the same or similar issues, or on current rates offered to the company for debt of the same remaining maturities and terms.
Fair Value Measurements on a Nonrecurring Basis
During the secondfirst quarter of 2019,2020, the Company recorded goodwill impairment charges related to the Nutrition & Biosciencesgoodwill and long-lived assets within the Non-Core segments.segment. See Note 13 for further discussion of these fair value measurements.
The Internal SP Distribution served as a triggering event to assess equity method investments for impairment. The Company recorded an other-than-temporary impairment, classified as Level 3 measurements, on an equity method investment for the threeNotes 11 and six months ended June 30, 2019. The impairment charge of $63 million was recorded in "Restructuring and asset related charges - net" in the interim Consolidated Statements of Operations. See Note 5 for further discussion of these fair value measurements.
NOTE 2321 - SEGMENTS AND GEOGRAPHIC REGIONS
Effective June 1, 2019,In the first quarter of 2020, in preparation for the Proposed N&B Transaction, DuPont changed its management and reporting structure resulting into realign costs associated with its polysaccharides pre-commercial activities from the creation of a new Non-Core segment ("Second Quarter Segment Realignment").
The Second Quarter Segment Realignment resulted into the following being realigned to Non-Core:
| |
◦ | Photovoltaic and Advanced Materials business unit (including the HSC Group joint ventures: DC HSC Holdings LLC and Hemlock Semiconductor L.L.C) from the Electronics & Imaging segment; |
| |
◦ | Biomaterials and Clean Technologies business units from the Nutrition & Biosciences segment; |
| |
◦ | DuPont Teijin Films joint venture from the Transportation & Industrial (formerly known as Transportation & Advanced Polymers) segment; and |
| |
◦ | Sustainable Solutions business unit from the Safety & Construction segment. |
•In addition, the following changes have occurred:
| |
◦ | Consolidation of the Nutrition & Health business with the Industrial Biosciences business within the Nutrition & Biosciences reportableN&B segment. Previously, Nutrition & Health and Industrial Biosciences were separate operating segments which did not meet the quantitative thresholds. |
| |
◦ | Pre-commercial activities related to the Biomaterials business unit was realigned from Corporate to Non‑Core, with the remaining pre-commercial activities realigned to the Nutrition & Biosciences segment. |
The reporting changes have been retrospectively reflected in the segment results for all periods presented.
Prior to April 1, 2019, the Company's measure of profit/profit / loss for segment reporting purposes is pro forma Operating EBITDA as this is the manner in which the Company's chief operating decision maker ("CODM") assessed performance and allocates resources. The Company defines pro forma Operating EBITDA as pro forma earnings (i.e. pro forma "Income (loss) from continuing operations before income taxes") before interest, depreciation, amortization, non-operating pension / other post employment benefits (“OPEB”) / charges, and foreign exchange gains/losses, excluding the impact of costs historically allocated to the materials science and agriculture businesses that did not meet the criteria to be recorded as discontinued operations and adjusted for significant items. Effective April 1, 2019, the Company's measure of profit/loss for segment reporting purposes is Operating EBITDA as this is the manner in which the Company's chief operating decision maker ("CODM") assesses performance and allocates resources. The Company defines Operating EBITDA as earnings (i.e., “Income from continuing operations before income taxes") before interest, depreciation, amortization, non-operating pension / OPEB benefits / charges, and foreign exchange gains / losses, adjusted for significant items. Reconciliations of these measures are provided on the following pages.
Pro forma adjustments were determined in accordance with Article 11 of Regulation S-X. Pro forma financial information is based on the Consolidated Financial Statements of DuPont, adjusted to give effect to the impact of certain items directly attributable to the Distributions, and the Term Loan Facilities, the 2018 Senior Notes and the Funding CP Issuance (together, the "Financings"), including the use of proceeds from such Financings (collectively the "Transactions"). The historical consolidated financial information has been adjusted to give effect to pro forma events that are (1) directly attributable to the Transactions, (2) factually supportable and (3) with respect to the statements of operations, expected to have a continuing impact on the results. Events that are not expected to have a continuing impact on the combined results are excluded from the pro forma adjustments. Pro forma adjustments impacting consolidated results are outlined in the Supplemental Unaudited Pro Forma Combined Financial Information section contained in Management's Discussion and Analysis ("MD&A"). Those pro forma adjustments include the impact of various supply agreements entered into in connection with the Dow Distribution ("supply agreements") and are outlined in the Supplemental Unaudited Pro Forma Combined Information section of the MD&A as adjustments to "Cost of sales". The impact of these supply agreements are reflected in prosales." Pro forma Operating EBITDA for the periods noted abovethree months ended March 31, 2019 has been adjusted to reflect the supply agreements if they had been effective January 1, 2018 as they are included in the measure of profit/loss reviewed by the CODM in order to show meaningful comparability among periods while assessing performance and making resource allocation decisions. There were no pro forma adjustments for the three months ended June 30, 2019.March 31, 2020.
|
| | | | | | | | | | | | | | | | | | | | | |
| Segment Information | Elect. & Imaging | Nutrition & Biosciences | Transp. & Industrial | Safety & Const. | Non-Core | Corp. | Total |
| In millions |
| Three Months Ended March 31, 2020 | | | | | | | |
| Net sales | $ | 884 |
| $ | 1,551 |
| $ | 1,144 |
| $ | 1,276 |
| $ | 366 |
| $ | — |
| $ | 5,221 |
|
Operating EBITDA 1 | $ | 253 |
| $ | 385 |
| $ | 308 |
| $ | 368 |
| $ | 42 |
| $ | (35 | ) | $ | 1,321 |
|
| Equity in earnings of nonconsolidated affiliates | $ | 9 |
| $ | — |
| $ | 1 |
| $ | 7 |
| $ | 22 |
| $ | — |
| $ | 39 |
|
| Three months ended March 31, 2019 | | | | | | | |
| Net sales | $ | 825 |
| $ | 1,535 |
| $ | 1,317 |
| $ | 1,283 |
| $ | 454 |
| $ | — |
| $ | 5,414 |
|
Pro forma operating EBITDA 1 | $ | 288 |
| $ | 349 |
| $ | 373 |
| $ | 374 |
| $ | 98 |
| $ | (52 | ) | $ | 1,430 |
|
Equity in earnings of nonconsolidated affiliates 2 | $ | 3 |
| $ | — |
| $ | — |
| $ | 8 |
| $ | 30 |
| $ | — |
| $ | 41 |
|
|
| | | | | | | | | | | | | | | | | | | | | |
| Segment Information | Elect. & Imaging | Nutrition & Biosciences | Transp. & Industrial | Safety & Const. | Non-Core | Corp. | Total |
| In millions |
| Three months ended June 30, 2019 | | | | | | | |
| Net sales | $ | 858 |
| $ | 1,558 |
| $ | 1,269 |
| $ | 1,341 |
| $ | 442 |
| $ | — |
| $ | 5,468 |
|
Operating EBITDA 1 | $ | 246 |
| $ | 391 |
| $ | 357 |
| $ | 382 |
| $ | 99 |
| $ | (53 | ) | $ | 1,422 |
|
| Equity in earnings (losses) of nonconsolidated affiliates | $ | 5 |
| $ | — |
| $ | 2 |
| $ | 7 |
| $ | 35 |
| $ | — |
| $ | 49 |
|
| Three months ended June 30, 2018 | | | | | | | |
| Net sales | $ | 921 |
| $ | 1,621 |
| $ | 1,417 |
| $ | 1,372 |
| $ | 526 |
| $ | — |
| $ | 5,857 |
|
Pro forma operating EBITDA 1 | $ | 290 |
| $ | 383 |
| $ | 402 |
| $ | 296 |
| $ | 123 |
| $ | (72 | ) | $ | 1,422 |
|
| Equity in earnings (losses) of nonconsolidated affiliates | $ | 6 |
| $ | — |
| $ | 1 |
| $ | 8 |
| $ | 39 |
| $ | — |
| $ | 54 |
|
| Six months ended June 30, 2019 | | | | | | | |
| Net sales | $ | 1,683 |
| $ | 3,093 |
| $ | 2,586 |
| $ | 2,624 |
| $ | 896 |
| $ | — |
| $ | 10,882 |
|
Pro forma operating EBITDA 1 | $ | 534 |
| $ | 744 |
| $ | 730 |
| $ | 756 |
| $ | 193 |
| $ | (105 | ) | $ | 2,852 |
|
| Equity in earnings (losses) of nonconsolidated affiliates | $ | 8 |
| $ | — |
| $ | 2 |
| $ | 15 |
| $ | 64 |
| $ | — |
| $ | 89 |
|
| Six months ended June 30, 2018 | | | | | | | |
| Net sales | $ | 1,785 |
| $ | 3,198 |
| $ | 2,795 |
| $ | 2,636 |
| $ | 1,040 |
| $ | — |
| $ | 11,454 |
|
Pro forma operating EBITDA 1 | $ | 567 |
| $ | 751 |
| $ | 791 |
| $ | 622 |
| $ | 233 |
| $ | (136 | ) | $ | 2,828 |
|
| Equity in earnings (losses) of nonconsolidated affiliates | $ | 13 |
| $ | 1 |
| $ | 3 |
| $ | 13 |
| $ | 81 |
| $ | — |
| $ | 111 |
|
| |
| 1. | A reconciliation of "Income (loss) from continuing operations, net of tax" to Operating EBITDA and pro forma Operating EBITDA, as applicable, is provided below. |
| |
| 2. | Represents equity in earnings (losses) of nonconsolidated affiliates included in pro forma Operating EBITDA, the Company's measure of profit/loss for segment reporting purposes, which excludes significant items. Accordingly, the Non-Core segment presented above excludes a restructuring charge of $1 million which is presented in "Equity in earnings of nonconsolidated affiliates" in the Company's interim Consolidated Statement of Operations. |
|
| | | | | | |
| Reconciliation of "(Loss) Income from continuing operations, net of tax" to Operating EBITDA for the Three Months Ended June 30, 2019 and 2018 | Three Months Ended |
| In millions | June 30, 2019 | June 30, 2018 |
| (Loss) Income from continuing operations, net of tax | $ | (1,103 | ) | $ | 31 |
|
| + Provision for income taxes on continuing operations | 155 |
| 99 |
|
| (Loss) income from continuing operations before income taxes | $ | (948 | ) | $ | 130 |
|
| + Depreciation and amortization | 507 |
| 551 |
|
- Interest income 1 | 9 |
| 11 |
|
| + Interest expense | 165 |
| 171 |
|
- Non-operating pension/OPEB benefit1 | 18 |
| 28 |
|
- Foreign exchange gains (losses), net 1 | (17 | ) | 53 |
|
+ Costs historically allocated to the materials science and agriculture businesses 2 | — |
| 352 |
|
+ Pro forma adjustments 3 | — |
| (52 | ) |
| - Adjusted significant items | (1,708 | ) | (362 | ) |
Operating EBITDA 3 | $ | 1,422 |
| $ | 1,422 |
|
|
| | | | | | |
| Reconciliation of "Income (loss) from continuing operations, net of tax" to Operating EBITDA for the Three Months Ended March 31, 2020 and 2019 | Three Months Ended March 31, |
| In millions | 2020 | 2019 |
| Loss from continuing operations, net of tax | $ | (610 | ) | $ | (74 | ) |
| + Provision for (benefit from) income taxes on continuing operations | 44 |
| (91 | ) |
| Loss from continuing operations before income taxes | $ | (566 | ) | $ | (165 | ) |
+ Pro forma adjustments 1 | — |
| 122 |
|
| + Depreciation and amortization | 772 |
| 527 |
|
- Interest income 2 | 2 |
| 40 |
|
+ Interest expense 3 | 173 |
| 180 |
|
- Non-operating pension/OPEB benefit 2 | 11 |
| 21 |
|
- Foreign exchange gains (losses), net 2 | (8 | ) | (61 | ) |
+ Costs historically allocated to the materials science and agriculture businesses 4 | — |
| 256 |
|
- Significant items 5 | (947 | ) | (510 | ) |
Operating EBITDA 1 | $ | 1,321 |
| $ | 1,430 |
|
1. For the three months ended March 31, 2019, operating EBITDA is on a pro forma basis. The pro forma adjustment reflects the net pro forma impact of items directly attributable to the Transactions, as applicable.
| |
1.2. | Included in Sundry"Sundry income (expense) - net." |
2.3. The three months ended March 31, 2020 excludes N&B financing fee amortization. Refer to details of significant items below.
4. Costs previously allocated to the materials science and agriculture businesses that did not meet the definition of expenses related to discontinued operations in accordance with ASC 205.
3. For the three months ended June 30, 2018, operating EBITDA is on a pro forma basis. Refer to the Supplemental Unaudited Pro Forma Combined Financial Information contained in the MD&A for additional information related to the pro forma adjustments.
|
| | | | | | |
| Reconciliation of "(Loss) Income from continuing operations, net of tax" to Pro Forma Operating EBITDA for the Six months Ended June 30, 2019 and 2018 | Six Months Ended |
| In millions | June 30, 2019 | June 30, 2018 |
| Loss from continuing operations, net of tax | $ | (1,177 | ) | $ | (42 | ) |
| + Provision for income taxes on continuing operations | 64 |
| 164 |
|
| (Loss) Income from continuing operations before income taxes | $ | (1,113 | ) | $ | 122 |
|
| + Depreciation and amortization | 1,034 |
| 1,102 |
|
- Interest income 1 | 49 |
| 21 |
|
| + Interest expense | 345 |
| 342 |
|
| - Non-operating pension/OPEB benefit | 39 |
| 55 |
|
- Foreign exchange gains (losses), net 1, 2 | (78 | ) | (72 | ) |
+ Costs historically allocated to the materials science and agriculture businesses 3 | 256 |
| 608 |
|
+ Pro forma adjustments 4 | 122 |
| (150 | ) |
| - Adjusted significant items | (2,218 | ) | (808 | ) |
Pro Forma Operating EBITDA 4 | $ | 2,852 |
| $ | 2,828 |
|
| |
1. | Included in "Sundry income (expense) - net." |
| |
2. | Excludes a $50 million pretax foreign exchange loss significant item related to adjustments to Historical EID's foreign currency exchange contracts as a result of U.S. tax reform during the six months ended June 30, 2018. |
3. Costs previously allocated to the materials science and agriculture businesses that did not meet the definition of expenses related to discontinued operations in accordance with ASC 205.
4. Refer to the Supplemental Unaudited Pro Forma Combined Financial Information contained in the MD&A section for additional information related to the pro forma adjustments.
5. The significant items for the three months ended June 30, 2019,March 31, 2020, are presented on an as reported basis. The adjusted significant items for the sixthree months ended June 30,March 31, 2019 andare presented on a pro forma basis.
The significant items for the three and six months ended June 30, 2018,March 31, 2020, are presented on an as reported basis. The adjusted significant items for the three months ended March 31, 2019 are presented on a pro forma basis. The following tables summarize the pretaxpre-tax impact of adjusted significant items by segment that are excluded from Operating EBITDA and pro forma Operating EBITDA above: |
| | | | | | | | | | | | | | | | | | | | | |
| Significant Items by Segment for the Three Months Ended March 31, 2020 | Elect. & Imaging | Nutrition & Biosciences | Transp. & Industrial | Safety & Construction | Non-Core | Corporate | Total |
| In millions |
Integration and separation costs 1 | $ | — |
| $ | — |
| $ | — |
| $ | — |
| $ | — |
| $ | (197 | ) | $ | (197 | ) |
Restructuring and asset related charges - net 2 | (4 | ) | (6 | ) | (25 | ) | (25 | ) | — |
| (74 | ) | (134 | ) |
Goodwill impairment charge 3 | — |
| — |
| — |
| — |
| (533 | ) | — |
| (533 | ) |
Asset impairment charges 4 | — |
| — |
| — |
| — |
| (270 | ) | — |
| (270 | ) |
Gain on divestiture 5 | 197 |
| — |
| — |
| — |
| — |
| — |
| 197 |
|
N&B financing fee amortization 6 | — |
| — |
| — |
| — |
| — |
| (10 | ) | (10 | ) |
| Total | $ | 193 |
| $ | (6 | ) | $ | (25 | ) | $ | (25 | ) | $ | (803 | ) | $ | (281 | ) | $ | (947 | ) |
1. Integration and separation costs related to the post-Merger integration and the intended separation of the N&B Business. |
| | | | | | | | | | | | | | | | | | | | | |
| Significant Items by Segment for the Three Months Ended June 30, 2019 | Elect. & Imaging | Nutrition & Biosciences | Transp. & Industrial | Safety & Const. | Non-Core | Corp. | Total |
| In millions |
Integration and separation costs 1 | $ | — |
| $ | — |
| $ | — |
| $ | — |
| $ | — |
| $ | (347 | ) | $ | (347 | ) |
Restructuring and asset related charges - net 2 | (7 | ) | (85 | ) | (12 | ) | (20 | ) | (1 | ) | (13 | ) | (138 | ) |
Goodwill impairment charges 3 | — |
| (933 | ) | — |
| — |
| (242 | ) | — |
| (1,175 | ) |
Income tax related items 4 | — |
| — |
| — |
| (48 | ) | — |
| — |
| (48 | ) |
| Total | $ | (7 | ) | $ | (1,018 | ) | $ | (12 | ) | $ | (68 | ) | $ | (243 | ) | $ | (360 | ) | $ | (1,708 | ) |
| |
1. | Integration and separation costs related to the Merger, post-Merger integration and business separation activities. |
| |
2. | Includes Board approved restructuring plans and asset related charges, which include other asset impairments. See Note 5 for additional information. |
| |
3. | See Note 13 for additional information. |
3. See Note 11 for additional information.
4. $48 million charge includedSee Note 5 for additional information.
5. Reflected in "Sundry income (expense) - net" reflects a reductionnet." Refer to Note 3 for additional information.
6. Reflected in gross proceeds from lower withholding taxes related"Interest expense" and relates to a prior year legal settlement.the intended separation of the N&B Business.
|
| | | | | | | | | | | | | | | | | | | | | |
| Adjusted Significant Items by Segment for the Three Months Ended June 30, 2018 (Pro Forma) | Elect. & Imaging | Nutrition & Biosciences | Transp. & Industrial | Safety & Const. | Non-Core | Corp. | Total |
| In millions |
Merger-related inventory step-up amortization 1 | $ | — |
| $ | (4 | ) | $ | — |
| $ | — |
| $ | — |
| $ | — |
| $ | (4 | ) |
Net loss on divestitures and changes in joint venture ownership 2 | — |
| — |
| — |
| — |
| (21 | ) | — |
| (21 | ) |
Integration and separation costs 3 | — |
| — |
| — |
| — |
| — |
| (291 | ) | (291 | ) |
Restructuring and asset related charges - net 4 | (1 | ) | — |
| — |
| (12 | ) | 5 |
| (38 | ) | (46 | ) |
| Total | $ | (1 | ) | $ | (4 | ) | $ | — |
| $ | (12 | ) | $ | (16 | ) | $ | (329 | ) | $ | (362 | ) |
| |
1. | Includes the fair value step-up in Historical EID's inventories as a result of the Merger and the acquisition of FMC Corporation's Health and Nutrition business in November 2017. |
| |
2. | Reflected in "Sundry income (expense) - net." |
| |
3. | Integration and separation costs related to the Merger, post-Merger integration and business separation activities. |
| |
4. | Includes Board approved restructuring plans and asset related charges, which includes other asset impairments. See Note 5 for additional information. |
| | | Adjusted Significant Items by Segment for the Six Months Ended June 30, 2019 (Pro Forma) | Elect. & Imaging | Nutrition & Biosciences | Transp. & Industrial | Safety & Const. | Non-Core | Corp. | Total | |
| Adjusted Significant Items by Segment for the Three Months Ended March 31, 2019 (Pro Forma) | Elect. & Imaging | Nutrition & Biosciences | Transp. & Industrial | Safety & Construction | Non-Core | Corporate | Total |
| In millions | Elect. & Imaging | Nutrition & Biosciences | Transp. & Industrial | Safety & Const. | Non-Core | Corp. | Total |
Integration and separation costs 1 | — |
| — |
| — |
| — |
| — |
| $ | (438 | ) | $ | (438 | ) |
Restructuring and asset related charges - net 2 | (7 | ) | (112 | ) | (12 | ) | (22 | ) | — |
| (57 | ) | (210 | ) | — |
| (27 | ) | — |
| (2 | ) | 1 |
| (44 | ) | (72 | ) |
Goodwill impairment charges 3 | — |
| (933 | ) | — |
| — |
| (242 | ) | — |
| (1,175 | ) | |
Income tax related items 4 | — |
| — |
| — |
| (48 | ) | — |
| — |
| (48 | ) | |
| Total | $ | (7 | ) | $ | (1,045 | ) | $ | (12 | ) | $ | (70 | ) | $ | (242 | ) | $ | (842 | ) | $ | (2,218 | ) | $ | — |
| $ | (27 | ) | $ | — |
| $ | (2 | ) | $ | 1 |
| $ | (482 | ) | $ | (510 | ) |
| |
| 1. | Integration and separation costs related to the Merger, post-Merger integration and business separation activities. |
| |
| 2. | Includes Board approved restructuring plans and asset related charges, which include other asset impairments.charges. See Note 5 for additional information. |
| |
3. | See Note 13 for additional information. |
4. $48 million charge included in "Sundry income (expense) - net" reflects a reduction in gross proceeds from lower withholding taxes related to a prior year legal settlement.
|
| | | | | | | | | | | | | | | | | | | | | |
| Adjusted Significant Items by Segment for the Six Months Ended June 30, 2018 (Pro Forma) | Elect. & Imaging | Nutrition & Biosciences | Transp. & Industrial | Safety & Const. | Non-Core | Corp. | Total |
| In millions |
Merger-related inventory step-up amortization 1 | $ | — |
| $ | (68 | ) | $ | — |
| $ | (5 | ) | $ | — |
| $ | — |
| $ | (73 | ) |
Net loss on divestitures and changes in joint venture ownership 2 | — |
| — |
| — |
| — |
| (21 | ) | — |
| (21 | ) |
Integration and separation costs 3 | — |
| — |
| — |
| — |
| — |
| (565 | ) | (565 | ) |
Restructuring and asset related charges - net 4 | (2 | ) | — |
| 1 |
| (19 | ) | 6 |
| (85 | ) | (99 | ) |
Income tax related item 5 | — |
| — |
| — |
| — |
| — |
| (50 | ) | (50 | ) |
| Total | $ | (2 | ) | $ | (68 | ) | $ | 1 |
| $ | (24 | ) | $ | (15 | ) | $ | (700 | ) | $ | (808 | ) |
| |
1. | Includes the fair value step-up in Historical EID's inventories as a result of the Merger and the acquisition of FMC Corporation's Health and Nutrition business in November 2017. |
| |
2. | Reflected in "Sundry income (expense) - net". |
| |
3. | Integration and separation costs related to the Merger, post-Merger integration and business separation activities. |
| |
4. | Includes Board approved restructuring plans and asset related charges, which includes other asset impairments. See Note 5 for additional information. |
| |
5. | Includes a foreign exchange loss related to adjustments to Historical EID's foreign currency exchange contracts as a result of U.S. tax reform. |
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
Effective August 31, 2017, pursuant to the merger of equals transactions contemplated by the Agreement and Plan of Merger, dated as of December 11, 2015, as amended on March 31, 2017 ("Merger Agreement"), The Dow Chemical Company ("Historical Dow") and E. I. du Pont de Nemours and Company ("Historical EID") each merged with subsidiaries of DowDuPont Inc. ("DowDuPont") and, as a result, Historical Dow and Historical EID became subsidiaries of DowDuPont (the "Merger"). Prior to the Merger, DowDuPont did not conduct any business activities other than those required for its formation and matters contemplated by the Merger Agreement. Historical Dow was determined to be the accounting acquirer in the Merger.
As discussedDowDuPont completed a series of internal reorganizations and realignment steps in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018, DowDuPont previously announced its intentorder to separate into three, independent, publicly traded companies - one for each of its agriculture, materials science and specialty products businesses. DowDuPont formed two wholly owned subsidiaries: Dow Inc. ("Dow", formerly known as Dow Holdings Inc.), to serve as a holding company for its materials science business, and Corteva, Inc. ("Corteva"), to serve as a holding company for its agriculture business.
Effective as of 5:00 p.m. on April 1, 2019, DowDuPont completed the previously announced separation of its materials science business into a separate and independent public company by way of a distribution of Dow through a pro rata dividend in-kind of all of the then-issued and outstanding shares of Dow’s common stock, par value $0.01 per share (the “Dow Common Stock”), to holders of the Company’s common stock, par value $0.01 per share (the “DowDuPont common stock”), as of the close of business on March 21, 2019 (the “Dow Distribution”).
Effective as of 12:01 a.m. on June 1, 2019, DuPont de Nemours, Inc. (formerly known as DowDuPont Inc.), completed the previously announced separation of its agriculture business into a separate and independent public company by way of a distribution of Corteva through a pro rata dividend in-kind of all of the then-issued and outstanding shares of Corteva’s common stock, par value $0.01 per share (the “Corteva Common Stock”), to holders of the Company’s common stock, par value $0.01 per share, as of the close of business on May 24, 2019 (the “Corteva Distribution” and, together with the Dow Distribution, the “Distributions”).
Following the Corteva Distribution, the Company holds the specialty products business. On June 1, 2019, DowDuPont changed its registered name from "DowDuPont Inc." to "DuPont de Nemours, Inc." doing business as "DuPont" (the "Company"). Beginning on June 3, 2019, the Company's common stock is traded on the NYSE under the ticker symbol "DD".
These interim Consolidated Financial Statements present the consolidated financial position of DuPont as of June 30, 2019 and December 31, 2018 and theThe results of operations of DuPont for the three and six months ended June 30,March 31, 2019 and 2018 giving effect to the Distributions, withpresent the historical financial results of Dow and Corteva reflected as discontinued operations. The cash flows and comprehensive income related to Dow and Corteva have not been segregated and are included as applicable, in the interim Consolidated Statements of Cash Flows and interim Consolidated Statements of Comprehensive Income, respectively, for all periods presented.the applicable period. Unless otherwise indicated, the information included in Management's Discussion and Analysisthe notes to the interim Consolidated Financial Statements refer only to DuPont's continuing operations and do not include discussion of balances or activity of Dow or Corteva.
The statements of operations and pro forma statements of operations included in this report and as discussed below include costs previously allocated to the materials science and agriculture businesses that did not meet the definition of expenses related to discontinued operations in accordance with Financial Accounting Standards Codification 205, "Presentation of Financial Statements" ("ASC 205") and thus are reflected in the Company's results of continuing operations. A significant portion of these costs relate to Historical Dow and consist of leveraged services provided through service centers, as well as other corporate overhead costs related to information technology, finance, manufacturing, research & development, sales & marketing, supply chain, human resources, sourcing & logistics, legal and communications, public affairs & government affairs functions. These costs are no longer incurred by the Company following the Distributions.
RECENT DEVELOPMENTS
Business SeparationsCOVID-19
The novel coronavirus (“COVID-19”) pandemic has resulted in significant economic disruption and Separationcontinues to adversely impact the broader global economy, including certain of the Company’s customers and Distribution Agreements
DuPont completedsuppliers. Given the separationdynamic nature of Dowthis situation, the Company cannot reasonably estimate the impacts of COVID-19 on April 1, 2019 and Corteva on June 1, 2019. In connection with the Dow Distribution and Corteva Distribution, DuPont has entered into certain agreements that provide for the allocationits financial condition, results of DuPont’s assets, employees, liabilities and obligations (including its investments, property and employee benefits and tax-related assets and liabilities) among DuPont, Dow, and Corteva (together, the “Parties” and each a “Party”), and provides a framework for DuPont’s relationship with Dow and Corteva following the Distributions. Effective April 1, 2019, the Parties enteredoperations or cash flows into the following agreements:foreseeable future. The ultimate extent of the effects of the COVID-19 pandemic on the Company is highly uncertain and will depend on future developments, and such effects could exist for an extended period of time even after the pandemic subsides.
SeparationDuring the first quarter of 2020, the Company benefited from COVID-19 related demand in certain markets, principally personal protection, food & beverage, health & wellness and Distribution Agreement - The Parties entered into an agreement that sets forth, among other things, the agreements among the Parties regarding the principal transactions necessaryelectronics. Although management currently expects strong demand from these certain markets to effect the Distributions. It also sets forth other agreements that govern certain aspects of the Parties’ ongoing relationships after the completion of the Distributions (the "Separation and Distribution Agreement").
Tax Matters Agreement - The Parties entered into an agreement that governs their respective rights, responsibilities and obligations with respect to tax liabilities and benefits, tax attributes, the preparation and filing of tax returns, the control of audits and other tax proceedings and other matters regarding taxes.
Employee Matters Agreement - The Parties entered into an agreement that identifies employees and employee-related liabilities (and attributable assets) to be allocated (either retained, transferred and accepted, or assigned and assumed, as applicable) to the Parties as part of the Distributions and describes when and how the relevant transfers and assignments will occur.
Intellectual Property Cross-License Agreement - DuPont entered into an Intellectual Property Cross-License Agreement with Dow (the “DowDuPont-Dow IP Cross-License Agreement”). The DowDuPont-Dow IP Cross-License Agreement sets forth the terms and conditions under which the applicable Parties may use in their respective businesses, following each of the Distributions, certain know-how (including trade secrets), copyrights, software, and certain patents and standards, allocated to another Party pursuant to the Separation and Distribution Agreement.
In addition to the agreements above, DuPont has entered into certain various supply agreements with Dow. These agreements provide for different pricing than the historical intercompany and intracompany practices prior to the Distributions.
Effective June 1, 2019, in connection with the Corteva Distribution, DuPont and Corteva enteredcontinue into the following agreements:
Intellectual Property Cross-License Agreement - DuPontsecond quarter of 2020, the COVID-19 pandemic is expected to continue to significantly adversely impact demand in automotive, oil & gas, and Corteva entered into an Intellectual Property Cross-License Agreement (the “DuPont-Corteva IP Cross-License Agreement”). The DuPont-Corteva IP Cross-License Agreement sets forth the terms and conditions under which the applicable parties may use in their respective businesses, following the Corteva Distribution, certain know-how (including trade secrets), copyrights, software, and certain patents and standards, allocatedselect industrial end-markets. In response to another Party pursuant to the Separation and Distribution Agreement.
Letter Agreement - The Company entered into a letter agreement (the "Letter Agreement") with Corteva that sets forth certain additional terms and conditions related to the Corteva Distribution, including certain limitations on DuPont’s and Corteva's ability to transfer certain businesses and assets to third parties without assigning certain of such Party’s indemnification obligations under the Separation and Distribution Agreement to the other Party to the transferee of such businesses and assets or meeting certain other alternative conditions. The Letter Agreement further outlines the allocation between DuPont and Corteva of liabilities associated with certain legal and environmental matters, including liabilities associated with discontinued and/or divested operations and businesses of Historical EID. See Note 15 to the interim Consolidated Financial Statements for more information regarding the allocation.
Amended and Restated Tax Matters Agreement - The Parties entered into an amendment and restatement of the Tax Matters Agreement, between DuPont, Corteva and Dow, effective as of April 1, 2019 (as so amended and restated, the “Amended and Restated Tax Matters Agreement”). The Amended and Restated Tax Matters Agreement governs the Parties’ rights, responsibilities and obligations with respect to tax liabilities and benefits, tax attributes, the preparation and filing of tax returns, the control of audits and other tax proceedings and other matters regarding taxes. The Parties amended and restated the Tax Matters Agreement in connection with the Corteva Distribution in order to allocate between the DuPont and Corteva certain rights and obligations ofthis uncertainty, the Company providedis delaying certain capital investments in the original form of the Tax Matters Agreement.
Segment Realignment
Effective June 1, 2019, DuPont changed its managementselect sectors, and reporting structure resultingidling production at several manufacturing sites, predominantly production plants in the creation of a new Non-Core segment ("Second Quarter Segment Realignment").
These changes result in the following being realigned to Non-Core:
Photovoltaic and Advanced Materials business unit (including the HSC Group joint ventures: DC HSC Holdings LLC and Hemlock Semiconductor L.L.C) from the Electronics & Imaging segment;
Biomaterials and Clean Technologies business units from the Nutrition & Biosciences segment;
DuPont Teijin Films joint venture from the Transportation & Industrial (formerly Transportation & Advanced Polymers) segment; and
Sustainable Solutions business unit from the Safety & Construction segment.
In addition, in response to COVID-19 related market disruption and uncertainties, the following changes have occurred:
ConsolidationCompany has proactively taken steps to enhance its liquidity position. In April 2020, the Company entered into a $1.0 billion 364-day revolving credit facility (the “$1B Revolving Credit Facility") that replaces its $750 million 364-day revolving credit facility (the “Old 364-Day Revolving Credit Facility”), and completed a public underwritten offering of the Nutrition & Health business with the Industrial Biosciences business within the Nutrition & Biosciences reportable segment. Previously, Nutrition & Health and Industrial Biosciences were separate operating segments which did not meet the quantitative thresholds.
Pre-commercial activities related to the Biomaterials business unit was realigned from Corporate to Non-Core, with the remaining pre-commercial activities realigned to the Nutrition & Biosciences segment.
$2 billion of 2.169 percent fixed rate notes due May 1, 2023 (the “May Debt Offering”). Refer to Notes 4Liquidity and 23 to the interim Consolidated Financial StatementsCapital Resources for additionalmore information.
Nutrition & Biosciences Financing
On December 15, 2019, the Company entered into definitive agreements to separate and combine the Nutrition & Biosciences business segment (the "N&B Business") with International Flavors & Fragrances Inc. ("IFF") in a tax-efficient Reverse Morris Trust transaction, (the "Proposed N&B Transaction"). In the first quarter of 2020, DuPont and Nutrition & Biosciences, Inc. (presently a wholly owned subsidiary of DuPont) (“N&B Inc.”) entered into a senior unsecured term loan agreement in the amount of $1.25 billion split evenly between three- and five-year facilities. As a result of entry into the term loan agreement, the commitments under the Bridge Commitment Letter were reduced to $6.25 billion. The remaining $6.25 billion is expected to be funded through the N&B Notes Offering and/or the Bridge Loans. The proceeds from drawdowns on the term loan facilities and the N&B Notes Offering, if any, and/or Bridge Loans would be used to make a one-time $7.3 billion cash payment, subject to adjustment, to DuPont (the "Special Cash Payment") and to pay the related transaction fees and expenses. The commitments under the Bridge Letter and the availability of funding under the term loan are subject to customary closing conditions including among others, the satisfaction of substantially all the conditions to the consummation of the proposed transaction with IFF.
2020 Restructuring Program
During the first quarter of 2020, the Company approved restructuring actions designed to capture near-term cost reductions following the expected closure of the Proposed N&B Transaction (the "2020 Restructuring Program"). For the three months ended March 31, 2020, the Company recorded a pre-tax charge related to the 2020 Restructuring Program of $111 million, recognized in "Restructuring and asset related charges - net" in the Company's interim Consolidated Statements of Operations. At March 31, 2020, total liabilities related to the program were $96 million. Future cash payments related to the 2020 Restructuring Program are anticipated to be up to $130 million primarily related to the payment of severance and related benefits and contract termination charges.
Divestitures
In the first quarter of 2020, the Company completed the sale of its Compound Semiconductor Solutions business unit, a part of the Electronics & Imaging segment, to SK Siltron. Proceeds received in the first quarter of 2020 from the sale of the business were approximately $420 million. The sale resulted in a pre-tax gain of $197 million ($102 million net of tax) which was recorded in "Sundry income (expense) - net" in the Company's interim Consolidated Statements of Operations. Refer to Note 3 of the interim Consolidated Financial Statements.
Non-Core Goodwill Impairments
During the three months ended June 30, 2019,March 31, 2020, the Company was required to perform interim impairment tests of its goodwill dueand long-lived assets as expectations of proceeds related to certain potential divestitures within the internal distribution of the specialty products legal entities from Historical EIDNon-Core segment gave rise to DowDuPont (the "Internal SP Distribution")fair value indicators and, the Second Quarter Segment Realignment.thus, served as triggering events. As a result of the analysesanalysis performed, the Company recorded pre-tax, non-cash impairment charges during the three and six months ended June 30, 2019 totaling $1,175 million, of which $933 million related to the Nutrition & Biosciences segment and $242 million related to the Non-Core segment.goodwill of $533 million. The charges were recognized in "Goodwill impairment charge" in the interim Consolidated Statements of Operations. Refer to Note 1311 of the interim Consolidated Financial Statements.
Equity Method Investment Impairment
During the second quarter of 2019, in connection with the Internal SP Distribution and the impairment of the Industrial Biosciences reporting unit, the The Company performed an impairment analysis on the reporting unit's equity method investments. As a result of the analysis performed, the Companyalso recorded pre-tax, non-cash impairment charges of $63$270 million related to write-down the valuelong-lived assets. The charges were
recognized in "Restructuring“Restructuring and asset related charges - net"net” in the interim Consolidated Statements of Operations. Refer to Note 5 of the interim Consolidated Financial Statements.
Reverse Stock Split
On May 23, 2019, stockholders of DowDuPont approved a 1-for-3 reverse stock split of DowDuPont shares of common stock with par value of $0.01 per share, which became effective immediately following the Corteva Distribution on June 1, 2019. All comparable periods presented have been retrospectively revised to reflect this change.
Share Buyback Program
On June 1, 2019, the Company's Board of Directors approved a new $2 billion share buyback program, which expires on June 1, 2021. At June 30, 2019, the Company had repurchased 1.4 million shares under this program at a total cost of $102 million.
Dividends
On February 14, 2019,12, 2020, the Board of Directors declared a first quarter dividend of $0.30 per share, paid on March 16, 2020, to shareholders of record on February 28, 2020.
On April 29, 2020, the Company announced that its Board declared a pro rata dividend of $851 million, paid on March 15, 2019, to shareholders of record on February 28, 2019. On March 8, 2019, the Company announced that its Board declared a pro rata dividend of $325 million, paid on May 28, 2019, to shareholders of record on April 26, 2019.
On June 27, 2019, the Company announced that its Board declared a thirdsecond quarter dividend of $0.30 per share payable on September 13, 2019,June 15, 2020, to shareholders of record on July 31, 2019.
2019 Restructuring Program
During the second quarter of 2019 and in connection with the ongoing integration activities, DuPont approved restructuring actions to simplify and optimize certain organizational structures following the completion of the Distributions. As a result of these actions, the Company expects to record total pre-tax restructuring charges of $85 million to $130 million, comprised of approximately $55 million to $80 million of severance and related benefits costs; $30 million to $45 million of asset related charges; and up to $5 million of costs related to contract terminations. For the three and six months ended June 30, 2019, DuPont recorded a pre-tax charge of $53 million, recognized in "Restructuring and asset related charges - net" in the Company's interim Consolidated Statements of Operations. At June 30, 2019, total liabilities related to the program were $50 million. Future cash payments related to this program are anticipated to be approximately $55 million to $85 million, primarily related to the payment of severance and related benefits and contract termination costs.
DowDuPont Cost Synergy Program
In September and November 2017, the Company approved post-merger restructuring actions under the DowDuPont Cost Synergy Program (the “Synergy Program”), adopted by the DowDuPont Board of Directors. The Synergy Program was designed to integrate and optimize the organization following the Merger and in preparation for the Distributions. The Company has recorded pre-tax restructuring charges of $466 million inception-to-date, consisting of severance and related benefit costs of $222 million, asset related charges of $184 million and contract termination charges of $60 million. The Company does not expect to incur further significant charges related to the DowDuPont Cost Synergy program and at June 30, 2019 the program is considered substantially complete.
In connection with these actions, the Company recorded pre-tax charges of $22 million and $94 million for the three and six months ended June 30, 2019, respectively. Future cash payments related to this program are anticipated to be approximately $124 million, primarily related to the payment of severance and related benefits.May 29, 2020.
SELECTED FINANCIAL DATA
| | | | Three Months Ended | Six Months Ended | Three Months Ended |
| In millions, except per share amounts | June 30, 2019 | June 30, 2018 | June 30, 2019 | June 30, 2018 | March 31, 2020 | March 31, 2019 |
| Net sales | $ | 5,468 |
| $ | 5,857 |
| $ | 10,882 |
| $ | 11,454 |
| $ | 5,221 |
| $ | 5,414 |
|
| | | | | | |
| Gross Margin | $ | 1,972 |
| $ | 1,772 |
| $ | 3,765 |
| $ | 3,564 |
| |
| Gross Margin Percentage | 36.1 | % | 30.3 | % | 34.6 | % | 31.1 | % | |
| Cost of sales | | $ | 3,318 |
| $ | 3,621 |
|
| Percent of net sales | | 63.6 | % | 66.9 | % |
| | | | | | |
| Research and development expenses | $ | 232 |
| $ | 270 |
| $ | 499 |
| $ | 544 |
| $ | 236 |
| $ | 267 |
|
| Percent of net sales | 4.2 | % | 4.6 | % | 4.6 | % | 4.7 | % | 4.5 | % | 4.9 | % |
| | | | | | |
| Selling, general and administrative expenses | $ | 642 |
| $ | 768 |
| $ | 1,368 |
| $ | 1,570 |
| $ | 633 |
| $ | 726 |
|
| Percent of net sales | 11.7 | % | 13.1 | % | 12.6 | % | 13.7 | % | 12.1 | % | 13.4 | % |
| | | | | | |
| Effective tax rate - continuing operations | (16.4 | )% | 76.2 | % | (5.8 | )% | 134.4 | % | (7.8 | )% | 55.2 | % |
| | | | | | |
| Net (loss) income available for DuPont common stockholders | $ | (571 | ) | $ | 1,769 |
| $ | (50 | ) | $ | 2,862 |
| $ | (616 | ) | $ | 521 |
|
| | | | | | |
| (Loss) earnings per common share – basic | $ | (0.76 | ) | $ | 2.29 |
| $ | (0.07 | ) | $ | 3.69 |
| |
| (Loss) earnings per common share – diluted | $ | (0.76 | ) | $ | 2.27 |
| $ | (0.07 | ) | $ | 3.69 |
| |
| Earnings per common share – basic | | $ | (0.83 | ) | $ | 0.69 |
|
| Earnings per common share – diluted | | $ | (0.83 | ) | $ | 0.69 |
|
RESULTS OF OPERATIONS
| | | Summary of Sales Results | Three Months Ended | Six Months Ended | Three Months Ended |
| In millions | June 30, 2019 | June 30, 2018 | June 30, 2019 | June 30, 2018 | March 31, 2020 | March 31, 2019 |
| Net sales | $ | 5,468 |
| $ | 5,857 |
| $ | 10,882 |
| $ | 11,454 |
| $ | 5,221 |
| $ | 5,414 |
|
The following table summarizes sales variances by segment and geographic region from the prior year:
| | Sales Variances by Segment and Geographic Region | | | Three Months Ended June 30, 2019 | Six Months Ended June 30, 2019 | |
| Percentage change from prior year | | Three Months Ended March 31, 2020 |
| Local Price & Product Mix | Currency | Volume | Portfolio & Other | Total | Local Price & Product Mix | Currency | Volume | Portfolio & Other | Total | Local Price & Product Mix | Currency | Volume | Portfolio & Other | Total |
| Electronics & Imaging | — | % | (2 | )% | (5 | )% | — | % | (7 | )% | — | % | (2 | )% | (4 | )% | — | % | (6 | )% | (1 | )% | (1 | )% | 9 | % | — | % | 7 | % |
| Nutrition & Biosciences | 1 |
| (3 | ) | (1 | ) | (1 | ) | (4 | ) | 1 |
| (3 | ) | (1 | ) | — |
| (3 | ) | 2 |
| (2 | ) | 1 |
| — |
| 1 |
|
| Transportation & Industrial | 5 |
| (3 | ) | (12 | ) | — |
| (10 | ) | 6 |
| (3 | ) | (10 | ) | — |
| (7 | ) | (4 | ) | (1 | ) | (8 | ) | — |
| (13 | ) |
| Safety & Construction | 4 |
| (3 | ) | 1 |
| (4 | ) | (2 | ) | 4 |
| (2 | ) | 2 |
| (4 | ) | — |
| 2 |
| (1 | ) | (4 | ) | 2 |
| (1 | ) |
| Non-Core | — |
| (2 | ) | (14 | ) | — |
| (16 | ) | (2 | ) | (2 | ) | (10 | ) | — |
| (14 | ) | 2 |
| — |
| (12 | ) | (9 | ) | (19 | ) |
| Total | 2 | % | (3 | )% | (5 | )% | (1 | )% | (7 | )% | 3 | % | (3 | )% | (4 | )% | (1 | )% | (5 | )% | — | % | (1 | )% | (2 | )% | (1 | )% | (4 | )% |
| U.S. & Canada | 1 | % | — | % | (3 | )% | — | % | (2 | )% | 1 | % | — | % | (2 | )% | — | % | (1 | )% | — | % | — | % | (2 | )% | — | % | (2 | )% |
EMEA 1 | 3 |
| (6 | ) | (6 | ) | (4 | ) | (13 | ) | 4 |
| (6 | ) | (4 | ) | (4 | ) | (10 | ) | 1 |
| (3 | ) | (5 | ) | (1 | ) | (8 | ) |
| Asia Pacific | 2 |
| (3 | ) | (6 | ) | — |
| (7 | ) | 2 |
| (3 | ) | (5 | ) | — |
| (6 | ) | (1 | ) | (1 | ) | — |
| — |
| (2 | ) |
| Latin America | 4 |
| (4 | ) | (3 | ) | (1 | ) | (4 | ) | 5 |
| (4 | ) | (2 | ) | (1 | ) | (2 | ) | 2 |
| (3 | ) | (3 | ) | (2 | ) | (6 | ) |
| Total | 2 | % | (3 | )% | (5 | )% | (1 | )% | (7 | )% | 3 | % | (3 | )% | (4 | )% | (1 | )% | (5 | )% | — | % | (1 | )% | (2 | )% | (1 | )% | (4 | )% |
| |
| 1. | Europe, Middle East and Africa. |
The Company reported net sales for the three months ended June 30, 2019March 31, 2020 of $5.5$5.2 billion, down 74 percent from $5.9$5.4 billion for the three months ended June 30, 2018,March 31, 2019, due to a 52 percent decrease in volume, a 31 percent unfavorable currency impact and a 1 percent decline in portfolio actions slightly offset a by 2 percent increase in local price.actions. Local price and product mix remained flat. Volume declined across all geographic regions andwith the exception of Asia Pacific where it remained flat. Volume declined across all segments with the exception of SafetyElectronics & ConstructionImaging (up 9 percent) and Nutrition & Biosciences (up 1 percent). The most notable volume decreasesdecrease were in Non-Core (down 14 percent) and Transportation & Industrial (down 8 percent) and Non-Core (down 12 percent). Currency was down 1 percent compared with the same period last year, driven primarily by EMEA currencies (down 3 percent). Portfolio and other changes contributed 1 percent of the sales decrease which impacted Safety & ConstructionNon-Core (down 4 percent; within EMEA) and Nutrition & Biosciences (down 19 percent). Local price was up 2 percentflat compared with the same period last year. Local price increased in all geographic regionsLatin America (up 2 percent) and EMEA (up 1 percent) and in all segments except Electronics & Imaging and Non-core (flat in both). Currency was down 3 percent compared with the same period last year, driven primarily by EMEA currencies (down 6 percent).
Net sales for the six months ended June 30, 2019 were $10.9 billion, down 5 percent from $11.5 billion for the six months ended June 30, 2018, due to a 4 percent decrease in volume, a 3 percent unfavorable currency impact and a 1 percent decline in portfolio actions slightly offset by a 3 percent increase in local price. Volume declined across all geographic regions and in all segments with the exception of Safety & Construction (up 2 percent). The most notable volume decreases were in Transportation & Industrial (down 104 percent) and Non-Core (down 10 percent). Portfolio and other changes decreased 1 percent due to a 4 percent decrease related to Safety & Construction within EMEA. Local price was up 3 percent compared with the same period last year. Local price increased in all geographic regions and in most segments except Electronics & Imaging (flat) and Non-core (down 2 percent). Currency was down 3 percent compared with the same period last year, driven primarily by EMEA currencies (down 61 percent).
Cost of Sales
Cost of sales was $3.5$3.3 billion for the three months ended June 30, 2019,March 31, 2020, down from $4.1$3.6 billion for the three months ended June 30, 2018.March 31, 2019. Cost of sales decreased for the three months ended June 30, 2019March 31, 2020 primarily due to lower sales volume, cost synergies, currency impacts, and the absence of costs previously allocated to the materials science and agriculture businesses that did not meet the definition of expenses related to discontinued operations in accordance with ASC 205 and therefore remained as costs of continuing operations for periods prior to the Distributions.
Cost of Sales as a percentage of net sales for the three months ended June 30, 2019March 31, 2020 was 64 percent compared with 7067 percent for the three months ended June 30, 2018.
For the six months ended June 30, 2019, cost of sales was $7.1 billion, down from $7.9 billion for the six months ended June 30, 2018. Cost of sales decreased for the six months ended June 30, 2019 primarily due to lower sales volume, cost synergies, currency impacts, and lower costs previously allocated to the materials science and agriculture businesses that did not meet the definition of expenses related to discontinued operations in accordance with ASC 205 and therefore remained as costs of continuing operations for periods prior to the Distributions. Cost of sales for the six months ended June 30, 2018 was also negatively impacted by a $73 million charge related to amortization of the fair value step-up in Historical EID's inventories as a result of the Merger and the acquisition of FMC Corporation's Health and Nutrition business in November 2017; there were no charges related to this fair value step-up during the first half ofMarch 31, 2019.
Cost of sales as a percentage of net sales for the six months ended June 30, 2019 was 65 percent compared with 69 percent for the six months ended June 30, 2018.
Research and Development Expenses ("R&D")
R&D expenses totaled $232 million in the second quarter of 2019, down from $270 million in the second quarter of 2018. R&D as a percentage of net sales was 4 percent and 5 percent for the three months ended June 30, 2019 and 2018, respectively.
For the first six months of 2019, R&D expenses totaled $499 million, down from $544$236 million in the first six monthsquarter of 2018.2020, down from $267 million in the first quarter of 2019. R&D as a percentage of net sales was 5 percent for both the sixthree months ended June 30, 2019March 31, 2020 and 2018.2019.
The decrease for the three months ended June 30, 2019March 31, 2020 as compared with the same periodperiods of the prior year was primarily due to the absence of R&D costs previously allocated to the materials science and agriculture businesses that did not meet the definition of expenses related to discontinued operations in accordance with ASC 205 and therefore remained as costs of continuing operations for periods prior to the Distributions.
Selling, General and Administrative Expenses ("SG&A")
SG&A expenses were $642$633 million in the secondfirst quarter of 2019,2020, down from $768$726 million in the secondfirst quarter of 2018.2019. SG&A as a percentage of net sales was 12 percent and 13 percent for the three months ended June 30,March 31, 2020 and 2019, and 2018, respectively.
For the first six months of 2019, SG&A expenses totaled $1,368 million, down from $1,570 million in the first six months of 2018. SG&A as a percentage of net sales was 13 percent and 14 percent for the six months ended June 30, 2019 and 2018, respectively.
The decrease for the three months ended June 30, 2019March 31, 2020 as compared with the same period of the prior year was primarily due to the absence of SG&A costs previously allocated to the materials science and agriculture businesses that did not meet the definition of expenses related to discontinued operations in accordance with ASC 205 and therefore remained as costs of continuing operations for periods prior to the Distributions. In addition to the absence of similar SG&A costs related to the discontinued operations for the six months ended June 30, 2019, SG&A decreased due to cost synergies.
Amortization of Intangibles
Amortization of intangibles was $252$533 million in the secondfirst quarter of 2020, up from $256 million in the first quarter of 2019. The increase was primarily due to the amortization of the Nutrition and Biosciences tradenames that were reclassified to definite-lived intangibles in the fourth quarter of 2019 down from $266 million in connection with the second quarter of 2018. In the first six months of 2019, amortization of intangibles was $508 million, down from $531 million in the same period last year. See Note 13 to the interim Consolidated Financial Statements for additional information on intangible assets.Proposed N&B Transaction.
Restructuring and Asset Related Charges - Net
Restructuring and asset related charges - net were $137$404 million and $46in the first quarter of 2020, up from $71 million forin the three months ended June 30, 2019 and 2018, respectively.first quarter of 2019. The activity in the secondfirst quarter of 2019 was primarily related to2020 included a $63$270 million impairment charge related to an equity method investment,long-lived assets in the Non-Core segment, a $53$111 million charge related to the new2020 Restructuring Program, $18 million charge related to the 2019 Restructuring Program and a $21$5 million charge related to the DowDuPont Cost Synergy Program. The charges in the second quarter of 2018 related to the DowDuPont Cost Synergy Program.
Restructuring and asset related charges - net were $208 million and $99 million for the six months ended June 30, 2019 and 2018, respectively. The activity for the six months ended June 30, 2019 was related to the equity method investment impairment charge and 2019 Restructuring Program both described above, as well as a $92 million charge related to the DowDuPont Cost Synergy Program.(the “Synergy Program”). The charges in the first halfquarter of 20182019 related to the DowDuPont Cost Synergy Program.
See Note 5 to the interim Consolidated Financial Statements for additional information.
Goodwill Impairment Charge
Goodwill Impairment Charges
Goodwill impairments charges were $1,175impairment charge was $533 million in the three and six months ended June 30, 2019.March 31, 2020. The goodwill impairment charges relatecharge relates to the Nutrition & Biosciences and Non-Core segments.segment. There were no goodwill related impairments in the same periodsperiod of 2018.2019. See Note 1311 to the interim Consolidated Financial Statements for additional information.
Integration and Separation Costs
Integration and separation costs, which primarily reflect costs related to the post-Merger integration, and activities related to the Distributions, and, during 2020, the intended separation of the Nutrition & Biosciences business, were $347$197 million in the secondfirst quarter of 2019,2020, down from $428$611 million in the secondfirst quarter of 2018. In2019. The decline was primarily related to the first six monthstiming of 2019, integration and separation costs were $958 million, up from $793 million in the same period last year.Distributions.
Equity in Earnings of Nonconsolidated Affiliates
The Company's share of the earnings of nonconsolidated affiliates was $49 million in the second quarter of 2019, down from $54 million in the second quarter of 2018. In the first six months of 2019, the Company's share of the earnings of nonconsolidated affiliates was $89 million, down from $111$39 million in the first six monthsquarter of 2018. The decrease2020, down from $40 million in the 2019 periodsfirst quarter of 2019. The decrease is primarily due to lower equity earnings from the HSC Group.
Sundry Income (Expense) - Net
Sundry income (expense) - net includes a variety of income and expense items such as foreign currency exchange gains or losses, interest income, dividends from investments, gains and losses on sales of investments and assets, non-operating pension and other post employment benefit plan credits or costs, and certain litigation matters. Sundry income (expense) - net in the secondfirst quarter of 20192020 was a lossincome of $19$211 million compared with income of $82$84 million in the secondfirst quarter of 2018.2019. The secondfirst quarter of 20192020 included benefits related to sale of the Compound Semiconductor Solutions business unit of $197 million, income related to non-operating pension and other post employment benefit credits of $18 million, a gain on sale of assets of $10$11 million and interestmiscellaneous income of $9 million, partially offset by foreign currency exchange losses of $17 million and a $48 million charge reflecting a reduction in gross proceeds from lower withholding taxes$8 million. The first quarter of 2019 included benefits related to a prior year legal settlement included insales of assets of $53 million, interest income of $40 million, miscellaneous income. The second quarterincome of 2018 included$31 million and income related to non-operating pension and other post employment benefit credits of $28 million and foreign currency exchange gains of $53 million partially offset by the loss on divestiture and changes in joint venture ownership of $21 million.
In the first six months of 2019, sundry income (expense) - net was income of $65 million compared with a loss of $16 million in the first six months of 2018. In addition to the amounts previously discussed, the first six months of 2019 included income related to non-operating pension and other post employment benefit plans of $39 million, a gain on sale of assets of $63 million and interest income of $49 million, partially offset by foreign currency exchange losses of $78$61 million. The first six months of 2018 included foreign currency exchange losses of $122 million, including a $50 million foreign currency exchange loss related to adjustments to foreign currency exchange contracts as a result of U.S. tax reform. The loss was offset by income related to non-operating pension and other post employment benefit plans of $55 million and miscellaneous income of $45 million. See Notes 6 and 19 to the interim Consolidated Financial Statements for additional information.
Interest Expense
Interest expense was $165$183 million and $316$151 million for the three and six months ended June 30,March 31, 2020 and 2019, respectively. There was no interest expense relatedThe increase primarily relates to continuing operationsfinancing facilities that were drawn after March 31, 2019 for the threeCompany to operate on a stand-alone basis and six months ended June 30, 2018 ascomplete the Company did not have outstanding borrowings untilcapital structures of Corteva and Dow in advance of their respective separations, which include the 2018 Senior Notes issuance inTerm Loan Facilities and the fourth quarter of 2018.DuPont Commercial Paper Program.
Provision for Income Taxes on Continuing Operations
The Company's effective tax rate fluctuates based on, among other factors, where income is earned and the level of income relative to tax attribute. The effective tax rate on continuing operations for the secondfirst quarter of 20192020 was (16.4)(7.8) percent, compared with an effective tax rate of 76.2 percent for the second quarter of 2018. For the first six months of 2019, the effective tax rate was (5.8) percent, compared with 134.455.2 percent for the first six months of 2018.
The negative tax rate in the second quarter of 2019 and2019. The effective tax rate for the first six monthsquarter of 2019,2020 was principally the result of the non-tax-deductible goodwill impairment chargescharge impacting the Nutrition & Biosciences and Non-Core segments. See Note 13 for more information regarding the goodwill impairment charges.
Income from Discontinued Operations, Net of Tax
Income from discontinued operations, net of tax was $566 million and $1,773 million for the three months ended June 30, 2019 and 2018, respectively, and $1,212 million and $2,983 million for the six months ended June 30, 2019 and 2018, respectively. The decreases are attributable to the timing of the Distributions. Refer to Note 3 to the interim Consolidated Financial Statements for additional information.
Net Income Attributable to Noncontrolling Interests
Net income attributable to noncontrolling interests, including the portion attributable to discontinued operations, was $34 million in the second quarter of 2019, down from $35 million in the second quarter of 2018. For the first six months of 2019, net income attributable to noncontrolling interests, including the portion attributable to discontinued operations, was $85 million, compared with $79 million for the same period last year.
Net income attributable to noncontrolling interests of continuing operations for the three and six months ended June 30, 2019 was $9 million and $13 million, respectively, as compared to a loss of $2 million and income of $11 million for the same periods in the prior year, respectively.Non-core segment.
SUPPLEMENTAL UNAUDITED PRO FORMA COMBINED FINANCIAL INFORMATION
The following supplemental unaudited pro forma financial information (the “unaudited pro forma financial statements”) areis derived from DuPont’s Consolidated Financial Statements, adjusted to give effect to certain events directly attributable to the Distributions. In contemplation of the Distributions and to achieve the respective credit profiles of each of the current companies, in the fourth quarter of 2018, DowDuPont borrowed $12.7 billion under the 2018 Senior Notes and entered the Term Loan Facilities with an aggregate principal amount of $3.0 billion. Additionally, DuPont issued approximately $1.4 billion in commercial paper in May 2019 in anticipation of the Corteva Distribution (the “Funding CP Issuance” together with the 2018 Senior Notes and the Term Loan Facilities, the "Financings"). The unaudited pro forma financial statements for the sixthree months ended June 30,March 31, 2019 and for three and six months ended June 30, 2018 were prepared in accordance with Article 11 of Regulation S-X. The historical consolidated financial information has been adjusted to give effect to pro forma events that are (1) directly attributable to the Distributions and the Financings (collectively the "Transactions"), (2) factually supportable and (3) with respect to the statements of operations, expected to have a continuing impact on the results. The unaudited pro forma statements of operations for the sixthree months ended June 30,March 31, 2019 and for three and six months ended June 30, 2018 give effect to the pro forma events as if they had been consummated on January 1, 2018. There were no pro forma adjustments for the three months ended June 30, 2019.March 31, 2020.
Restructuring or integration activities or other costs following the Distributions that may be incurred to achieve cost or growth synergies of DuPont are not reflected. The unaudited pro forma income statements provides shareholders with summary financial information and historical data that is on a basis consistent with how DuPont reports current financial information.
The unaudited pro forma financial statements are presented for informational purposes only, and do not purport to represent what DuPont's results of operations or financial position would have been had the Transactions occurred on the dates indicated, nor do they purport to project the results of operations or financial position for any future period or as of any future date.
| | Unaudited Pro Forma Combined Statement of Operations | Three Months Ended June 30, | |
| 2018 | |
Unaudited Pro Forma Combined Statements of Operations | | Three Months Ended March 31, |
| 2019 |
| In millions, except per share amounts | DuPont 1 | Pro Forma Adjustments2 | Pro Forma | DuPont 1 | Pro Forma Adjustments2 | Pro Forma |
| Net sales | $ | 5,857 |
| $ | — |
| $ | 5,857 |
| $ | 5,414 |
| $ | — |
| $ | 5,414 |
|
| Cost of sales | 4,085 |
| 18 |
| 4,103 |
| 3,621 |
| 22 |
| 3,643 |
|
| Research and development expenses | 270 |
| — |
| 270 |
| 267 |
| — |
| 267 |
|
| Selling, general and administrative expenses | 768 |
| — |
| 768 |
| 726 |
| — |
| 726 |
|
| Amortization of intangibles | 266 |
| — |
| 266 |
| 256 |
| — |
| 256 |
|
| Restructuring and asset related charges - net | 46 |
| — |
| 46 |
| 71 |
| — |
| 71 |
|
| Goodwill impairment charge | | — |
| — |
| — |
|
| Integration and separation costs | 428 |
| (137 | ) | 291 |
| 611 |
| (173 | ) | 438 |
|
| Equity in earnings of nonconsolidated affiliates | 54 |
| — |
| 54 |
| 40 |
| — |
| 40 |
|
| Sundry income (expense) - net | 82 |
| — |
| 82 |
| 84 |
| — |
| 84 |
|
| Interest expense | — |
| 171 |
| 171 |
| 151 |
| 29 |
| 180 |
|
| Income (Loss) from continuing operations before income taxes | 130 |
| (52 | ) | 78 |
| |
| Provision (Credit) for income taxes on continuing operations | 99 |
| (10 | ) | 89 |
| |
| Income (Loss) from continuing operations, net of tax | 31 |
| (42 | ) | (11 | ) | |
| Net loss attributable to noncontrolling interests of continuing operations | (2 | ) | — |
| (2 | ) | |
| Net income (loss) from continuing operations attributable to DuPont | 33 |
| (42 | ) | (9 | ) | |
| (Loss) Income from continuing operations before income taxes | | (165 | ) | 122 |
| (43 | ) |
| (Benefit from) Provision for income taxes on continuing operations | | (91 | ) | 30 |
| (61 | ) |
| (Loss) Income from continuing operations, net of tax | | (74 | ) | 92 |
| 18 |
|
| Net income attributable to noncontrolling interests of continuing operations | | 4 |
| — |
| 4 |
|
| Net (loss) income from continuing operations attributable to DuPont | | $ | (78 | ) | $ | 92 |
| $ | 14 |
|
| | | |
| Per common share data: | | | | | | |
| Earnings (Loss) per common share from continuing operations - basic | $ | 0.03 |
| | $ | (0.02 | ) | |
| Earnings (Loss) per common share from continuing operations - diluted | $ | 0.03 |
| | $ | (0.02 | ) | |
| (Loss) Earnings per common share from continuing operations - basic | | $ | (0.11 | ) | | $ | 0.02 |
|
| (Loss) Earnings per common share from continuing operations - diluted | | $ | (0.11 | ) | | $ | 0.02 |
|
| | | |
| Weighted-average common shares outstanding - basic | 769.6 |
| | 769.6 |
| 750.0 |
| | 750.0 |
|
| Weighted-average common shares outstanding - diluted | 774.5 |
| | 769.6 |
| 750.0 |
| | 753.1 |
|
| |
| 1. | See the historical U.S. GAAP Consolidated Statements of Operations. |
| |
| 2. | Certain pro forma adjustments were made to illustrate the estimated effects of the Transactions, assuming that the Transactions had occurred on January 1, 2018. The adjustments include the impact to "Cost of sales" of different pricing than historical intercompany and intracompany practices related to various supply agreements entered into with the Dow Distribution, adjustments to "Integration and separation costs" to eliminate one time transaction costs directly attributable to the Distributions, and adjustments to "Interest expense" to reflect the impact of the Financings. |
|
| | | | | | | | | | | | | | | | | | |
Unaudited Pro Forma Combined Statement of Operations | Six Months Ended June 30, |
| 2019 | 2018 |
| In millions, except per share amounts | DuPont 1 | Pro Forma Adjustments2 | Pro Forma | DuPont 1 | Pro Forma Adjustments2 | Pro Forma |
| Net sales | $ | 10,882 |
| $ | — |
| $ | 10,882 |
| $ | 11,454 |
| $ | — |
| $ | 11,454 |
|
| Cost of sales | 7,117 |
| 22 |
| 7,139 |
| 7,890 |
| 36 |
| 7,926 |
|
| Research and development expenses | 499 |
| — |
| 499 |
| 544 |
| — |
| 544 |
|
| Selling, general and administrative expenses | 1,368 |
| — |
| 1,368 |
| 1,570 |
| — |
| 1,570 |
|
| Amortization of intangibles | 508 |
| — |
| 508 |
| 531 |
| — |
| 531 |
|
| Restructuring and asset related charges - net | 208 |
| — |
| 208 |
| 99 |
| — |
| 99 |
|
| Goodwill impairment charge | 1,175 |
| — |
| 1,175 |
| — |
| — |
| — |
|
| Integration and separation costs | 958 |
| (173 | ) | 785 |
| 793 |
| (228 | ) | 565 |
|
| Equity in earnings of nonconsolidated affiliates | 89 |
| — |
| 89 |
| 111 |
| — |
| 111 |
|
| Sundry income (expense) - net | 65 |
| — |
| 65 |
| (16 | ) | — |
| (16 | ) |
| Interest expense | 316 |
| 29 |
| 345 |
| — |
| 342 |
| 342 |
|
| (Loss) Income from continuing operations before income taxes | (1,113 | ) | 122 |
| (991 | ) | 122 |
| (150 | ) | (28 | ) |
| Provision (Credit) for income taxes on continuing operations | 64 |
| 30 |
| 94 |
| 164 |
| (31 | ) | 133 |
|
| (Loss) Income from continuing operations, net of tax | (1,177 | ) | 92 |
| (1,085 | ) | (42 | ) | (119 | ) | (161 | ) |
| Net income attributable to noncontrolling interests of continuing operations | 13 |
| — |
| 13 |
| 11 |
| — |
| 11 |
|
| Net (loss) income from continuing operations attributable to DuPont | (1,190 | ) | 92 |
| (1,098 | ) | (53 | ) | (119 | ) | (172 | ) |
| | | | | | | |
| Per common share data: | | | | | | |
| Loss per common share from continuing operations - basic | $ | (1.59 | ) | | $ | (1.47 | ) | $ | (0.09 | ) | | $ | (0.24 | ) |
| Loss per common share from continuing operations - diluted | $ | (1.59 | ) | | $ | (1.47 | ) | $ | (0.09 | ) | | $ | (0.24 | ) |
| | | | | | | |
| Weighted-average common shares outstanding - basic | 749.6 |
| | 749.6 |
| 771.0 |
| | 771.0 |
|
| Weighted-average common shares outstanding - diluted | 749.6 |
| | 749.6 |
| 771.0 |
| | 771.0 |
|
| |
1. | See the historical U.S. GAAP Consolidated Statements of Operations. |
| |
2. | Certain pro forma adjustments were made to illustrate the estimated effects of the Transactions, assuming that the Transactions had occurred on January 1, 2018. The adjustments include the impact to "Cost of sales" of different pricing than historical intercompany and intracompany practices related to various supply agreements entered into with the Dow Distribution, adjustments to "Integration and separation costs" to eliminate one time transaction costs directly attributable to the Distributions, and adjustments to "Interest expense" to reflect the impact of the Financings. |
SEGMENT RESULTS
In the first quarter of 2020, in preparation for the Proposed N&B Transaction, DuPont changed its management and reporting structure to realign costs associated with its polysaccharides pre-commercial activities from the Non-Core segment to the N&B segment. The reporting changes have been retrospectively reflected in the following discussion of segment results for all periods presented. Refer to Note 21 to the interim Consolidated Financial Statements for additional information.
Prior to April 1, 2019, the Company's measure of profit/loss for segment reporting purposes is pro forma Operating EBITDA as this is the manner in which the Company's chief operating decision maker ("CODM") assessesassessed performance and allocates resources. The Company defines pro forma Operating EBITDA as pro forma earnings (i.e., pro forma “Income from continuing operations before income taxes") before interest, depreciation, amortization, non-operating pension / other post employment benefits (“OPEB”) / charges, and foreign exchange gains / losses, excluding the impact of costs historically allocated to the materials science and agriculture businesses that did not meet the criteria to be recorded as discontinued operations and adjusted for significant items. Effective April 1, 2019, the Company's measure of profit/loss for segment reporting purposes is Operating EBITDA as this is the manner in which the Company's CODM assesses performance and allocates resources. The Company defines Operating EBITDA as earnings (i.e., “Income from continuing operations before income taxes") before interest, depreciation, amortization, non-operating pension / OPEB benefits / charges, and foreign exchange gains / losses, adjusted for significant items. Reconciliations of these measures can be found in Note 2321 to the interim Consolidated Financial Statements. Prior year data has been updated to conform with the current year presentation.
Pro forma adjustments used in the calculation of pro forma Operating EBITDA were determined in accordance with Article 11 of Regulation S-X and were derived from DuPont's historical Consolidated Financial Statements and accompanying notes, adjusted to give effect to the Distributions as if they had been consummated on January 1, 2018. The pro forma adjustments impacting pro forma Operating EBITDA reflect the impact of various supply agreements ("supply agreements") entered into in connection with the Dow Distribution and are outlined in the preceding section, Supplemental Unaudited Pro Forma Combined Financial Information, as adjustments to "Cost of sales".sales." The impact of these supply agreements areis reflected in pro forma Operating EBITDA for the periods noted above as they areit is included in the measure of profit/loss reviewed by the CODM in order to show meaningful comparability among periods while assessing performance and making resource allocation decisions. There were no pro forma adjustments for the three months ended June 30, 2019.March 31, 2020.
ELECTRONICS & IMAGING
The Electronics & Imaging segment is a leading global supplier of differentiated materials and systems for a broad range of consumer electronics including mobile devices, television monitors, personal computers and electronics used in a variety of industries. The segment is a leading provider of materials and solutions for the fabrication of semiconductors and integrated circuits, and also provides innovative metallization processes for metal finishing, decorative, and industrial applications. Electronics & Imaging inis a leading provider of platemaking systems and photopolymer plates for the advanced printing and packaging graphics industry provides flexographicand digital printing inks photopolymer plates, and platemaking systems usedfor a variety of applications in digital printing applications forthe textile, commercial printing, and home-office use.markets. In addition, the segment provides cutting-edge materials for the manufacturing of rigid and flexible displays for advanced-matrix organic light emitting diode ("AMOLED"OLED"), and quantum dotother display applications.
In March 2019, the Company announced plans to invest more than $200 million in its Electronics & Imaging segment to increase capacity for the manufacture of KAPTON® film at its Circleville, Ohio, site due to growing global demand.
| | | Electronics & Imaging | Three Months Ended | Six Months Ended | Three Months Ended |
| In millions | Jun 30, 2019 | Jun 30, 2018 | Jun 30, 2019 | Jun 30, 2018 | March 31, 2020 | March 31, 2019 |
| Net sales | $ | 858 |
| $ | 921 |
| $ | 1,683 |
| $ | 1,785 |
| $ | 884 |
| $ | 825 |
|
Operating EBITDA 1 | $ | 246 |
| $ | 290 |
| $ | 534 |
| $ | 567 |
| $ | 253 |
| $ | 288 |
|
| Equity earnings | $ | 5 |
| $ | 6 |
| $ | 8 |
| $ | 13 |
| $ | 9 |
| $ | 3 |
|
| |
| 1. | For the sixthree months ended June 30,March 31, 2019, and for the three and six months ended June 30, 2018, operating EBITDA is on a pro forma basis. |
|
| | | | |
| Electronics & Imaging | Three Months Ended | Six Months Ended |
| Percentage change from prior year | Jun 30, 2019 | Jun 30, 2019 |
| Change in Net Sales from Prior Period due to: | | |
| Local price & product mix | — | % | — | % |
| Currency | (2 | ) | (2 | ) |
| Volume | (5 | ) | (4 | ) |
| Portfolio & other | — |
| — |
|
| Total | (7 | )% | (6 | )% |
|
| | |
| Electronics & Imaging | Three Months Ended |
| Percentage change from prior year | March 31, 2020 |
| Change in Net Sales from Prior Period due to: | |
| Local price & product mix | (1 | )% |
| Currency | (1 | ) |
| Volume | 9 |
|
| Portfolio & other | — |
|
| Total | 7 | % |
Electronics & Imaging net sales were $858$884 million for the three months ended June 30, 2019, downMarch 31, 2020, up 7 percent from $921$825 million for the three months ended June 30, 2018.March 31, 2019. Net sales decreasedincreased due to a 59 percent increase in volume partially offset by a 1 percent decline in price and a 21 percent unfavorable currency impact,impact. Volume growth was driven primarily by Asia Pacific.Semiconductor Technologies new technology ramps within the logic and foundry segment and increased memory demand in servers and data centers. Volume growth within Interconnect Solutions was driven by higher material content in next-generation smartphones. Within Image Solutions, volume gains in Display Technologiesflexographic printing were more thanmostly offset by softer volumes in Semiconductor Technologies and Interconnect Solutions. Volume growth in Display Technologies reflects increaseddeclined demand for organic light emitting diode ("OLED")digital printing inks and OLED materials. Increased demand for semiconductor packaging materials in Semiconductor Technologies was more than offset by weakened demand in the memory sector. Demand for advanced materials for smartphones remained strong but overall volumes in Interconnect Solutions were down due to soft circuit board demand.
Operating EBITDA was $246$253 million for the three months ended June 30, 2019,March 31, 2020, down 1512 percent compared with pro forma Operating EBITDA of $290$288 million for the three months ended June 30, 2018. Cost synergies were more than offset by volume decline and higher raw material costs in the second quarter ofMarch 31, 2019 compared with the second quarter of 2018.
Electronics & Imaging net sales were $1,683 million for the six months ended June 30, 2019, down from $1,785 million for the six months ended June 30, 2018. Net sales decreased due to a 4 percent volume decline and a 2 percent unfavorable currency impact, driven primarily by Asia Pacific. Volume growththe absence of $51 million in Display Technologies driven by increased OLED demand was more than offset by volume declines in Interconnect Solutions and Semiconductor Technologies.
Pro forma Operating EBITDA was $534 million for the six months ended June 30, 2019, down 6 percent compared with $567 million for the six months ended June 30, 2018. Favorable impactsincome from an asset sale in 2019 partially offset by volume gains and cost synergies were more than offset by higher raw material costs and volume declines.savings.
NUTRITION & BIOSCIENCES
The Nutrition & Biosciences segment is an innovation-driven and customer-focused segment that provides solutions for the global food and beverage, dietary supplements, home and personal care, energy, animal nutrition and pharma markets. The segment is one of the world's largest producers of specialty ingredients, developing and manufacturing solutions for the global food and beverage, dietary supplements, enzymes and pharmaceutical excipient markets. Additionally, the segment is an industry pioneer and innovator that works with customers to improve the performance, productivity and sustainability of their products and processes, through differentiated technology in ingredients applications, fermentation, biotechnology, chemistry and manufacturing process excellence.
| | | Nutrition & Biosciences | Three Months Ended | Six Months Ended | Three Months Ended |
| In millions | Jun 30, 2019 | Jun 30, 2018 | Jun 30, 2019 | Jun 30, 2018 | March 31, 2020 | March 31, 2019 |
| Net sales | $ | 1,558 |
| $ | 1,621 |
| $ | 3,093 |
| $ | 3,198 |
| $ | 1,551 |
| $ | 1,535 |
|
Operating EBITDA 1 | $ | 391 |
| $ | 383 |
| $ | 744 |
| $ | 751 |
| $ | 385 |
| $ | 349 |
|
| Equity earnings | $ | — |
| $ | — |
| $ | — |
| $ | 1 |
| $ | — |
| $ | — |
|
1. For the sixthree months ended June 30,March 31, 2019, and for the three and six months ended June 30, 2018, operating EBITDA is on a pro forma basis.
|
| | | | |
| Nutrition & Biosciences | Three Months Ended | Six Months Ended |
| Percentage change from prior year | Jun 30, 2019 | Jun 30, 2019 |
| Change in Net Sales from Prior Period due to: | | |
| Local price & product mix | 1 | % | 1 | % |
| Currency | (3 | ) | (3 | ) |
| Volume | (1 | ) | (1 | ) |
| Portfolio & other | (1 | ) | — |
|
| Total | (4 | )% | (3 | )% |
|
| | |
| Nutrition & Biosciences | Three Months Ended |
| Percentage change from prior year | Mar 31, 2020 |
| Change in Net Sales from Prior Period due to: | |
| Local price & product mix | 2 | % |
| Currency | (2 | ) |
| Volume | 1 |
|
| Portfolio & other | — |
|
| Total | 1 | % |
Nutrition & Biosciences net sales were $1,558$1,551 million for the three months ended June 30, 2019, downMarch 31, 2020, up from $1,621$1,535 million for the three months ended June 30, 2018,March 31, 2019. The increase was due to a 2 percent increase in local price and a 1 percent increase in local price, which was more thanvolume partially offset by a 32 percent unfavorable currency impact, a 1 percent decrease in volume and a 1 percent decrease from portfolio actions. Volume gains inimpact. Health & Biosciences volume gains were more than offsetdriven by lower volumesprobiotics along with strong demand in home & personal care and animal nutrition. Volume gains in Food & Beverage and Pharma Solutions. Volume gains in Health & Biosciences were led by increased probiotics and microbial control demand partially offset by volume declines in bioactives resulting from ongoing challenged conditions in U.S. energy markets. Food & Beverage volumes were lower than the same quarter of last year as volume gains in specialty proteins and cellulosics driven by growingincreased demand in packaged foods and on-going strength in the meat-free market were more thanplant-based meat category partially offset by declines in functional solutions and emulsifiers & sweeteners. Pharma Solutions volumes declinedsweeteners due to capacity constraints and product mix shift.challenges in supply chain.
Operating EBITDA was $391$385 million for the three months ended June 30, 2019,March 31, 2020, up 210 percent compared with pro forma Operating EBITDA of $383$349 million for the three months ended June 30, 2018March 31, 2019 due to cost synergies and pricing gains which were partially offset by unfavorable currency impacts, higher raw material costs and volume declines.
Nutrition & Biosciences net sales were $3,093 million for the six months ended June 30, 2019, down from $3,198 million for the six months ended June 30, 2018. The decrease was due to a 1 percent increase in local price, which was more than offset by a 3 percent unfavorable currency impact and a 1 percent decrease in volume. Volume gains in Food & Beverage as a result of increased demand in cellulosic and proteins were more than offsetfavorable product mix led by volume declines in Health & Biosciences due to decreased biorefinery and microbial control demand.
Pro forma Operating EBITDA was $744 million for the six months ended June 30, 2019, down 1 percent compared with $751 million for the six months ended June 30, 2018. Cost synergies and pricing gains were more than offset by unfavorable currency impacts, higher raw material costs and volume declines.Biosciences.
TRANSPORTATION & INDUSTRIAL
The Transportation & Industrial segment provides high-performance engineering resins, adhesives, silicones, lubricants and parts to engineers and designers in the transportation, electronics, healthcare, industrial and consumer end-markets to enable systems solutions for demanding applications and environments. The segment delivers a broad range of polymer-based high-performance materials in its product portfolio, including elastomers and thermoplastic and thermoset engineering polymers which are used by customers to fabricate components for mechanical, chemical and electrical systems. In addition, the segment produces innovative engineering polymer solutions, high performance parts, specialty silicones and differentiated adhesive technologies to meet customer specifications in automotive, aerospace, electronics, industrial, healthcare and consumer markets. Transportation & Industrial is a global leader of advanced materials that provides technologies that differentiate customers’ products with improved performance characteristics enabling the transition to hybrid-electric-connected vehicles, High Speed High Frequencyhigh speed high frequency connectivity and smart Healthcare.healthcare.
| | | Transportation & Industrial | Three Months Ended | Six Months Ended | Three Months Ended |
| In millions | Jun 30, 2019 | Jun 30, 2018 | Jun 30, 2019 | Jun 30, 2018 | March 31, 2020 | March 31, 2019 |
| Net sales | $ | 1,269 |
| $ | 1,417 |
| $ | 2,586 |
| $ | 2,795 |
| $ | 1,144 |
| $ | 1,317 |
|
Operating EBITDA 1 | $ | 357 |
| $ | 402 |
| $ | 730 |
| $ | 791 |
| $ | 308 |
| $ | 373 |
|
| Equity earnings | $ | 2 |
| $ | 1 |
| $ | 2 |
| $ | 3 |
| $ | 1 |
| $ | — |
|
1. For the sixthree months ended June 30,March 31, 2019, and for the three and six months ended June 30, 2018, operating EBITDA is on a pro forma basis.
|
| | | | |
| Transportation & Industrial | Three Months Ended | Six Months Ended |
| Percentage change from prior year | Jun 30, 2019 | Jun 30, 2019 |
| Change in Net Sales from Prior Period due to: | | |
| Local price & product mix | 5 | % | 6 | % |
| Currency | (3 | ) | (3 | ) |
| Volume | (12 | ) | (10 | ) |
| Portfolio & other | — |
| — |
|
| Total | (10 | )% | (7 | )% |
|
| | |
| Transportation & Industrial | Three Months Ended |
| Percentage change from prior year | March 31, 2020 |
| Change in Net Sales from Prior Period due to: | |
| Local price & product mix | (4 | )% |
| Currency | (1 | ) |
| Volume | (8 | ) |
| Portfolio & other | — |
|
| Total | (13 | )% |
Transportation & Industrial net sales were $1,269$1,144 million for the three months ended June 30, 2019,March 31, 2020, down from $1,417$1,317 million for the three months ended June 30, 2018.March 31, 2019. The change in net sales was due to a 5 percent increase in local price which was more than offset by a 12an 8 percent decrease in volume, a 4 percent decrease in local price, and a 31 percent unfavorable currency impact, primarily in EMEA and Asia Pacific.EMEA. Volume declines were primarily due to decreased demand inimpact of the COVID-19 pandemic on the automotive industry and electronics markets as trade and tariff concerns impact Asia Pacific and EMEA. Local price increased in all regions compared to the same quarter of last year.other key industrial markets.
Operating EBITDA was $357$308 million for the three months ended June 30, 2019,March 31, 2020, down 1117 percent compared with pro forma Operating EBITDA of $402$373 million for the three months ended June 30, 2018 as pricing gainsMarch 31, 2019 driven primarily by the impact of the volume and cost synergies were more than offset by volumenylon price declines and unfavorable currency impacts.within Mobility Solutions.
Transportation & Industrial net sales were $2,586 million for the six months ended June 30, 2019, down from $2,795 million for the six months ended June 30, 2018 as a 6 percent increase in local price, led by Mobility Solutions, was more than offset by a 10 percent
Pro forma Operating EBITDA was $730 million for the six months ended June 30, 2019, down 8 percent compared with $791 million for the six months ended June 30, 2018 due to pricing gains and cost synergies, which were more than offset by volume declines, higher raw material costs and unfavorable currency impacts.
SAFETY & CONSTRUCTION
The Safety & Construction segment is a leading provider of engineered products and integrated systems for a number of industries including construction, worker safety, energy, oil and gas, transportation, medical devices and water purification and separation.separation, aerospace, energy, medical packaging and building materials. The segment satisfies the growing global needs of businesses, governments, and consumers for solutions that make life safer, healthier, and better. By uniting market-driven science with the strength of highly regarded brands, the segment strives to bring new products and solutions to solve customers' needs faster, better and more cost effectively.
| | | Safety & Construction | Three Months Ended | Six Months Ended | Three Months Ended |
| In millions | Jun 30, 2019 | Jun 30, 2018 | Jun 30, 2019 | Jun 30, 2018 | March 31, 2020 | March 31, 2019 |
| Net sales | $ | 1,341 |
| $ | 1,372 |
| $ | 2,624 |
| $ | 2,636 |
| $ | 1,276 |
| $ | 1,283 |
|
Operating EBITDA 1 | $ | 382 |
| $ | 296 |
| $ | 756 |
| $ | 622 |
| $ | 368 |
| $ | 374 |
|
| Equity earnings | $ | 7 |
| $ | 8 |
| $ | 15 |
| $ | 13 |
| $ | 7 |
| $ | 8 |
|
1. For the sixthree months ended June 30,March 31, 2019, and for the three and six months ended June 30, 2018, operating EBITDA is on a pro forma basis.
|
| | | | |
| Safety & Construction | Three Months Ended | Six Months Ended |
| Percentage change from prior year | Jun 30, 2019 | Jun 30, 2019 |
| Change in Net Sales from Prior Period due to: | | |
| Local price & product mix | 4 | % | 4 | % |
| Currency | (3 | ) | (2 | ) |
| Volume | 1 |
| 2 |
|
| Portfolio & other | (4 | ) | (4 | ) |
| Total | (2 | )% | — | % |
|
| | |
| Safety & Construction | Three Months Ended |
| Percentage change from prior year | March 31, 2020 |
| Change in Net Sales from Prior Period due to: | |
| Local price & product mix | 2 | % |
| Currency | (1 | ) |
| Volume | (4 | ) |
| Portfolio & other | 2 |
|
| Total | (1 | )% |
Safety & Construction net sales were $1,341$1,276 million for the three months ended June 30, 2019,March 31, 2020, down from $1,372$1,283 million for the three months ended June 30, 2018March 31, 2019 as a 42 percent increase in local price and 1a 2 percent of volume growthincrease in portfolio were more than offset by portfoliovolume declines of 4 percent and a 31 percent unfavorable impact from currency. Volume growthcurrency globally. The portfolio impact reflects the recent acquisitions in the segment wasWater Solutions business. Local price increased led by the Safety and Water Solutions. Volume gains in Water Solutions partiallyand demand for TYVEK® protective garments were more than offset by volume declines in Safety and Shelter Solutions due to weakened demand across end markets and declined construction slowdown inactivity as a result of the U.S. residential market. Safety Solutions volumes were flat compared with the prior year driven by supply constraints.COVID-19 pandemic.
Operating EBITDA was $382$368 million for the three months ended June 30, 2019, up 29March 31, 2020, down 2 percent compared with pro forma Operating EBITDA of $296$374 million for the three months ended June 30, 2018March 31, 2019 due to local price gains, cost synergies, productivity improvementslower volumes and volume gains partially offset by an unfavorable impact from currency.
Safety & Construction net sales were $2,624 million for the six months ended June 30, 2019, slightly down from $2,636 million for the six months ended June 30, 2018 as a 4 percent increase in local price and 2 percentabsence of volume growth were offset by portfolio declines of 4 percent and a 2 percent unfavorable impact from currency. Volume growth in the segment was led by gains in Water Solutions and Safety Solutions. Safety Solutions growth was driven by strong industrial markets and increased demand in medical packaging and garments. These gains were partially offset by volume declines in Shelter Solutions, primarily due to weakness in the construction global residential market.
Pro forma Operating EBITDA was $756 million for the six months ended June 30, 2019, up 22 percent compared with $622 million for the six months ended June 30, 2018, due tolicensing income more than offsetting pricing gains, cost synergiesimproved product mix, and volume growth, partially offset by unfavorable currency impacts.productivity actions.
NON-CORE
The Non-Core segment is a leading global supplier of key materials for the manufacturing of photovoltaicsphotovoltaic cells and solar cells,panels, including innovative metallization pastes, and backsheet materials for the production of solar cells and solar modules,silicone encapsulants and components and films for consumer electronics, automotive, and aerospace markets.adhesives. The segment also includes the Company's share of the results of the HSC Group, a U.S.-based group of companies that manufacture and sell polycrystalline silicon products. In addition,products for the photovoltaic and semiconductor industries. Additionally, the segment provides materials used in components and films for consumer electronics, automotive, and aerospace markets. The segment also provides sustainable materials and services for sulfuric acid production and regeneration technologies, alkylation technology for production of clean, high-octane gasoline, and a comprehensive suite of aftermarket service and solutions offerings, including safety consulting and services, to improve the safety, productivity, and sustainability of organizations across a range of industries. The Non-Core segment is also a leading producer of specialty biotechnology materials for residential carpet and stretch comfort apparel markets as well as polyester films for the healthcare, photovoltaics, electronics, packaging and labels, and electrical insulation industries.
| | | Non-Core | Three Months Ended | Six Months Ended | Three Months Ended |
| In millions | Jun 30, 2019 | Jun 30, 2018 | Jun 30, 2019 | Jun 30, 2018 | March 31, 2020 | March 31, 2019 |
| Net sales | $ | 442 |
| $ | 526 |
| $ | 896 |
| $ | 1,040 |
| $ | 366 |
| $ | 454 |
|
Operating EBITDA 1 | $ | 99 |
| $ | 123 |
| $ | 193 |
| $ | 233 |
| $ | 42 |
| $ | 98 |
|
| Equity earnings | $ | 35 |
| $ | 39 |
| $ | 64 |
| $ | 81 |
| |
Equity earnings 2 | | $ | 22 |
| $ | 30 |
|
1. For the sixthree months ended June 30,March 31, 2019, and for the three and six months ended June 30, 2018, operating EBITDA is on a pro forma basis.
2. Represents equity in earnings (losses) of nonconsolidated affiliates included in pro forma Operating EBITDA, the Company's measure of profit/loss for segment reporting purposes, which excludes significant items. Accordingly, the Non-Core segment presented above excludes a restructuring charge of $1 million which is presented in "Equity in earnings of nonconsolidated affiliates" in the Company's interim Consolidated Statement of Operations.
|
| | | | |
| Non-Core | Three Months Ended | Six Months Ended |
| Percentage change from prior year | Jun 30, 2019 | Jun 30, 2019 |
| Change in Net Sales from Prior Period due to: | | |
| Local price & product mix | — | % | (2 | )% |
| Currency | (2 | ) | (2 | ) |
| Volume | (14 | ) | (10 | ) |
| Portfolio & other | — |
| — |
|
| Total | (16 | )% | (14 | )% |
|
| | |
| Non-Core | Three Months Ended |
| Percentage change from prior year | March 31, 2020 |
| Change in Net Sales from Prior Period due to: | |
| Local price & product mix | 2 | % |
| Currency | — |
|
| Volume | (12 | ) |
| Portfolio & other | (9 | ) |
| Total | (19 | )% |
Non-Core net sales were $442$366 million for the three months ended June 30, 2019,March 31, 2020, down from $526$454 million for the three months ended June 30, 2018March 31, 2019 due to 2 percent pricing gains more than offset by a 1412 percent volume decline and a 29 percent unfavorable impact from currency.portfolio decline. The third quarter 2019 sale of the Sustainable Solutions business reduced sales by 9 percent. Volume gains in metallization pastes were more than offset by declines were driven by weak demand forin trichlorosilane due to historically low polysilicon pricing and lower paste sales into electronic component end markets.demand. Biomaterials volume declines were primarily a result of a slow-down in demandweakened demands in the U.S. residential carpet market. and apparel markets.
Operating EBITDA was $99$42 million for the three months ended June 30, 2019,March 31, 2020, down 2057 percent compared with pro forma Operating EBITDA of $123$98 million for the three months ended June 30, 2018 mainlyMarch 31, 2019 primarily due to volume declines and an unfavorable impact from currency.
Non-Core net sales were $896 million for the six months ended June 30, 2019, down from $1,040 million for the six months ended June 30, 2018. Net sales declined due to a 10 percent decline in volume, a 2 percent decline in local price and a 2 percent unfavorable impact from currency. Volume declines were driven by weak demand for trichlorosilane due to historically low polysilicon pricing and lower paste sales into electronic component end markets. Biomaterials volume declines were primarily a result of a slow-down in demand in the U.S. residential carpet market.
Pro forma Operating EBITDA was $193 million for the six months ended June 30, 2019, down 17 percent compared with $233 million for the six months ended June 30, 2018 as cost synergies were more than offset by higher raw material costs, volume declines and an unfavorable impact from currency.HSC Group equity earnings.
CHANGES IN FINANCIAL CONDITION
Liquidity & Capital Resources
Information related to the Company's liquidity and capital resources can be found in the Company's 2019 Annual Report, Part II, Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations, Liquidity and Capital Resources. Discussion below provides the updates to this information for the three months ended March 31, 2020.
The Company continually reviews its sources of liquidity and debt portfolio and occasionally may make adjustments to one or both to ensure adequate liquidity.liquidity and increase the Company’s optionality and financing efficiency as it relates to financing cost and balancing terms/maturities. The Company’s primary source of incremental liquidity is cash flows from operating activities. COVID-19 continues to adversely impact the broader global economy, including negatively impacting economic growth and creating disruption and volatility in the global financial and capital markets, which increases the cost of capital and adversely impacts the availability of and access to capital,which could negatively affect DuPont’s liquidity. Management expects the generation of cash from operations and the ability to access the debt capital markets and other sources of liquidity will continue to provide sufficient liquidity and financial flexibility to meet the Company’s and its subsidiaries obligations as they come due.due; however, DuPont is unable to predict the extent of COVID-19 related impacts which depends on highly uncertain and unpredictable future developments, including the duration and spread of the COVID-19 outbreak, and the speed and extent of the resumption of normal economic and operating conditions. In light of this uncertainty, the Company has taken steps to further ensure liquidity and capital resources, as discussed below.
| | | In millions | June 30, 2019 | December 31, 2018 | March 31, 2020 | December 31, 2019 |
| Cash, cash equivalents and marketable securities | $ | 1,669 |
| $ | 8,577 |
| |
| Cash and cash equivalents | | $ | 1,748 |
| $ | 1,540 |
|
| Total debt | $ | 17,229 |
| $ | 12,639 |
| $ | 17,543 |
| $ | 17,447 |
|
In November 2018, DuPont consummatedThe Company's cash and cash equivalents at March 31, 2020 and December 31, 2019 were $1.7 billion and $1.5 billion, respectively, of which $1.1 billion at March 31, 2020 and $1.4 billion at December 31, 2019 were held by subsidiaries in foreign countries, including United States territories. The decrease in cash and cash equivalents held by subsidiaries in foreign countries is due to repatriation activities. For each of its foreign subsidiaries, the offering ofCompany makes an assertion regarding the senior unsecured notes (the "2018 Senior Notes") in an aggregate principal amount of $12.7 billion. The offering consisted of $0.5 billion in floating rate notes due November 2020, $0.3 billion in floating rate notes due November 2023, and six tranches of fixed-rate notes: $1.5 billion due November 2020, $2.5 billion due November 2023, $1.85 billion due November 2025, $2.25 billion due November 2028, $1.65 billion due November 2038 and $2.15 billion due November 2048. The net proceeds ofearnings intended for permanent reinvestment, with the offering after the underwriting discount was $12.6 billion. See Note 14balance available to be repatriated to the interim Consolidated Financial Statements for additional informationUnited States.
Total debt at March 31, 2020 and December 31, 2019 was $17.5 billion and $17.4 billion, respectively. The increase was primarily due to a $250 million draw on the interest364-Day Revolving Credit Facility, which was partially off-set by a decline in the Commercial Paper outstanding balance. As discussed below, the draw on the 364-Day Facility was related to temporary dislocation in the 2018 Senior Notes.market for commercial paper in March 2020.
Term Loan and Revolving Credit Facilities
In November 2018, the Company entered into a term loan agreement that establishes two term loan facilities in the aggregate principal amount of $3 billion, (the “Term Loan Facilities”) as well as a five-year $3 billion revolving credit facility (the “Five-Year Revolving Credit Facility”). Effective May 2, 2019, the Company fully drew the two Term Loan Facilities in the aggregate principal amount of $3.0 billion and the Five-Year Revolving Credit Facility became effective and available. In June 2019, the Company entered into a 364-day $750 million revolving credit facility (the “364-Day Revolving Credit Facility”). The Five-Year Revolving Credit Facility is generally expected to remain undrawn, and serve as a backstop to the Company’s commercial paper and letter of credit issuance. TheIn June 2019, the Company entered into a 364-day $750 million revolving credit facility (the “Old 364-Day Revolving Credit Facility”). In March 2020, the Company made a draw on the Old 364-Day Revolving Credit Facility in the aggregate principal amount of $250 million.
Subsequent to March 31, 2020, the Company repaid the $250 million draw on the Old 364-Day Revolving Credit Facility.
In April 2020, the Company entered into a $1.0 billion 364-day revolving credit facility (the “$1B Revolving Credit Facility"). The $1B Revolving Credit Facility replaced the Old 364-Day Revolving Credit Facility, improving the Company’s liquidity position in response to near term uncertainties. As of the effectiveness of the $1B Revolving Credit Facility, the Old 364-Day Revolving Credit Facility was terminated. The $1B Revolving Credit facility may be drawn againstused for general corporate purposes, includingpurposes.
Debt Offering
On May 1, 2020, the Company completed an underwritten public offering of senior unsecured notes (the “Notes”) in the aggregate principal amount of $2 billion of 2.169 percent fixed rate Notes due May 1, 2023 (the “May Debt Offering”). The proceeds from the May Debt Offering are expected to be used by the Company to repay or redeem the Company’s $0.5 billion in floating rate notes due November 2020 and $1.5 billion of 3.77 percent fixed-rate notes due November 2020 (collectively, the “2020 Notes”). Upon consummation of the Proposed N&B Transaction, the Company will be required to mail a notice of redemption to holders of the Notes, with a copy to the Trustee, setting forth the date of redemption of all of the Notes on the date (“Special Mandatory
Redemption Date”) that is the later of (i) three (3) Business Days after the consummation of the Proposed N&B Transaction and (ii) May 1, 2021. On the Special Mandatory Redemption Date, the Company will be required to redeem all of the Notes at a redemption price equal to 100% of the aggregate principal amount of the Notes plus accrued and unpaid interest, if any, up to but not limitedexcluding the Special Mandatory Redemption Date. In the event a special mandatory redemption is triggered, the Company expects to net working capital, costs and expenses.fund the redemption with proceeds from the Special Cash Payment.
Commercial Paper
In April 2019, DuPont authorized a $3 billion commercial paper program (the “DuPont Commercial Paper Program”). At March 31, 2020, the Company had issued $1.7 billion of commercial paper ($1.8 billion at December 31, 2019). As noted previously, the Company did experience some temporary illiquidity in the commercial paper market in March 2020, attributable to overall disruptions to financial markets from the ongoing COVID-19 outbreak. Since March 31, 2020, the Company has noted greater stability and liquidity in the commercial paper market. The Company’s issuanceCompany expects commercial paper to remain a primary liquidity source going forward.
Nutrition & Biosciences Financing
In connection with the Proposed N&B Transaction, N&B Inc. entered into a Bridge Commitment Letter in an aggregate principal amount of $7.5 billion, (the “Bridge Loans”) to secure committed financing for the Special Cash Payment and related financing fees and expenses. The aggregate commitment under the Commercial Paper Program includedBridge Letter is reduced by, among other things, (1) the Funding CP Issuanceamount of net cash proceeds received by N&B Inc. from any issuance of senior unsecured notes pursuant to a Rule 144A offering or other private placement, (the "N&B Notes Offering") and (2) certain qualifying term loan commitments under senior unsecured term loan facilities.
In January 2020, N&B Inc. entered into a senior unsecured term loan agreement in May 2019 in anticipationthe amount of $1.25 billion split evenly between three- and five-year facilities. As a result of entry into the term loan agreement, the commitments under the Bridge Commitment Letter were reduced to $6.25 billion. The remaining $6.25 billion is expected to be funded through the N&B Notes Offering and/or the Bridge Loans. The proceeds from drawdowns on the term loan facilities and the N&B Notes Offering, if any, and/or the Bridge Loans would be used to make the Special Cash Payment and to pay the related financing fees and expenses. The commitments under the Bridge Commitment Letter and the availability of funding under the term loan agreement are subject to customary closing conditions including among others, the satisfaction of substantially all the conditions to the consummation of the Corteva Distribution, as well as borrowingsproposed transaction with IFF.
Borrowing under the term loan agreement and, if any, under the Bridge Loans would occur immediately prior to the closing of the Proposed N&B Transaction. Any issuance of the N&B Note Offering for general corporate purposes.some or all the remaining $6.25 billion would likely occur in advance of the closing.
The net proceeds fromPursuant to the 2018 Senior Notes, Term Loan Facilities, and commercial paper together with cash from operations were used to fund cash contributions to Dow and Corteva, and DowDuPont’s November 2018 $3.0 billion share repurchase program, which was completed inMerger Agreement, the first quarter of 2019. The remaining proceeds were used to reduce outstanding liabilities of Historical EID that would otherwise be attributed to Corteva; and further pay any related premiums, fees and expenses.expenses associated with the financing, including fees associated with any prepayment will be borne (A) entirely by N&B Inc. if the transaction closes; and (B) equally by DuPont and IFF if the Merger Agreement terminates. However, if the Merger Agreement is terminated by IFF, in accordance with its terms, for breach by DuPont, such fees and expenses will be borne entirely by DuPont; and if terminated by DuPont in accordance with its terms for breach by IFF, such fees and expenses will be borne entirely by IFF.
Credit Ratings
The Company's credit ratings impact its access to the debt capital markets and cost of capital. The Company remains committed to a strong financial position and strong investment-grade rating. At July 31, 2019,April 30, 2020, DuPont's credit ratings were as follows:
|
| | | |
| Credit Ratings | Long-Term Rating | Short-Term Rating | Outlook |
| Standard & Poor’s | A-BBB+ | A-2 | StableNegative Watch |
| Moody’s Investors Service | Baa1 | P-2 | Stable |
| Fitch Ratings | BBB+ | F-2 | Stable |
The Company's indenture covenants include customaryrelated to its 2018 Senior Notes and May Debt Offering contains certain limitations on the Company’s ability to incur liens and enter into sale and leasebacklease-back transactions, and mergers and consolidations subject to certain limitations. The 2018 Senior Notes also containas well as customary default provisions.events of default. The Term Loan Facilities, the Five-Year Revolving Credit Facility and the 364-Day$1B Revolving Credit Facility contain a financial covenant, typical for companies with similar credit ratings, requiring that the ratio of Total Indebtedness to Total Capitalization for the Company and its consolidated subsidiaries not exceed 0.60. At June 30, 2019,March 31, 2020, the Company was in compliance with this financial covenant.
The Company's cash, cash equivalents and marketable securities at June 30, 2019 and December 31, 2018 were $1.7 billion and $8.6 billion, respectively, of which $1.6 billion at June 30, 2019 and $2.1 billion at December 31, 2018 were held by subsidiaries in foreign countries, including United States territories. The decrease in cash and cash equivalents held by subsidiaries in foreign countries is due to the repatriation activities discussed below. For each of its foreign subsidiaries, the Company makes an assertion
regarding the amount of earnings intended for permanent reinvestment, with the balance available to be repatriated to the United States.
The Tax Cuts and Jobs Act (“The Act”) requires companies to pay a one-time transition tax on earnings50
Summary of Cash Flows
The Company’s cash flows from operating, investing and financing activities, as reflected in the interim Consolidated Statements of Cash Flows, are summarized in the following table. The cash flows related to Dow and Corteva have not been segregated and are included in the interim Consolidated Statements of Cash Flows for all periods presented, as applicable.the three months ended March 31, 2019.
| | | Cash Flow Summary | Six Months Ended | Three Months Ended |
| In millions | June 30, 2019 | June 30, 2018 | March 31, 2020 | March 31, 2019 |
| Cash provided by (used for): | | | | |
| Operating activities | $ | (51 | ) | $ | (47 | ) | $ | 718 |
| $ | 26 |
|
| Investing activities | $ | (1,657 | ) | $ | (390 | ) | $ | (124 | ) | $ | (1,000 | ) |
| Financing activities | $ | (10,661 | ) | $ | (3,602 | ) | $ | (344 | ) | $ | (1,032 | ) |
| Effect of exchange rate changes on cash, cash equivalents and restricted cash | $ | 48 |
| $ | (171 | ) | $ | (45 | ) | $ | 50 |
|
| Cash, cash equivalents and restricted cash reclassified as discontinued operations | $ | — |
| $ | 7,961 |
| — |
| $ | 5,204 |
|
Cash Flows from Operating Activities
In the first sixthree months of 2019,2020, cash used forprovided by operating activities was $51$718 million, compared with cash used forprovided by operating activities of $47$26 million in the same period last year. The increase in the use of cash provided by operating activities was primarily due to a decrease in cash used for working capital, offset by the impact of the Dow and Corteva Distributions to period earnings, largely counter-balanced by lesser use of cash for net working capital versus the prior period.earnings.
|
| | | | | | |
Net Working Capital 1 | June 30, 2019 | Dec 31, 2018 |
| In millions (except ratio) |
| Current assets | $ | 10,623 |
| $ | 16,380 |
|
| Current liabilities | 6,457 |
| 3,878 |
|
| Net working capital | $ | 4,166 |
| $ | 12,502 |
|
| Current ratio | 1.65:1 |
| 4.22:1 |
|
1. Net working capital has been restated to exclude the assets and liabilities related to the Distributions. The assets and liabilities related to the Distributions are presented as assets of discontinued operations and liabilities of discontinued operations, respectively, in the Condensed Consolidated Balance Sheets for all periods presented. |
| | | | | | |
| Net Working Capital | March 31, 2020 | Dec 31, 2019 |
| In millions (except ratio) |
| Current assets | $ | 10,392 |
| $ | 9,999 |
|
| Current liabilities | 8,545 |
| 8,346 |
|
| Net working capital | $ | 1,847 |
| $ | 1,653 |
|
| Current ratio | 1.22:1 |
| 1.20:1 |
|
Cash Flows from Investing Activities
In the first sixthree months of 2019,2020, cash used for investing activities was $1,657$124 million, compared to cash used for investing of $390$1,000 million in the first sixthree months of 2018.2019. The increasedecrease in cash used was primarily attributable to increasedlower capital expenditures a decreaseand an increase in proceeds from sales of property and maturitiesbusinesses. The first three months of investments, as well as a decline in trade accounts receivable conduits.2019 also contains activity related to the materials science and agriculture businesses prior to the Distributions.
Cash Flows from Financing Activities
In the first sixthree months of 2019,2020, cash used for financing activities was $10,661$344 million compared with $3,602$1,032 million in the same period last year. The primary driver of the increased usedecrease in cash used was a reduction in share purchases of cash is the cash heldcommon stock, a reduction in dividends paid to stockholders, partially offset by Dowdecreased issuances of short-term notes payable and Corteva at the respective Distributions, reflecting cash on the balance sheet of each at the time of their respective spinoff; as well as paymentslower proceeds from issuance of long-term debtdebt. The first three months of Historical Dow2019 also contains activity related to the materials science and Historical EIDagriculture businesses prior to the Distributions. These uses were partly offset by issuance of long-term debt in the form of the Term Loan Facilities draw in May 2019.
Free Cash Flow
The Company defines free cash flow as cash from operating activities less capital expenditures. Under this definition, free cash flow represents the cash generated by the Company from operations after investing in its asset base. Free cash flow, combined with cash balances and other sources of liquidity, represent the cash available to fund obligations and provide returns to shareholders. Free cash flow is an integral financial measure used in the Company's financial planning process. This financial measure is not recognized in accordance with U.S. GAAP and should not be viewed as an alternative to U.S. GAAP financial measures of performance. All companies do not calculate non-GAAP financial measures in the same manner and, accordingly, the Company's free cash flow definition may not be consistent with the methodologies used by other companies.
For additional information relating to the change in cash used for operating activities, see the discussion in the previous section entitled "Cash Flows from Operating Activities."
|
| | | | | | |
| Reconciliation of "Cash From Operating Activities" to Free Cash Flow (non-GAAP) | Six Months Ended |
| In millions | June 30, 2019 | June 30, 2018 |
| Cash from operating activities (GAAP) | $ | (51 | ) | $ | (47 | ) |
| Capital expenditures | (1,800 | ) | (1,586 | ) |
| Free cash flow (non-GAAP) | $ | (1,851 | ) | $ | (1,633 | ) |
Dividends
On February 14, 2019,12, 2020, the Board of Directors declared a first quarter dividend of $0.30 per share, paid on March 16, 2020, to shareholders of record on February 28, 2020.
On April 29, 2020, the Company announced that its Board declared a dividend of $851 million in aggregate on a pro rata basis, paid on March 15, 2019, to shareholders of record on February 28, 2019. On March 8, 2019, the Company announced that its Board declared a dividend of $325 million in the aggregate on a pro rata basis, which was paid on May 28, 2019, to shareholders of record on April 26, 2019.
On June 27, 2019, the Company announced that its Board declared a thirdsecond quarter dividend of $0.30 per share payable on September 13, 2019,June 15, 2020, to shareholders of record on July 31, 2019.May 29, 2020.
Share Buyback Programs
On June 1, 2019, the Company's Board of Directors authorized a new $2 billion share buyback program, which expires on June 1, 2021. At June 30, 2019,As of March 31, 2020, the Company had repurchased 1.416.9 million shares under this program since inception at a total cost of $102$982 million.
See Part II, Item 2. Unregistered Sales of Equity Securities and Use of Proceeds, for additional information.
Pension and Other Post Employment Plans
DuPont expects to make additional contributions in the aggregate of approximately $240$60 million by year-end 20192020 to certain non-US pension and other post employment benefit plans. Any such contribution could be funded by existing cash balances and/or cash from other available sources of liquidity.
Restructuring
In March 2020, the Company approved restructuring actions designed to capture near-term cost reductions following the expected closure of the Proposed N&B Transaction (the "2020 Restructuring Program"). As a result of these actions, the Company recorded pre-tax restructuring charges of $111 million during the first quarter of 2020, consisting of severance and related benefit costs of $96 million and asset related charges of $15 million. The Company expects actions related to this program to be substantially complete by the end of 2020. Future cash payments related to the 2020 Restructuring Program are anticipated to be up to $130 million primarily related to the payment of severance and related benefits and contract termination charges.
In June 2019, DuPont approved restructuring actions to simplify and optimize certain organizational structures following the completion of the Distributions (the "2019 Restructuring Program"). As a result of these actions, the Company has recorded pre-tax restructuring charges of $156 million inception-to-date, consisting of severance and related benefit costs of $122 million and asset related charges of $34 million. The Company expects actions related to this program to be substantially complete in the second quarter of 2020. Future cash payments related to the 2019 Restructuring Program are anticipated to be approximately $55 million to $85$75 million, primarily related to the payment of severance and related benefits, lease terminationbenefits.
In September and November 2017, the Company approved post-merger restructuring actions under the DowDuPont Cost Synergy Program, adopted by the DowDuPont Board of Directors. The Synergy Program was designed to integrate and optimize the organization following the Merger and in preparation for the Distributions whereby the Company has recorded pre-tax restructuring charges attributable to the continuing operations of DuPont of $490 million inception-to-date, consisting of severance and related benefit costs of $215 million, asset related charges of $209 million and contract termination costs.charges of $66 million. The activities related to the DowDuPont Cost Synergy Program are expected to result in additional cash expenditures of approximately $124$59 million consisting of severance and related benefit costs and contract terminations. Actions associated with the DowDuPont Cost Synergy Program, including employee separations, are considered substantially complete (see Note 5 to the interim Consolidated Financial Statements). It is possible that additional charges and future cash payments could occur in relation to the Company's restructuring actions. The Company expects to incur additional employee-related costs, including involuntary termination benefits, related to its other optimization activities. These costs cannot be reasonably estimated at this time.
Off-balance Sheet Arrangements
Guarantees arise in the ordinary course of business from relationships with customers and nonconsolidated affiliates when the Company undertakes an obligation to guarantee the performance of others if specific triggering events occur. At June 30, 2019March 31, 2020 and December 31, 2018,2019, the Company had directly guaranteed $185 million and $199$187 million, respectively, of such obligations. Additional information related to the guarantees of the Subsidiaries can be found in the “Guarantees” section of Note 1513 to the interim Consolidated Financial Statements.
Contractual Obligations
Information related to the Company's contractual obligations at December 31, 20182019 can be found in the Company's 20182019 Annual Report, Part II, Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations, Contractual Obligations. ThereIn the first quarter of 2020, there have been no material changes in the Company'scompany's contractual obligations since December 31, 2018 as a result of the distributions of Dow and Corteva. Information related to DuPont's significant contractual obligations is summarized in the following table:
|
| | | | | | | | | | | | | | | |
| | | Payments Due In |
| In millions | Total at June 30, 2019 | Remainder of 2019 | 2020-2021 | 2022-2023 | 2024 and beyond |
Long-term debt obligations 1,2 | $ | 15,713 |
| $ | 3 |
| $ | 2,009 |
| $ | 5,801 |
| $ | 7,900 |
|
Expected cash requirements for interest 3 | 7,640 |
| 345 |
| 1,306 |
| 1,062 |
| 4,927 |
|
| Finance lease obligations | 4 |
| 1 |
| 2 |
| — |
| 1 |
|
| Operating leases | 612 |
| 92 |
| 221 |
| 120 |
| 179 |
|
| Pension and other post employment benefits | 1,184 |
| 237 |
| 138 |
| 123 |
| 686 |
|
Purchase obligations 4 | 647 |
| 108 |
| 312 |
| 179 |
| 48 |
|
Other liabilities 5 | 178 |
| 27 |
| 73 |
| 24 |
| 54 |
|
| Total contractual obligations | $ | 25,978 |
| $ | 813 |
| $ | 4,061 |
| $ | 7,309 |
| $ | 13,795 |
|
| |
1. | Included in the interim Consolidated Financial Statements. |
| |
2. | Excludes unamortized debt fees of $103 million. |
| |
3. | Cash requirement for interest on long-term debt was calculated using current interest rates at June 30, 2019 and includes $383 million of various floating rate notes and debt instruments. |
| |
4. | Represents enforceable and legally binding agreements in excess of $1 million to purchase goods or services that specify fixed or minimum quantities; fixed, minimum or variable price provisions; and the approximate timing of the agreement. |
| |
5. | Includes liabilities related to environmental remediation, legal settlements, and other noncurrent liabilities. The table excludes uncertain tax positions due to uncertainties in the timing of the effective settlement of tax positions with the respective taxing authorities and deferred tax liabilities as it is impractical to determine whether there will be a cash impact related to these liabilities. The table also excludes deferred revenue as it does not represent future cash requirements arising from contractual payment obligations. |
The Company expects to meet its contractual obligations through its normal sources of liquidity and believes it has the financial resources to satisfy the contractual obligations that arise in the ordinary course of business.2019.
OTHER MATTERS
Recent Accounting Guidance
See Note 2 to the interim Consolidated Financial Statements for a description of recent accounting guidance.
Critical Accounting Estimates
The preparation of financial statements and related disclosures in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”) requires management to make judgments, assumptions and estimates that affect the amounts reported in the interim Consolidated Financial Statements and accompanying notes. Note 1 to the Consolidated Financial Statements in the Company’s Annual Report on Form 10-K for the year ended December 31, 20182019 (“20182019 Annual Report”) describes the significant accounting policies and methods used in the preparation of the Consolidated Financial Statements. DuPont’s accounting policies that are impacted by judgments, assumptions and estimates are described in Management’s Discussion and Analysis of Financial Condition and Results of Operations in the Company’s 20182019 Annual Report. Since December 31, 2018,2019, there have been no material changes in the Company’s accounting policies that are impacted by judgments, assumptions and estimates. See the discussion in this section for information regarding the valuation of assets and impairment considerations.
Valuation of Assets and Impairment Considerations
The Company tests goodwill for impairment annually during the fourth quarter as of October 1, or more frequently when events or changes in circumstances indicate that the fair value is below its carrying value. Goodwill is evaluated for impairment using qualitative and/or quantitative testing procedures. The Company performs goodwill impairment testing at the reporting unit level which is defined as the operating segment or one level below the operating segment. One level below the operating segment, or component, is a business in which discrete financial information is available and regularly reviewed by segment management. The Company aggregates certain components into reporting units based on economic similarities. The Company assessed and re-defined certain reporting units effective June 1, 2019 in connection with the Second Quarter Segment Realignment. At June 30, 2019, the Company had identified 11 reporting units, eight of which carried goodwill.
During the second quarter 2019, the Company recorded goodwill impairment charges of $1,175 million. Refer to Note 13 to the interim Consolidated Financial Statements for further information.
As a result of the related acquisition method of accounting in connection with the Merger, Historical EID’s assets and liabilities were measured at fair value resulting in increases to the Company’s goodwill and other intangible assets. The fair value valuation increased the risk that any declines in financial projections, including changes to key assumptions, could have a material, negative impact on the fair value of the Company’s reporting units and assets, and therefore could result in an impairment. There were no other indicators for
COVID-19 continues to adversely impact the Company’s other reporting units that would suggest that itbroader global economy and has caused significant volatility in financial markets. If there is more likely than not thata of lack of recovery or further global softening in certain markets, mainly in which the fair value is less than its carrying value at June 30, 2019. The Company will perform its annual goodwillTransportation & Industrial segment operates in such as automotive, oil & gas and intangible asset impairment testselect industrial end-markets, or a sustained decline in the fourth quarter.value of the Company's common stock, the Company may be required to perform additional impairment assessments for its goodwill, other intangibles, and long-lived assets, the results of which could result in material impairment charges.
ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
The Company’s global operations are exposed to financial market risks relating to fluctuations in foreign currency exchange rates, commodity prices, and interest rates. The Company has established a variety of programs including the use of derivative instruments and other financial instruments to manage the exposure to financial market risks as to minimize volatility of financial results. In the ordinary course of business, the Company enters into derivative instruments to hedge its exposure to foreign currency, interest rate and commodity price risks under established procedures and controls. For additional information on these derivatives and related exposures, seeSee Note 2119 to the interim Consolidated Financial Statements. Decisions regarding whether or not to hedge a given commitment are made on a case-by-case basis, taking into consideration the amountSee also Part II, Item 7A. Quantitative and duration of the exposure, market volatility and economic trends. Foreign currency exchange contracts are also used, from time to time, to manage near-term foreign currency cash requirements.
Foreign Currency Exchange Rate Risks
The Company has significant international operations resulting in a large number of currency transactions that result from international sales, purchases, investments and borrowings. The primary currencies for which the Company has an exchange rate exposure are the European euro ("EUR"), Chinese renminbi, Swiss franc, and South Korean won. The Company uses forward exchange contracts to offset its net exposures, by currency, related to the foreign currency denominated monetary assets and liabilities of its operations. In addition to the contracts disclosed in Note 21 to the interim Consolidated Financial Statements, from time to time, the Company will enter into foreign currency exchange contracts to establish with certainty the U.S. dollar ("USD") amount of future firm commitments denominated in a foreign currency.
The following table illustrates the fair values of outstanding foreign currency contracts at June 30, 2019, and the effect on fair values of a hypothetical adverse change in the foreign exchange rates that existed at June 30, 2019. The sensitivities for foreign currency contracts are based on a 10 percent adverse change in foreign exchange rates.
|
| | | | | | |
| | Fair Value Asset/(Liability) | Fair Value Sensitivity |
| In millions | June 30, 2019 | June 30, 2019 |
| Foreign currency contracts | $ | 7 |
| $ | (285 | ) |
Since the Company's risk management programs are highly effective, the potential loss in value for each risk management portfolio described above would be largely offset by changes in the value of the underlying exposure.
Concentration of CreditQualitative Disclosures About Market Risk,
The Company maintains cash and cash equivalents, marketable securities, derivatives and certain other financial instruments with various financial institutions. These financial institutions are generally highly rated and geographically dispersed and the Company has a policy to limit the dollar amount of credit exposure with any one institution.
As part of the Company's 2019 Annual Report on Form 10-K for information on the Company's utilization of financial risk management processes, it continuously evaluates the relative credit standing of allinstruments and an analysis of the financial institutions that service DuPont and monitors actual exposures versus established limits. The Company has not sustained credit losses from instruments held at financial institutions.
The Company's sales are not materially dependent on any single customer. Assensitivity of June 30, 2019, no one individual customer balance represented more than five percent of the Company's total outstanding receivables balance. Credit risk associated with its receivables balance is representative of the geographic, industry and customer diversity associated with the Company's global product lines.
The Company also maintains strong credit controls in evaluating and granting customer credit. As a result, it may require that customers provide some type of financial guarantee in certain circumstances. Length of terms for customer credit varies by industry and region.these instruments.
ITEM 4. CONTROLS AND PROCEDURES
Evaluation of Disclosure Controls and Procedures
The Company maintains a system of disclosure controls and procedures to give reasonable assurance that information required to be disclosed in the Company's reports filed or submitted under the Securities Exchange Act of 1934 (Exchange Act) is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC. These controls and procedures also give reasonable assurance that information required to be disclosed in such reports is accumulated and communicated to management to allow timely decisions regarding required disclosures.
As of March 31, 2020, the end of the period covered by this Quarterly Report on Form 10-Q, the Company carried out an evaluation, under the supervision and with the participation of the Company’s Disclosure Committee and the Company’s management, including theCompany's Chief Executive Officer (CEO) and the Chief Financial Officer (CFO), together with management, conducted an evaluation of the effectiveness of the design and operation of the Company’sCompany's disclosure controls and procedures pursuant to paragraph (b)Rules 13a-15(e) and 15d-15(e) of the Exchange Act Rules 13a-15 and 15d-15.Act. Based uponon that evaluation, the Chief Executive OfficerCEO and the Chief Financial OfficerCFO concluded that the Company’sthese disclosure controls and procedures wereare effective.
Changes in Internal Control Over Financial Reporting
There were no changes in the Company's internal control over financial reporting identified in connection with the evaluation required by paragraph (d) of Exchange Act Rules 13a-15 and 15d-15 that was conducted during the last fiscal quarter that have materially affected, or are reasonably likely to materially affect, the Company's internal control over financial reporting.
In connection with the Distributions, there arewere several processes, policies, operations, technologies and information systems that were integrated following the Merger which have been or will be replicated, transferred or separated. TheDuring the quarter ended March 31, 2020, the Company continuescontinued to take steps to ensure that adequate controls arewere designed and maintained, throughout this transition period.including planning for separation activities related to the Proposed N&B Transaction.
|
|
DuPont de Nemours Inc. PART II - OTHER INFORMATION |
ITEM 1. LEGAL PROCEEDINGS
The Company and its subsidiaries are subject to various litigation matters, including, but not limited to, product liability, patent infringement, antitrust claims, and claims for third party property damage or personal injury stemming from alleged environmental torts. Information regarding certain of these matters is set forth below and in Note 1513 to the interim Consolidated Financial Statements.
Litigation
See Note 1513 to the interim Consolidated Financial Statements.
Environmental Proceedings
The Company believes it is remote that the following matters will have a material impact on its financial position, liquidity or results of operations. The description is included per Regulation S-K, Item 103(5)(c) of the Securities Exchange Act of 1934. Refer to Note 15 of the Consolidated Financial Statements for additional discussion of the allocation of liabilities under the Separation and Distribution Agreement and the Letter Agreement.
Divested Neoprene Facility, La Place, Louisiana - EPA Compliance InspectionInspection
In 2016, the EPA conducted a focused compliance investigation at the Denka Performance Elastomer LLC (“Denka”) neoprene manufacturing facility in La Place, Louisiana. Historical EID sold the neoprene business, including this manufacturing facility, to Denka in the fourth quarter of 2015. Subsequent to this inspection, the U.S. Environmental Protection Agency (“EPA)”EPA”), the U.S. Department of Justice (“DOJ”), the Louisiana Department of Environmental Quality (“DEQ”), the Company originally(originally through Historical EID,EID), and Denka began discussions in the spring of 2017 relating to the inspection conclusions and allegations of noncompliance arising under the Clean Air Act, including leak detection and repair. DuPont, Denka, EPA, DOJ and DEQ are continuing these discussions, which include potential settlement options.
FilmTec Edina, Minnesota Matter
On March 14, 2017, FilmTec Corporation ("FilmTec"), a wholly owned subsidiary of Historical Dow, received notification from the EPA, Region 5 and the DOJ of a proposed penalty for alleged violations of the Clean Air Act at FilmTec’s Edina, Minnesota, manufacturing facility. In the second quarter 2019, the EPA, the DOJ and FilmTec agreed, subject to publication and entry of a final Consent Decree, to settle the matter for a civil penalty of $250,000 and FilmTec’s agreement to undertake certain remedial actions.
New Jersey Directive PFAS
On March 25, 2019, the New Jersey Department of Environmental Protection (“NJDEP”) issued a Directive and Notice to Insurers to a number of companies, including Chemours, DowDuPont, Historical EID, and certain DuPont subsidiaries. NJDEP’s allegations relate to former operations of Historical EID involving poly- and perfluoroalkyl substances, (“PFAS”), including PFOA and PFOA- replacement products. The NJDEP seeks past and future costs of investigating, monitoring, testing, treating, and remediating New Jersey’s drinking water and waste systems, private drinking water wells and natural resources including groundwater, surface water, soil, sediments and biota. The Directive seeks certain information as to future costs and information related to the historic uses of PFAS and replacement chemicals including “information ranging from use and discharge of the chemicals through wastewater treatment plants, air emissions, and sales of products containing the chemicals to current development, manufacture, use and release of newer chemicals in the state.”
ITEM 1A. RISK FACTORS
Other than the risk factor set forth below, there have been no material changes in the Company's risk factors discussed in Part I, Item 1A, Risk Factors, in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019.
The Company'sextent to which the novel coronavirus (COVID-19) and measures taken in response to it, impact DuPont’s business, results of operations, couldaccess to sources of liquidity and financial condition depends on future developments, which are highly uncertain and cannot be predicted.
DuPont is actively monitoring the global impacts of COVID-19, including the impacts from responsive measures, and remains focused on its top priorities - the safety and health of its employees and the needs of its customers. The company’s business and financial condition, and the business and financial condition of the company’s customers and suppliers, have been impacted by the significantly increased economic and demand uncertainties created by the COVID-19 outbreak. In addition, public and private sector responsive measures, such as the imposition of travel restrictions, quarantines, adoption of remote working, and suspension of non-essential business and government services, have impacted the company’s business and financial condition. Many of DuPont’s facilities and employees are based in areas impacted by the virus. While most DuPont manufacturing sites remain in operation, DuPont has reduced or furloughed certain operations in response to government measures, employee welfare concerns and the impact of COVID-19 on the global demand and supply chain. DuPont’s manufacturing operations may be further adversely affected by various risks, manyimpacts from COVID-19 including, among other things, additional government actions and other responsive measures, more and /or deeper supply chain disruptions, quarantines and health and availability of which are beyond its control. Based on current information,essential onsite personnel. Furthermore, COVID-19 continues to adversely impact the Company believes that the following identifies the most significant risk factors that could affect its operations. Past financial performance may not be a reliable indicator of future performancebroader global economy, including negatively impacting economic growth and historical trends should not be used to anticipate results or trends in future periods.
Risks Relating to the Separationscreating disruption and Distributions
DuPont is subject to continuing contingent tax-related liabilities of Dow and Corteva following the separations and Distributions.
After the separations and Distributions, there are several significant areas where the liabilities of Dow and Corteva may become the Company’s obligations, either in whole or in part. For example, to the extent that any subsidiary of the Company was includedvolatility in the consolidated tax reporting groupglobal financial and capital markets, which increases the cost of either Historical Dow or Historical EID for any taxable period or portioncapital and adversely impacts the availability of any taxable period ending on or before the effective date of the Merger, such subsidiary is jointly and severally liable for the U.S. federal income tax liability of the entire consolidated tax reporting group of Historical Dow or Historical EID, as applicable, for such taxable period. In connection with the separations and Distributions, DuPont, Dow and Corteva have entered into a Tax Matters Agreement, as amended, that allocates the responsibility for prior period consolidated taxes among Dow, Corteva and DuPont. If Dow or Corteva are unableaccess to pay any prior period taxes for which it is responsible, however, DuPont could be required to pay the entire amount of such taxes, and such amounts could be significant. Other provisions of federal, state, local, or foreign law may establish similar liability for other matters, including laws governing tax-qualified pension plans, as well as other contingent liabilities.
Restrictions under the intellectual property cross-license agreements will limit the Company’s ability to develop and commercialize certain products and services and/or prosecute, maintain and enforce certain intellectual property.
Following the separations and Distributions, DuPont is dependent to a certain extent on Dow and Corteva to prosecute, maintain and enforce certain of the intellectual property licensed under the intellectual property cross-license agreements entered into by DuPont, Dow and Corteva in connection with the separations and Distributions. For example, Dow and Corteva are responsible for filing, prosecuting and maintaining (at their respective discretion) patents that Dow and Corteva, respectively, license to the Company. Dow or Corteva, as applicable, will also have the first right to enforce their respective patents, trade secrets and know-how licensed to the Company. If Dow or Corteva, as applicable, fails to fulfill its obligations or chooses to not enforce the licensed patents, trade secrets or know-how under the intellectual property cross-license agreements, DuPont may not be able to prevent competitors from making, using and selling competitive products and services.
In addition, the Company’s use of the intellectual property licensed to it under the intellectual property cross-license agreements is restricted to certain fields, capital,which could limit the Company’s ability to develop and commercialize certain products and services. For example, the licenses granted to it under the agreements do not extend to all fields of use that DuPont may in the future decide to enter. These restrictions may make it more difficult, time consuming and/or expensive for it to develop and commercialize certain new products and services, or may result in certain of the Company’s products or services being later to market than those of the Company’s competitors.
Certain of the contracts transferred or assigned to it as part of the separations and Distributions contain provisions requiring the consent of a third party in connection with the transactions contemplated by the separations and Distributions. If such consent is not given, DuPont may not be entitled to the benefit of such contracts in the future.
Certain of the contracts transferred or assigned to it in connection with the separations and Distributions contain provisions that require the consent of a third party. Some parties may use consent requirements or other rights to seek to terminate contracts or obtain more favorable contractual terms from it. If negatively affect DuPont’s liquidity. DuPont is unable to obtain such consents on commercially reasonable and satisfactory terms, the Company’s ability to obtain the benefit of such contracts in the future may be impaired and DuPont may be required to seek alternative arrangements which may be less advantageous to it.
The Company’s customers, prospective customers, suppliers or other companies with whom DuPont conducts business may need assurances that the Company’s financial stability on a stand-alone basis is sufficient to satisfy their requirements for doing or continuing to do business with them.
Some of the Company’s customers, prospective customers, suppliers or other companies with whom DuPont conducts business may need assurances that the Company’s financial stability on a stand-alone basis is sufficient to satisfy their requirements for doing or continuing to do business with them, and may require it to provide additional credit support, such as letters of credit or other financial guarantees. Obtaining such credit support could increase the Company’s costs. Any failure of parties to be satisfied with the Company’s financial stability could have a material adverse effect on the Company’s business, financial condition, results of operations and cash flows.
Non-compete restrictions in the Separation and Distribution Agreement limit the Company’s ability to compete with certain businesses of Dow for certain periods of time and may limit strategic transactions or discourage the Company’s potential investors from purchasing the Company’s securities. Moreover, when the non-compete restrictions expire, Dow may re-enter these limited business areas, which could cause DuPont to lose market share.
Pursuant to the Separation and Distribution Agreement, and subject to specified exceptions, DuPont and Dow agree not to compete in limited areas of the other’s businesses for a period 30 months from the date of the Dow Distribution. As a result, even if market conditions or the Company’s strategic direction change, DuPont would not be able to enter the subject materials science businesses during the non-compete period. This non-compete restriction could delay, defer or prevent a change of control, merger, consolidation, takeover or other business combination involving it that the Company’s board of directors or the Company’s shareholders may otherwise support, and could also discourage a potential investor from acquiring the Company’s securities and may harm the market price of the Company’s securities, including the Notes.
Once the non-compete period terminates, Dow could elect to re-enter the Company’s subject business areas, in which case DuPont would face increased competition. This may cause it to lose market share and could have an adverse effect on the Company’s business, financial condition, results of operations and cash flows.
In connection with the separations and Distributions, certain liabilities are allocated to or retained by DuPont through assumption or indemnification of Dow and/or Corteva, as applicable. If DuPont is required to make payments pursuant to these indemnities to Dow and/or Corteva, DuPont may need to divert cash to meet those obligations, and the Company’s financial results could be negatively impacted. In addition, certain liabilities are allocated to or retained by Dow and/or Corteva through assumption or indemnification, or subject to indemnification by other third parties. These indemnities may not be sufficient to insure the Company against the full amount of liabilities allocated to or retained by it, and Dow and/or Corteva may not be able to satisfy its indemnification obligations in the future.
Pursuant to the Separation and Distribution Agreement, the Employee Matters Agreement, and the Tax Matters Agreement, as amended, (collectively, the “Core Agreements”) with Dow and Corteva, as well as the Letter Agreement between DuPont and Corteva, DuPont has agreed to assume, and indemnify Dow and Corteva for, certain liabilities. (See discussion of the Core Agreements in Note 3 to the interim Consolidated Financial Statements and Litigation and Environmental Matters in Note 15 to the interim Consolidated Financial Statements.) Payments pursuant to these indemnities may be significant and could negatively impact the Company’s business, particularly indemnities relating to the Company’s actions that could impact the tax-free nature of the distributions. Third parties could also seek to hold it responsible for any of the liabilities allocated to Dow and Corteva, including those related to Historical EID’s materials science and/or agriculture businesses, or for the conduct of such businesses prior to the distributions, and such third parties could seek damages, other monetary penalties (whether civil or criminal) and/or other remedies. Additionally, DuPont generally assumes and is responsible for the payment of the Company’s share of (i) certain liabilities of DowDuPont relating to, arising out of or resulting from certain general corporate matters of DuPont and (ii) certain separation expenses not otherwise allocated to Corteva or Dow (or allocated specifically to it) pursuant to the Core Agreements, and third parties could seek to hold it responsible for Dow’s or Corteva’s share of any such liabilities. Dow and/or Corteva, as applicable, have agreed to indemnify it for such liabilities; however, such indemnities may not be sufficient to protect it against the full amount of such liabilities or from other remedies, and Dow and/or Corteva, as applicable, may not be able to fully satisfy their indemnification obligations. Even if DuPont ultimately succeeds in recovering from Dow and/or Corteva, as applicable, any amounts for which DuPont are held liable, DuPont may be temporarily required to bear these losses. Each of these risks could negatively affect the Company’s business, financial condition, results of operations and cash flows.
Generally, as described in Litigation and Environmental Matters, losses related from liabilities related to discontinued and/or divested operations and businesses of Historical EID that are not primarily related to its agriculture business or specialty products business, (“Stray Liabilities”), are allocated to or shared by each of Corteva and DuPont. Certain Stray Liabilities are subject to third party indemnities; however, such indemnities may not be sufficient to protect the Company against the full amount of such liabilities or such third parties may refuse or otherwise claim defenses to payment. Although the Company believes it is remote, there can be no assurance that any such third party would have adequate resources to satisfy its indemnification obligation when due, or, would not ultimately be successful in claiming defenses against payment. Even if recovery from the third party is ultimately successful, DuPont may be temporarily required to bear these losses. Each of these risks could negatively affect the Company’s business, financial condition, results of operations and cash flows.
If the completed distribution of Corteva or Dow, in each case, together with certain related transactions, were to fail to qualify for non-recognition treatment for U.S. federal income tax purposes, then the Company could be subject to significant tax and indemnification liability.
The completed distributions of Corteva and Dow were each conditioned upon the receipt of an opinion from Skadden, Arps, Slate, Meagher & Flom LLP, the Company’s tax counsel, regarding the qualification of the applicable distribution along with certain related transactions as a tax-free transaction under Section 355 and Section 368(a)(1)(D) of the Internal Revenue Code of 1986, as amended (the “Code,” and such opinions, collectively, the “Tax Opinions”). The Tax Opinions relied on certain facts, assumptions,
and undertakings, and certain representations from the Company, Dow and Corteva, as applicable, as well as the IRS Ruling (as defined below). Notwithstanding the Tax Opinions and the IRS Ruling, the Internal Revenue Service (the “IRS”) could determine on audit that either, or both, of the distributions and certain related transactions should be treated as taxable transactions if it determines that any of these facts, assumptions, representations or undertakings are not correct or have been violated, or that the distributions should be taxable for other reasons, including if the IRS were to disagree with the conclusions of the Tax Opinions.
Even if a distribution otherwise constituted a tax-free transaction to stockholders under Section 355 of the Code, the Company could be required to recognize corporate level tax on such distribution and certain related transactions under Section 355(e) of the Code if the IRS determines that, as a result of the Merger or other transactions considered part of a plan with such distribution, there was a 50 percent or greater change in ownership in the Company, Dow or Corteva, as relevant. In connection with the Merger, the Company sought and received a private letter ruling from the IRS regarding the proper time, manner and methodology for measuring common ownership in the stock of the Company, Historical EID and Historical Dow for purposes of determining whether there was a 50 percent or greater change of ownership under Section 355(e) of the Code as a result of the Merger (the “IRS Ruling”). The Tax Opinions relied on the continued validity of the IRS Ruling and representations made by the Company as to the common ownership of the stock of Historical Dow and Historical EID immediately prior to the Merger, and concluded that there was not a 50 percent or greater change of ownership for purposes of Section 355(e) as a result of the Merger. Notwithstanding the Tax Opinions and the IRS Ruling, the IRS could determine that a distribution or a related transaction should nevertheless be treated as a taxable transaction to the Company if it determines that any of the Company’s facts, assumptions, representations or undertakings was not correct or that a distribution should be taxable for other reasons, including if the IRS were to disagree with the conclusions in the Tax Opinions that are not covered by the IRS Ruling.
Generally, corporate taxes resulting from the failure of a distribution to qualify for non-recognition treatment for U.S. federal income tax purposes would be imposed on the Company. Under the Tax Matters Agreement, as amended, that the Company entered into with Dow and Corteva, Dow and Corteva are generally obligated to indemnify the Company against any such taxes imposed on it. However, if a distribution fails to qualify for non-recognition treatment for U.S. federal income tax purposes for certain reasons relating to the overall structure of the Merger and the distributions, then under the Tax Matters Agreement, as amended, the Company and Corteva, on the one hand, and Dow, on the other hand, would share the tax liability resulting from such failure in accordance with the relative equity values of the Company and Dow on the first full trading day following the distribution of Dow, and the Company and Corteva would in turn share any such resulting tax liability in accordance with the relative equity values of the Company and Corteva on the first full trading day following the distribution of Corteva. Furthermore, under the terms of the Tax Matters Agreement, as amended, a party also generally will be responsible for any taxes imposed on the other parties that arise from the failure of either distribution to qualify as tax-free for U.S. federal income tax purposes within the meaning of Section 355 of the Code or the failure of certain related transactions to qualify for tax-free treatment, topredict the extent such failure to qualify is attributable to actions, events or transactions relating to such party, or such party's affiliates’, stock, assets or business, or any breach of such party's representations made in connection with the IRS Ruling or in any representation letter provided to a tax advisor in connection with certain tax opinions, including the Tax Opinions, regarding the tax-free status of the distributions and certainCOVID-19 related transactions. To the extent that the Company is responsible for any liability under the Tax Matters Agreement, as amended, there could be a material adverse impactimpacts on the Company's business, financial condition, results of operations and cash flows in future reporting periods.
The separations and Distributions may expose the Company to potential liabilities arising out of state and federal fraudulent conveyance laws and legal distribution requirements.
Although DuPont received a solvency opinion from an investment bank confirming that DuPont, Dow and Corteva would each be adequately capitalized following the separations and Distributions, the separations and Distributions could be challenged under various state and federal fraudulent conveyance laws. Fraudulent conveyances or transfers are generally defined to include transfers made or obligations incurred with the actual intent to hinder, delay or defraud current or future creditors or transfers made or obligations incurred for less than reasonably equivalent value when the debtor was insolvent, or that rendered the debtor insolvent, inadequately capitalized or unable to pay its debts as they become due. Any unpaid creditor could claim that DuPont did not receive fair consideration or reasonably equivalent value in the separations and distributions, and that the separations and distributions left DuPont insolvent or with unreasonably small capital or that DuPont intended or believed DuPont would incur debts beyond the Company’s ability to pay such debts as they mature. If a court were to agree with such a plaintiff, then such court could void the separations and distributions as a fraudulent transfer or impose substantial liabilities on it, which could adversely affect the Company’s financial condition and the Company’s results of operations.
The separations and Distributions are also subject to review under state corporate distribution statutes. Under the Delaware General Corporation Law, a corporation may only pay dividends to its stockholders either (i) out of its surplus (net assets minus capital) or (ii) if there is no such surplus, out of its net profits for the fiscal year in which the dividend is declared and/or the preceding fiscal year. Although DuPont’s Board of Directors made the distributions out of DuPont’s surplus and received an opinion that
DuPont had adequate surplus under Delaware law to declare the dividends of Corteva and Dow common stock in connection with the Distributions, there can be no assurance that a court will not later determine that some or all of the distributions were unlawful.
Risks Related to DuPont’s Operations After the Separations and Distributions
Changes in the Company’s credit ratings could increase the Company’s cost of borrowing or restrict the Company’s ability to access debt capital markets. The Company’s credit ratings are important to the Company’s cost of capital.
DuPont relies on access to the debt capital markets and other short-term borrowings to finance the Company’s long-term and day-to-day operations. A decrease in the ratings assigned to it by the ratings agencies may negatively impact the Company’s access to the debt capital markets and increase the Company’s cost of borrowing. The major rating agencies will routinely evaluate the Company’s credit profile and assign debt ratings to it. This evaluation is based on a number of factors, which include weighing the Company’s financial strength versus business, industry and financial risk. The addition of further leverage to the Company’s capital structure could impact the Company’s credit ratings. Failure to maintain an investment grade rating at the Company’s current level would adversely affect the Company’s cost of funding and the Company’s results of operations and could adversely affect the Company’s liquidity and access to the capital markets. Any limitation on the Company’s ability to continue to raise money in the debt capital markets could have a substantial negative effect on the Company’s liquidity. If DuPont is unable to generate sufficient cash flow or maintain access to adequate external financing, including from significant disruptions in the global credit markets, it could restrict the Company’s current operations, activities under its current and future stock buyback programs, and the Company’s growth opportunities, which could adversely affect the Company’s operating results.
A significant percentage of the Company’s net sales are generated from the Company’s international operations and are subject to economic, political, regulatory, foreign exchange and other risks.
The percentage of net sales generated by the international operations of DuPont, including U.S. exports, was approximately 65 percent of net sales on a continuing operations basis for the three months ended June 30, 2019. With Asia Pacific as the Company’s largest and currently highest growth region, DuPont expects the percentage of the Company’s net sales derived from international operations to continue to be significant. Risks related to international operations include:
difficulties and costs associated with complying with a wide variety of complex, and often conflicting, laws, treaties and regulations, including antitrust regulations;
restrictions on, as well as difficulties and costs associated with, the repatriation of cash from foreign countries to the United States and the allocation of revenues or distributions of cash between the Company’s foreign subsidiaries;
exchange control regulations;
fluctuations in foreign exchange rates;
labor compliance costs, including wage, salary and benefit controls and other costs associated with a global workforce, as will as difficulties in hiring and maintaining a qualified staff outside of the United States, especially in the Asia Pacific region;
government mandated price controls;
foreign investment laws;
potential for changes in global trade policies, including import, export and other trade restrictions (such as sanctions and embargoes) and tariffs;
trends such as populism, economic nationalism and negative sentiment toward multinational companies, as well as government takeover or nationalization of businesses; and
instability and uncertainty arising from the global geopolitical environment and the evolving international and domestic political, regulatory and economic landscape.
These and other factors can impair the Company’s flexibility in modifying product, marketing, pricing or other strategies for growing the Company’s businesses, as well as the Company’s ability to improve productivity and maintain acceptable operating margins.
The Company’s international operations expose it to fluctuations in foreign currencies relative to the U.S. dollar, which could adversely affect the Company’s results of operations. For its continuing operations as of the six months ended June 30, 2019, the Company’s largest currency exposures are the European euro and Chinese renminbi. U.S. dollar fluctuations against foreign currency have an impact to commercial prices and raw material costs in some cases and could result in local price increases if the price or raw material costs is denominated in U.S. dollar.
Sales and expenses of the Company’s non-U.S. businesses are also translated into U.S. dollars for reporting purposes and fluctuations of foreign currency against the U.S. dollar could impact U.S. dollar-denominated earnings. In addition, the Company’s assets and liabilities denominated in foreign currencies can also be impacted by foreign currency exchange rates against the U.S. dollar, which could result in exchange gain or loss from revaluation.
DuPont also faces exchange rate risk from the Company’s investments in subsidiaries owned and operated in foreign countries.
DuPont has a balance sheet hedging program and actively looks for opportunities in managing currency exposures related to earnings. However, foreign exchange hedging activities bear a financial cost and may not always be available to it or be successful in completely mitigating such exposures.
DuPont generates significant amounts of cash outside of the United States that is invested with financial and non-financial counterparties. While DuPont employs comprehensive controls regarding global cash management to guard against cash or investment loss and to ensure the Company’s ability to fund the Company’s operations and commitments, a material disruption to the counterparties with whom DuPont transacts business could expose it to financial loss.
Any one or more of the above factors could adversely affect the Company’s international operations and could significantly affect the Company’s business, results of operations, access to sources of liquidity and financial condition which depends on highly uncertain and cash flows.
Volatilityunpredictable future developments, including, but not limited to, the duration and spread of the COVID-19 outbreak, its severity, the actions to contain the virus or treat its impact, and how quickly and to what extent normal economic and operating conditions resume. DuPont’s financial results may be materially and adversely impacted by a variety of factors that have not yet been determined, including potential impairments of goodwill and other assets. DuPont is taking actions, including reducing costs, restructuring actions, and delaying certain capital expenditures and non-essential spend. In addition, the company may consider further reductions in energy and raw material costs could have a significant impact on the Company’s sales and earnings.
The Company’s manufacturing processes consume significant amounts of energy and raw materials, the costs of which are subjector furloughing additional operations in response to worldwidefurther and/or deeper declines in demand and/or or supply and demand as well as other factors beyond the Company’s control. Significant variations in the cost of energy, which primarily reflect market prices for oil, natural gas and raw materials, affect the Company’s operating results from period to period. Legislation to address climate change by reducing greenhouse gas emissions, creating a carbon tax or implementing a cap and trade program could create increases in energy costs and price volatility.
When possible, DuPont purchases raw materials through negotiated long-term contracts to minimizechain disruptions. There can be no guaranty that such actions will significantly mitigate the impact of price fluctuations. Additionally, DuPont uses over-the-counter and exchange traded derivative commodity instruments to hedge the Company’s exposure to price fluctuations on certain raw material purchases, including food ingredients. DuPont also takes actions to offset the effects of higher energy and raw material costs through selling price increases, productivity improvements and cost reduction programs. Success in offsetting higher raw material costs with price increases is largely influenced by competitive and economic conditions and could vary significantly dependingCOVID-19 on the market served. As a result, volatility in these costs may negatively impact the Company’scompany’s business, results of operations, access to sources of liquidity or financial condition and cash flows.
The Company’s results will be affected by competitive conditions and customer preferences.
Demand forcondition. After the Company’s products, which impacts revenue and profit margins, will be affected by (i) the development and timing of the introduction of competitive products; (ii) the Company’s response to downward pricing trends to stay competitive; (iii) changes in customer order patterns, such as changes in the levels of inventory maintained by customers and the timing of customer purchases which may be affected by announced price changes, changes in the Company’s incentive programs, or the customer’s ability to achieve incentive goals; (iv) the impact of tariffs or trade disputes on availability of raw materials; and (v) changes in customers’ preferences for the Company’s products, including the success of products offered by the Company’s competitors, and changes in customer’s designs for their products that can affect the demand for some of the Company’s products.
Additionally, success in achieving the Company’s growth objectives is significantly dependent on the timing and market acceptance of the Company’s new product offerings, including the Company’s ability to renew the Company’s pipeline of new product offerings and to bring those offerings to market. This ability may be adversely affected by difficulties or delays in product development, such as the inability to identify viable new products, obtain adequate intellectual property protection, or gain market acceptance of new products. There are no guarantees that new products will prove to be commercially successful. The Company’s success will depend on several factors, including the Company’s ability to:
correctly identify customer needs and preferences and predict future needs and preferences;
allocate the Company’s research & development funding to products and services with higher growth prospects;
anticipate and respond to the Company’s competitors’ development of new products and services and technological innovations;
differentiate the Company’s offerings from the Company’s competitors’ offerings and avoid commoditization;
innovate and develop new technologies and applications, and acquire or obtain rights to third-party technologies that may have valuable applications in the Company’s served markets;
obtain adequate intellectual property rights with respect to key technologies before the Company’s competitors do;
successfully commercialize new technologies in a timely manner, price them competitively and cost-effectively manufacture and deliver sufficient volumes of new products of appropriate quality on time;
obtain necessary regulatory approvals of appropriate scope; and
stimulate customer demand for, and convince customers, to adopt new technologies.
There are no guarantees that new product offerings will prove to be commercially successful.Additionally, the Company’s expansion into new markets may result in greater-than-expected risks, liabilities and expenses.
The costs of complying with evolving regulatory requirements could negatively impact the Company’s business, results of operations, financial condition and cash flows. Actual or alleged violations of environmental laws or permit requirements could result in restrictions or prohibitions on plant operations and substantial civil or criminal sanctions, as well as the assessment of strict liability and/or joint and several liability.
DuPont continues to be subject to extensive federal, state, local and foreign laws, regulations, rules and ordinances relating to pollution, protection of the environment, greenhouse gas emissions, and the generation, storage, handling, transportation, treatment, disposal and remediation of hazardous substances and waste materials. Costs and capital expenditures relating to environmental, health or safety matters are subject to evolving regulatory requirements and depend on the timing of the promulgation and enforcement of specific standards which impose the requirements. Moreover, changes in environmental regulations could inhibit or interrupt the Company’s operations, or require modifications to the Company’s facilities. Changes to regulations or the implementation of additional regulations, especially in certain highly regulated markets served by the Company’s Nutrition & Biosciences businesses, such as regulatory modernization of food safety laws and evolving standards and regulations affecting pharmaceutical excipients, or in reaction to new or next-generation technologies, including advances in protein engineering, gene editing and gene mapping, or novel uses of existing technologies may result in significant costs or capital expenditures or require changes in business practice that could result in reduced margins or profitability.
Accordingly, environmental, health or safety regulatory matters could result in significant unanticipated costs or liabilities causing a negative impact on the Company’s business, cash flows and results of operations.
The Company’s business, results of operations and reputation could be adversely affected by industry-specific risks including process safety and product stewardship/regulatory compliance issues.
DuPont is subject to risks which include, but are not limited to, product safety or quality; shifting consumer preferences; federal, state, and local regulations on manufacturing or labeling; environmental, health and safety regulations; and customer product liability claims. While DuPont maintains general liability insurance, the amount of liability that may result from certain of these risks may not always be covered by, or could exceed, the applicable insurance coverage. In addition, negative publicity related to product liability, food safety, safety, health and environmental matters may damage the Company’s reputation. The occurrence of any of the matters described above could adversely affect the Company’s business, results of operations, financial condition and cash flows.
In most jurisdictions, DuPont must test the safety, efficacy and environmental impact of the Company’s products to satisfy regulatory requirements and obtain the needed approvals. In certain jurisdictions, DuPont must periodically renew the Company’s approvals, which may require it to demonstrate compliance with then-current standards. The regulatory approvals process is lengthy, complex and in some markets unpredictable, with requirements that can vary by product, technology, industry and country. Additionally, the regulatory environment may be impacted by the activities of non-governmental organizations and special interest groups and stakeholder reactions to the actual or perceived impacts of new technology, products or processes on safety, health and the environment. Obtaining and maintaining regulatory approvals will require submitting a significant amount of information and data, which may require participation from technology providers. Regulatory standards and trial procedures are continuously changing. The pace of change together with the lack of regulatory harmony could result in unintended noncompliance. To maintain the Company’s right to produce or sell existing products or to commercialize new products, DuPont must be able to demonstrate the Company’s ability to satisfy the requirements of regulatory agencies.
The failure to meet existing and new requirements or receive necessary permits or approvals could have near- and long-term effects on the Company’s ability to produce and sell certain current and future products, which could significantly increase operating costs and adversely affect the Company’s business, results of operations, financial condition and cash flows.
The Company’s business, results of operations, financial condition and cash flows could be adversely affected by interruption of the Company’s supply chain, information technology or network systems and other business disruptions.
Supply chain disruptions, plant and/or power outages, labor disputes and/or strikes, information technology system and/or network disruptions, whether caused by acts of sabotage, employee error, malfeasance or other actions, geo-political activity, weather events and natural disasters, including hurricanes or flooding that impact coastal regions, could seriously harm the Company’s operations as well as the operations of the Company’s customers and suppliers. In addition, terrorist attacks and natural disasters have increased stakeholder concerns about the security and safety of chemical production and distribution.
Supply chain and other business disruptions may also be caused by security breaches, which could include, for example, attacks on information technology and infrastructure by hackers, viruses, breaches due to employee error, malfeasance or other actions or other disruptions. DuPont and/or the Company’s suppliers may fail to effectively prevent, detect and recover from these or
other security breaches and, therefore, such breaches could result in misuse of the Company’s assets, loss of property including trade secrets and confidential or personal information, some of which is subject to privacy and security laws, and other business disruptions. As a result,COVID-19 outbreak has subsided, DuPont may be subjectexperience materially adverse impacts to legal claims or proceedings, reporting errors, processing inefficiencies, negative media attention, loss of sales, interference with regulatory compliance which could result in sanctions or penalties, liability or penalties under privacy laws, disruption in the Company’s operations, and damage to the Company’s reputation, which could adversely affect the Company’s business, results of operations, financial condition and cash flows.
Like most major corporations, DuPont is the target of industrial espionage, including cyber-attacks, from time to time. DuPont has determined that these attacks have resulted, and could result in the future, in unauthorized parties gaining access to certain confidential business information. Although management does not believe that DuPont has experienced any material losses to date related to these security breaches, including cybersecurity incidents, there can be no assurance that DuPont will not suffer such losses in the future.
DuPont seeks to actively manage the risks within the Company’s control that could lead to business disruptions and security breaches. As these threats continue to evolve, particularly around cybersecurity, DuPont may be required to expend significant resources to enhance the Company’s control environment, processes, practices and other protective measures. Despite these efforts, such events could have a material adverse effect on the Company’s business, results of operations, financial condition and cash flows.
Enforcing the Company’s intellectual property rights, or defending against intellectual property claims asserted by others, could adversely affect the Company’s business, results of operations, financial condition and cash flows.
Intellectual property rights, including patents, trade secrets, know-how and other confidential information, trademarks, tradenames and other forms of trade dress, are important to the Company’s business. DuPont endeavors to protect the Company’s intellectual property rights in jurisdictions in which the Company’s products are produced or used and in jurisdictions into which the Company’s products are imported. However, DuPont may be unable to obtain protection for the Company’s intellectual property in key jurisdictions. Further, changes in government policies and regulations, including changes made in reaction to pressure from non-governmental organizations, or the public generally, could impact the extent of intellectual property protection afforded by such jurisdictions.
DuPont has designed and implemented internal controls intended to restrict access to and distribution of the Company’s intellectual property. Despite these precautions, the Company’s intellectual property is vulnerable to unauthorized access through employee error or actions, theft and cybersecurity incidents, and other security breaches. When unauthorized access and use or counterfeit products are discovered, DuPont considers the matter for report to governmental authorities for investigation, as appropriate, and take measures to mitigate any potential impact. Protecting intellectual property related to biotechnology is particularly challenging because theft is difficult to detect and biotechnology can be self-replicating. Accordingly, the impact of such theft can be significant.
Competitors are increasingly challenging the Company’s intellectual property positions, and the potential outcomes can be highly uncertain. Third parties may also claim the Company’s products violate their intellectual property rights. Defending such claims, even those without merit, is time-consuming and expensive. In addition, as a result of such claims, DuPont has and could be required in the future to enter into license agreements, develop non-infringing products or engage in litigation that could be costly. If challenges are resolved adversely, it could negatively impact the Company’s ability to obtain licenses on competitive terms, commercialize new products and generate sales from existing products.
In addition, because of the rapid pace of technological change, the confidentiality of patent applications in some jurisdictions and/or the uncertainty in predicting the outcome of complex proceedings relating to ownership or the scope of protection of patents relating to certain emerging technologies, competitors may be unexpectedly issued patents that DuPont does not anticipate. These patents could reduce the value of the Company’s commercial or pipeline products or, to the extent they cover key technologies on which DuPont has unknowingly relied, require it to seek to obtain licenses or cease using the technology, no matter how valuable to the Company’s business. If DuPont decided to obtain licenses to continue using the technology, it cannot ensure DuPont would be able to obtain such a license on acceptable terms.
Legislation and jurisprudence on patent protection is evolving, and changes in laws could affect the Company’s ability to obtain or maintain patent protection for the Company’s products.
Any one or more of the above factors could significantly affect the Company’s business, results of operations, financial condition and cash flows.
Increased concerns regarding chemicals in commerce and their potential impact on the environment have resulted in more restrictive regulations, may lead to new regulations and compliance may be costly.
Concerns about chemicals and biotechnology, as well as their potential impact on health and the environment, reflect a growing trend in societal demands for increasing levels of product safety and environmental protection. These concerns could manifest themselves in stockholder proposals, preferred purchasing, delays or failures in obtaining or retaining regulatory approvals, delayed product launches, lack of market acceptance, product discontinuation, continued pressure for and adoption of more stringent regulatory intervention and litigation. These concerns could also influence public perceptions, the viability or continued sales of certain of the Company’s products, the Company’s reputation and the cost to comply with regulations and, as a result, could have a negative impact on the Company’sits business, results of operations and financial condition.
An impairment of goodwill or intangible assets could negatively impact the Company’s financial results.
At least annually, DuPont must assess both goodwill and indefinite-lived intangible assets for impairment. Intangible assets with finite lives are tested for impairment when events or changes in circumstances indicate their carrying value may not be recoverable. If testing indicates that goodwill or intangible assets are impaired, their carrying values will be written down based on fair values with a charge against earnings. Where DuPont utilizes discounted cash flow methodologies in determining fair values, continued weak demand for a specific product line or business could result in an impairment. Accordingly, any determination requiring the write-off of a significant portion of goodwill or intangible assets could negatively impact the Company’s results of operations.
As a result of the Merger and related acquisition method of accounting, Historical EID’s assets and liabilities were measured at fair value, and any declines in projected cash flows could have a material, negative impact on the fair value of the Company’s reporting units and assets. Future impairments of the Company’s goodwill or intangible assets also could be recorded due to changes in assumptions, estimates or circumstances and the magnitude of such impairments may be material to it.
Failure to effectively manage acquisitions, divestitures, alliances and other portfolio actions could adversely impact the Company’s business, results of operations, financial condition and cash flows.
DuPont from time to time evaluates acquisition candidates that may strategically fit the Company’s business and/or growth objectives. If DuPont is unable to successfully integrate and develop acquired businesses, DuPont could fail to achieve anticipated synergies and cost savings, including any expected increases in revenues and operating results, which could have a material adverse effect on the Company’s financial results. DuPont expects to continually review the Company’s portfolio of assets for contributions to the Company’s objectives and alignment with the Company’s growth strategy. The Letter Agreement between the Company and Corteva limits DuPont’s ability to separate certain businesses and assets to third parties without assigning certain of its indemnification obligations under the Separation and Distribution Agreement to the transferee of such businesses and assets or meeting certain other alternative conditions. DuPont may be unable to meet the conditions under the Letter Agreement, if applicable.
Even if the conditions under the Letter Agreement are met or are not applicable, DuPont may not be successful in separating underperforming or non-strategic assets, and gains or losses on the divestiture of, or lost operating income from, such assets may affect the Company’s earnings. Moreover, DuPont might incur asset impairment charges related to acquisitions or divestitures that reduce the Company’s earnings. In addition, if the execution or implementation of acquisitions, divestitures, alliances, joint ventures and other portfolio actions is not successful, it could adversely impact the Company’s business, results of operations, financial condition and cash flows.
The Company’s results of operations could be adversely affected by litigation and other commitments and contingencies.
DuPont faces risks arising from various unasserted and asserted litigation matters, including product liability, patent infringement and other intellectual property disputes, contract and commercial litigation, claims for damage or personal injury, antitrust claims, governmental regulations and other actions. An adverse outcome in any one or more of these matters could be material to the Company’s business, results of operations, financial condition and cash flows.
In the ordinary course of business, DuPont may make certain commitments, including representations, warranties and indemnities relating to current and past operations, including those related to divested businesses, and DuPont may issue guarantees of third-party obligations. If DuPont is required to make payments as a result, they could exceed the amounts accrued therefor, thereby adversely affecting the Company’s results of operations.
DuPont is subject to numerous laws, regulations and mandates globally which could adversely affect the Company’s operating results and forward strategy.
DuPont does business globally in more than 60 countries. DuPont is required to comply with the numerous and far-reaching laws and regulations administered by United States federal, state, local and foreign governmental authorities. DuPont is required to comply with other general business regulations covering areas such as income taxes, anti-corruption, anti-bribery, global trade, trade sanctions, environmental protections, product safety, and handling and production of regulated substances. DuPont expects to frequently face challenges from U.S. and foreign tax authorities regarding the amount of taxes due. These challenges may include questions regarding the timing and amount of deductions and the allocation of income among various tax jurisdictions.
In evaluating the exposure associated with various tax filing positions, DuPont expects to record reserves for estimates of potential additional tax DuPont may owe. Any failure to comply with applicable laws and regulations or appropriately resolve these challenges could subject it to administrative, civil and criminal remedies including fines, penalties, disgorgement, injunctions and recalls of the Company’s products, and damage to the Company’s reputation.
Governmental policies, including antitrust and competition law, trade restrictions, regulations related to medical applications and devices, food safety regulations, sustainability requirements, traceability and other government regulations and mandates, can impact the Company’s ability to execute this strategy successfully. See also “-A significant percentage of the Company’s net sales are generated from the Company’s international operations and are subject to the economic, political, regulatory, foreign exchange and other risks.”
Failure to maintain a streamlined operating model and sustain operational improvements may reduce the Company’s profitability or adversely impact the Company’s business, results of operations, financial condition and cash flows.
The Company’s profitability and margin growth will depend in part on the Company’s ability to maintain a streamlined operating model and drive sustainable improvements, through actions and projects, such as consolidation of manufacturing facilities, transitions to cost-competitive regions and product line rationalizations. A variety of factors may adversely affect the Company’s ability to realize the targeted cost synergies, including failure to successfully optimize the Company’s facilities footprint, the failure to take advantage of the Company’s global supply chain, the failure to identify and eliminate duplicative programs, and the failure to otherwise integrate Historical EID’s or Historical Dow’s respective specialty products businesses, including their technology platforms. There can be no assurance that DuPont is be able to achieve or sustain any or all of the cost savings generated from restructuring actions.
The Company’s U.S. and non-U.S. tax liabilities will be dependent, in part, upon the distribution of income among various jurisdictions in which DuPont operate.
The Company’s future results of operations could be adversely affected by changes in the effective tax rate as a result of a changerelated global economic impacts, including any recession that has occurred or may occur in the mix of earnings in countries with differing statutory tax rates, changes in tax laws, regulations and judicial rulings (or changes in the interpretation thereof), changes in generally accepted accounting principles, changes in the valuation of deferred tax assets and liabilities, changes in the amount of earnings permanently reinvested offshore, the results of audits and examinations of previously filed tax returns and continuing assessments of the Company’s tax exposures and various other governmental enforcement initiatives. The Company’s tax expense includes estimates of tax reserves and reflects other estimates and assumptions, including assessments of future earnings of the Company which could impact the valuation of the Company’s deferred tax assets. Changes in tax laws or regulations, including further regulatory developments arising from U.S. tax reform legislation as well as multi-jurisdictional changes enacted in response to the action items provided by the Organization for Economic Co-operation and Development (OECD), will increase tax uncertainty and impact the Company’s provision for income taxesfuture.
ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS
Issuer Purchases of Equity Securities
The following table provides information regarding purchases of the Company’s common stock by the Company during the three months ended June 30, 2019:March 31, 2020:
|
| | | | | | | | | | |
| Issuer Purchases of Equity Securities | | Total number of shares purchased as part of the Company's publicly announced share repurchase program 1 | Approximate dollar value of shares that may yet be purchased under the Company's publicly announced share repurchase program 1 (In millions) |
| Period | Total number of shares purchased | Average price paid per share |
| April 2019 | — |
| $ | — |
| — |
| $ | — |
|
| May 2019 | — |
| $ | — |
| — |
| $ | — |
|
| June 2019 | 1,371,450 |
| $ | 74.18 |
| 1,371,450 |
| $ | 1,898 |
|
| Second quarter 2019 | 1,371,450 |
| $ | 74.18 |
| 1,371,450 |
| $ | 1,898 |
|
|
| | | | | | | | | | |
| Issuer Purchases of Equity Securities | | Total number of shares purchased as part of the Company's publicly announced share repurchase program 1 | Approximate dollar value of shares that may yet be purchased under the Company's publicly announced share repurchase program 1 (In millions) |
| Period | Total number of shares purchased | Average price paid per share |
| January | — |
| — |
| — |
| 1,250 |
|
| February | — |
| — |
| — |
| 1,250 |
|
| March | 6,079,728 |
| 38.2 |
| 6,079,728 |
| 1,018 |
|
| First Quarter 2020 | 6,079,728 |
| $ | 38.2 |
| 6,079,728 |
| $ | 1,018 |
|
| |
| 1. | On June 1, 2019, the Company announced a new $2 billion share buyback program, which expires on June 1, 2021. |
In July 2019, the Company purchased an additional 2,050,898 shares at a total cost of $148 million. Approximately $1.75 billion of the Company’s $2.0 billion share repurchase authorization is remaining.
ITEM 4. MINE SAFETY DISCLOSURES
Not applicableapplicable.
ITEM 5. OTHER INFORMATION
Not applicable.In anticipation of and to facilitate the proposed transaction with IFF, DuPont is planning for the internal separation of the N&B Business, both domestically and internationally, through a series of transactions that are intended to be tax-efficient from both a United States and foreign perspective (collectively, the "N&B Internal Separations"). See Part I, Item 1 and Part II, Item 1A of this report for more information regarding the proposed transaction. The N&B Internal Separations are currently expected to consist of internal transactions undertaken by DuPont and its subsidiaries to separate ownership of the N&B Business from ownership of their other businesses, including a number of distributions intended to qualify as tax-free spinoffs for United States tax purposes under Section355 of the Internal Revenue Code. The N&B Internal Separations are expected to occur in the United States and in (or involving entities domiciled in) various jurisdictions, including (but not limited to) China, India and the Netherlands. Following the completion of the N&B Internal Separations, DuPont expects that DuPont will effectuate the separation, pending DuPont Board approval, in a distribution intended to qualify as a tax-free spinoff for United States tax purposes under Section 355 of the Internal Revenue Code. The DuPont subsidiaries, or their successors, that are included in the current plans for the N&B Internal Separations as distributing corporations in the N&B Internal Separations (each in one or more tax-free spinoffs for United States tax purposes under Section 355 of the Internal Revenue Code) are the following: Rohm and Haas Electronic Materials (Shanghai) Ltd; DDP Specialty Products India Private Limited; Specialty Electronic Materials Netherlands Holding 5, B.V.; Specialty Electronic Materials Netherlands B.V.; DuPont Services Company B.V.; Performance Specialty Products NA, LLC; Specialty Products US 2, LLC; Specialty Products US, LLC; DDP Specialty Electronic Materials US, Inc; Rohm and Haas Electronic Materials CMP Inc; DDP Specialty Electronic Materials US 5, LLC; DDP Specialty Electronic Materials US 4, LLC; DDP Specialty Electronic Materials US 8, LLC; Specialty Products US 4, LLC; and DDP Specialty Electronic Materials US 9, LLC.
ITEM 6. EXHIBITS
|
| | | |
| | EXHIBIT NO. | | DESCRIPTION |
| | | | Second Amended and Restated Certificate of Incorporation of DowDuPont Inc. effective as of June 1, 2019, incorporated by reference to Exhibit 3.2 to the DuPont de Nemours, Inc. Current Report on Form 8-K filed June 3, 2019. |
| | | The Amended and Restated Bylaws of DuPont de Nemours, Inc., effective as of June 1, 2019, incorporated by reference to Exhibit 3.3 to the DuPont de Nemours, Inc. Current Report on Form 8-K filed June 3, 2019. |
| | | Intellectual Property Cross-License Agreement, effective as of June 1, 2019,Employment Contract by and amongbetween DuPont de Nemours, Inc. and Corteva, Inc., incorporatedMatthias Heinzel, effective August 1, 2011, as amended by reference to Exhibit 10.1 to the DuPont de Nemours, Inc. Current ReportTerms of Treatment dated October 28, 2014 as fully executed on Form 8-K filed June 3,November 21, 2014, and dated November 11, 2019 as fully executed on November 30, 2019. |
| | | | Letter Agreement, effective as of June 1, 2019 by and between DuPont de Nemours, Inc. and Corteva, Inc., incorporated by reference to Exhibit 10.2 to the DuPont de Nemours, Inc. Current Report on Form 8-K filed June 3, 2019. |
| | | Amended and Restated Tax Matters Agreement, effective as of June 1, 2019, by and among DowDuPont Inc., Corteva, Inc. and Dow Inc., incorporated by reference to Exhibit 10.3 to the DuPont de Nemours, Inc. Current Report on Form 8-K filed June 3, 2019. |
| | | DuPont Senior Executive Severance Plan, effective as of June 1, 2019, incorporated by reference to Exhibit 10.4 to the DuPont de Nemours, Inc. Current Report on Form 8-K filed June 3, 2019. |
| | | DuPont Management Deferred Compensation Plan, effective June 1, 2019. |
| | | DuPont Stock Accumulation and Deferred Compensation Plan for Directors, effective June 1, 2019. |
| | | DuPont Deferred Variable Compensation Plan, effective June 1, 2019. |
| | | DuPont Retirement Savings Restoration Plan, effective June 1, 2019. |
| | | DuPont Pension Restoration Plan, effective June 1, 2019. |
| | | DuPont Omnibus Incentive Plan effective June 1, 2019. |
| | | Amended and Restated Employment Agreement by and between DuPont de Nemours, Inc. and Edward D. Breen,Matthias Heinzel dated as of June 1,May 28, 2019. |
| | | | Preferability Letter of PricewaterhouseCoopers LLP, independent registered public accounting firm.Agreement by and between DuPont de Nemours, Inc. and Matthias Heinzel dated August 30, 2019 as fully executed on September 26, 2019. |
| | | Letter Agreement by and between DuPont de Nemours, Inc. and Matthias Heinzel dated October 25, 2019 as fully executed on October 28, 2019. |
| | | | Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. |
| | | | Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. |
| | | | Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. |
| | | | Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. |
| | 101.INS | | XBRL Instance Document – the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document. |
| | 101.SCH | | XBRL Taxonomy Extension Schema Document. |
| | 101.CAL | | XBRL Taxonomy Extension Calculation Linkbase Document. |
| | 101.DEF | | XBRL Taxonomy Extension Definition Linkbase Document. |
| | 101.LAB | | XBRL Taxonomy Extension Label Linkbase Document. |
| | 101.PRE | | XBRL Taxonomy Extension Presentation Linkbase Document. |
| 104 | | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101). |
*Filed herewith
**Upon request of the U.S. Securities and Exchange Commission, (the “SEC”), DuPont hereby undertakes to furnish supplementally a copy of any omitted schedule or exhibit to such agreement; provided, however, that DuPont may omit confidential information pursuant to Item 601(b)(10) or request confidential treatment pursuant to Rule 24b-2 of the Exchange Act for any schedule or exhibit so furnished.
|
|
DuPont de Nemours, Inc. Signatures |
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
DUPONT DE NEMOURS, INC.
Registrant
Date: August 6, 2019May 5, 2020
|
| | | | |
| By: | /s/ MICHAEL G. GOSS | | | |
| Name: | Michael G. Goss | | | |
| Title: | Vice President and Controller | | | |
| City: | Wilmington | | | |
| State: | Delaware | | | |